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1. Introduction 
According to the World Health Organization (WHO), an estimated 11 million people 
are diagnosed with cancer worldwide and over 7 million die from cancer every year; 
however, the number of unreported cases is expected to be far higher. In Germany 
over 400,000 people died from cancer in 2002, which means that - at current rates - 
every fourth living German citizen will die from cancer. Carcinoma of the breast (for 
women), prostate (for men), colorectal tract and lung are responsible for the majority 
of cancer cases and deaths. Obviously cancerogenesis is a process that develops 
differently in different organs, where often numerous subclasses of tumors can be 
distinguished from histology. Furthermore, carcinomas typically pass through specific 
hallmarks during development, where finally all events leading to tumor formation are 
due to a complex interplay of molecular factors dependent on the individual situation 
in the single patient.  
In addition to classical tumor therapies, which include surgical removal of tumors, 
radiation and chemotherapy a spectrum of innovative strategies are being developed 
specifically targeting cellular molecules, which are either unique for or 
overrepresented in cancer tissue. A number of these oncogenes, which dominantly 
drive tumor development by deregulating proliferation or differentiation of normal 
tissue, have so far been identified and various inhibitors against these entities are in 
development or already in clinical use (often in combination with conventional forms 
of therapy). Yet, the complexity of processes in tumorigenesis, as well as the 
heterogeneity of patient cohorts leads to often only moderate efficacy of these 
regiments, combined with high costs for individuals and for society as a whole. It is 
therefore of immanent importance to better understand the molecular mechanisms 
underlying cancerogenesis, to identify criteria by which tumor response towards a 
specific regiment can be robustly predicted and to classify patients prior to therapy 
according to individual suitability of treatment. It is a tempting, yet still inconceivable, 
conception that in the future there could be standard screening systems available, 
which are applied upon tumor diagnosis and which allow identification of the optimal 
individualized medication for every patient in need. 
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1.1 Receptor tyrosine kinases (RTKs) 
Cells communicate through various ways either directly via cell-cell contacts or 
indirectly via secretion and specific binding of messenger proteins, which allows a 
concerted and controlled action within tissues, organs and the organism. Reversible 
phosphorylation and dephosphorylation of proteins, which are part or endpoints of 
signal transduction pathways, has been identified to be a central mechanism of 
intracellular signal processing (Cohen, 2002). This is substantiated by the fact that 
over 500 genes coding for kinases and 130 genes coding for phosphatases have 
been identified by the Human Genome Project (Shawver et al., 2002). Kinases 
specifically catalyze phosphorylation of serine/threonine or tyrosine residues on 
target proteins and may occur in the cytoplasm or bound to membranes (Cohen, 
2002). Due to their high regulatory potential and their eminent role as driving forces 
for tumorigenesis, kinases are adequate target structures for specific anti-cancer 
therapy concepts.   
 
 
Figure1   Subfamilies of receptor tyrosine kinases. Abbreviation in the figure: AB: acidic box; CadhD: 
cadherin-like domain; CRD: cysteine-rich domain; DiscD: discoidin-like domain; EGFD: epidermal growth factor-
like domain; FNIII: fibronectin type III-like domain; IgD: immunoglobulin-like domain; KrinD: kringle-like domain; 
LRD: leucine-rich domain (from Blume-Jensen and Hunter, 2001). 
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Receptor tyrosine kinases (RTK) are transmembrane proteins with an intrinsic 
tyrosine kinase activity. They contain a highly glycosylated extracellular domain, 
which is engaged in protein-protein interactions, such as ligand binding or complex 
formation with other receptors and is therefore highly variable between different 
RTKs. The cytoplasmic domain of RTKs is highly conserved and is composed of the 
catalytic center, as well as of regulatory regions controlling the (auto-) 
phosphorylation of the receptor. A transmembrane domain connects the extracellular 
and intracellular domains. Beyond their common features, the known 58 RTKs are 
characterized by a wide structural and modular diversity (Blume-Jensen and Hunter, 
2001) (figure 1).  
All RTKs, with the exception of the insulin receptor (Van-Obberghen et al., 1994), are 
present as monomers in the membrane and dimerize upon ligand binding, which is 
paralleled by receptor activation. In the case of the fibroblast growth factor (FGF), 
binding to the receptor (FGFR) is dependent on stabilization with heparane sulfate 
proteoglycanes (HSPGs), which are localized in the extracellular matrix and on 
cellular surfaces (Spivak-Kroizman et al., 1994). The signaling capacity of activated 
RTK receptors can be blocked by antagonistic ligands, by the action of protein 
tyrosine phosphatases (PTPs) or by receptor degradation (Schlessinger, 2000). 
Activated RTKs are further subject to internalization and vesicular trafficking, which 
has been shown to significantly influence the receptor capacity for downstream 
signaling (Wiley, 2003; Mukherjee et al., 2006).  
 
1.1.1 ErbB family of RTKs 
The ErbB family encompasses four members, all of which are transmembrane 
receptor tyrosine kinases (RTKs), including EGFR (epidermal growth factor 
receptor), ErbB2/Neu/Her2, ErbB3/Her3 and ErbB4/Her4. All four receptors contain 
two cysteine-rich regions in their extracellular domain. Activation of ErbB family is 
controlled by the expression and secretion of natural ligand proteins. Ligand binding 
induces activation of the intrinsic kinase, which catalyzes trans-phosphorylation of 
the receptor dimers at specific tyrosine residues within their intracellular domain. 
Phosphorylation of tyrosine residues serves to recruit specific adaptors and other 
signaling proteins leading to the activation and modulation of intracellular signaling 
pathways (Pawson et al., 2001). ErbB2 forms dimers with all other ErbB family 
members, yet cannot bind any known natural ligands by itself (Graus-Porta et al., 
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1997), while ErbB3 has a non-functional kinase domain and can only signal in 
heterodimeric complexes (Guy et al., 1994). Interestingly, it has been observed that 
ErbB2 containing heterodimers are preferentially formed and that ErbB2 has a high 
intrinsic kinase activity, readily trans-phosphorylating tyrosine residues of the 
dimerization partner receptor (Graus-Porta et al., 1997). 
 
1.1.2 Modes of EGFR activation  
The EGFR gene is located on chromosome 7 and encodes a mature 170kDa protein 
that encompasses 1186 amino acids. The EGFR ectodomain consists of 621 amino 
acids and is subdivided into four structural domains (I-IV), where ligand binding 
domains I and III are leucine-rich repeats (L1 and L2) and domains II and IV are 
cysteine-rich (CR1 and CR2). Binding of ligands to EGFR forms a complex with 2:2 
stoichiometry, where the two receptors are directly bound to each other by 
interaction between their domains II, while the ligands are on opposite sites from the 
dimer interface (Ogiso et al., 2002; Garrett et al., 2002) (see figure 2).  
 
 
 
Figure 2   Crystal structure of the interaction between EGFR and EGF in a 2:2 stoichiometry. Ribbon 
diagram with the approximate two-fold axis oriented vertically. Ribbon diagram with the approximate two-fold axis 
oriented vertically. The EGF on the left side of the 2:2 EGF•EGFR complex is pale green. Domains I (yellow), II 
(orange), III (red), and IV (grey) in the left receptor of the dimer are as well highlighted in color. Most of domain IV 
is disordered (from Ogiso et al., 2002). 
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Recently, it has been shown that inactive EGF receptor dimers may occur, which are 
intrinsically auto-inhibited. It has been postulated that allosteric binding of EGF 
induces sterical changes leading to formation of an asymmetric dimer, which 
releases the receptors from inhibition and allows receptor activation (Zhang et al., 
2006).    
Ligand-mediated activation of EGFR can be accomplished by eight ligands, namely 
amphiregulin (AREG), betacellulin (BTC), epidermal growth factor (EGF), epiregulin 
(EREG), heparine-binding epidermal growth factor (HB-EGF), transforming growth 
factor α (TGFα) (Riese and Stern, 1998), epigen (EPGN) (Strachan et al., 2001) and 
cripto (Salomon et al., 1999). All these ligands have an EGF-like domain that 
consists of 30 to 50 amino acids and forms three disulphide bonded intramolecular 
loops. Many ErbB ligands are part of a transmembrane precursor and need to be 
proteolytically processed before getting freed from the membrane. Cleavage of 
ligand precursors is catalysed by metalloproteases, whose activity is again controlled 
by G-protein coupled receptors, allowing substantial cross-talk in between these 
receptor classes (Prenzel et al., 1999; Fischer et al., 2003). There is also evidence 
that already the membrane tethered precursors of e.g. TGFα may bind to EGFR on 
adjacent cells and trigger events of signal transduction (Wong et al., 1999). In 
addition, intracellular kinases, such as Janus kinase 2 (JAK-2) (Yamauchi et al., 
1997) or Src (v-src sarcoma viral oncogene homolog) can also directly 
phosphorylate tyrosine residues on EGFR. In essence, the interplay of ErbB 
receptors, ligands and other proteins causes a highly complex signaling output, 
which is sensitively concerted by the expression levels and activity of the involved 
proteins and which allows a fine regulation of intracellular signal responses and 
feedback mechanisms. Another mode of EGFR activation includes mutations that 
may cause a ligand- independent constitutive activation of the receptor. Such genetic 
alterations are frequent in EGFR driven cancerogenesis and thus are discussed in 
sections 1.2.2 and 1.2.3.   
 
1.1.3 EGFR-mediated signal transduction 
The intracellular domain of the EGF receptor contains a serine (Ser-1142), a 
threonine (Thr-654) and seven tyrosine residues (Tyr-845, 992, 1045, 1068, 1086, 
1148, 1173) that can be phosphorylated upon appropriate inputs. Which tyrosine 
residues of EGFR are phosphorylated and thus, which signaling pathways are 
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switched on is determined by the composition of the ErbB receptor dimer and the 
specific ligand involved (Olayioye et al., 1998). Important vertical intracellular signal 
transduction pathways, which can be activated by EGFR include the phosphatidyl-
inositol-3 kinase (PI3K)/Akt, as well as the Ras/Raf/MEK/MAPK and the JAK/STAT 
signaling cascades (Schlessinger, 2000; Yarden, 2001). Furthermore, a broad range 
of different adapter proteins may specifically bind to designate residues upon 
receptor phosphorylation and trigger horizontal signal transmission (figure 3). 
 
 
Figure 3   Details from the ErbB receptor signaling network. The input signal may vary with regard to the 
formed receptor pair and the bound ligands (green; receptor specificity for each ligand is indicated in brackets 
behind ligand name; ErbB receptor designation is indicated by number). For sake of simplicity only binding and 
signal of EGF at EGFR homodimers and NRG4 at ErbB2/ErbB3 heterodimers are displayed. Signal transmission 
is ensured by adaptor proteins (violet), which specifically bind to activated receptor dimers. Transactivation of 
ErbB receptors (thick arrows) is exemplarily portrayed for Lysophosphatidic acid (LPA) activated GPCR via Src 
kinase (left) and Jak-mediated transactivation of ErbB receptors through activated cytokine receptors (right). 
Activation and attenuation of transcription factors (pink) is the endpoint of each signaling cascade (blue), which 
allows fine control of an particular output (yellow) (from Yarden, 2001). 
 
Due to its many different modes and its wide-reaching levels of signal transduction, 
EGFR may control a multitude of cellular actions. This includes e.g. protection 
against programmed cell death (apoptosis): activation of the PI3K/Akt cascade 
causes phosphorylation of Akt, which inhibits activity of the pro-apoptotic protein Bad 
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(BCL-2 antagonist of cell death) (Datta et al., 1997) and may activate the anti-
apoptotic transcription factor NFκB (nuclear factor k in B-cells) (Madrid et al, 2000). 
Other outcomes are e.g. controlled by the Ras/Raf/Mek/MAPK cascade: EGFR-
mediated activation of Ras causes translocation of phosphorylated MAPK into the 
nucleus, which supports activation of specific transcription factors, such as c-Jun and 
c-Fos. This cascade is highly conserved and triggers various effects, including 
control of proliferation, differentiation, angiogenesis and migration (Hunter, 1998; 
Yoon et al., 2006).  
 
1.1.4 Physiological importance and functions of EGFR  
Expression of ErbB receptor and EGF orthologs has also been found in 
Caenorhabditis elegans and Drosophlia melanogaster, where they play roles in 
cellular differentiation processes and embryogenesis (Moghal et al., 2003; Shilo et 
al., 2003). EGFR knockout mice have been found to die during embryogenesis or 
early post birth. These mice have defects in epidermal cells of the skin, lung, 
gastrointestinal tract, eyes and teeth and display severely impaired gut development 
(Miettinen et al., 1995; Sibilia et al., 1995; Threadgill et al., 1995). Knockouts in 
EGFR ligands showed some functional redundancy, while combined loss of TGFα, 
EGF and AREG causes defects of the lung, skin, eyes and mammary glands as well 
as accelerated hair and weight loss (Luetteke et al. 1999). The essential role of 
EGFR for renewal and homeostasis of the skin has been shown in mice with tissue-
specific expression of a dominant negative EGF receptor (Murillas et al., 1995), but 
no further conditional tissue-specific knockouts have been reported so far. Yet, the 
fact that expression of EGFR can be found in most mature organs underlines its 
importance for the adult organism and suggests that more details of its functions will 
be deciphered in the future. 
 
1.2 Role for EGFR in cancer 
1.2.1 Cancer physiology 
Cancer is a genetic disease, caused by loss (tumor suppressor genes), amplification 
or mutation (oncogenes) of certain genes or major chromosomal changes. The 
majority of cancers are somatic, which means that they are occurring in the affected 
tissue during tumorigenesis. Yet, many tumors also have a hereditable dimension 
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caused by germline transmission of predisposing genetic alterations that contribute 
to the development of cancer. Cancerogenesis is a process, which can be 
subdivided into several intermediate stages. Over the full course of cancer 
development, which starts with somatic cells and ends up with a severely malignant 
successor cells, several hallmarks are passed through (see figure 4; Hanahan and 
Weinberg, 2000).  
 
 
 
Figure 4 Expected parallelism of oncogenic events leading to a malign cancer phenotype. The 
cancerogenesis model developed by Hanahan and Weinberg postulates that cancers need to acquire six 
capabilities for reaching full malignancy (A). The order by which these hallmarks are passed through, however, 
may be variable and is thought to be dependent on cancer types and subtypes (B) (from Hanahan and Weinberg, 
2000). 
  
At a early stage somatic cells gain self-sufficiency on the generation of growth 
signals. Other early steps include insensitivity to growth inhibitory signals, gain of the 
capacity to evade apoptosis and the acquisition of unlimited replicative potential. 
Local outgrowth of tumors causes high cellular densities leading to stress and high 
demand of nutrients and oxygen for the fast-growing cells. Further genetic alterations 
may thus confer the cancer cells with the potential to promote angiogenesis. Finally 
malign tumors may start to leave the tumor tissue through the vascular system and 
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metastasize into other organs of the body. The order by which the cells acquire 
these capabilities, however, is thought to vary from tumor to tumor. 
 
1.2.2 Modes of EGFR-mediated cell transformation 
In many tumors natural ligands of EGFR, such as EGF or TGFα, are produced and 
secreted either by tumor cells themselves or by the stromal tissue. Overexpression 
of EGFR together with autocrine ligand secretion and concomitant receptor 
activation provides multiple advantages to tumors by promoting cell proliferation, 
survival, angiogenesis, invasion and metastasis (Salomon et al., 1995; Huang and 
Harari, 1999; Normanno et al., 2005). EGFR is frequently expressed in carcinomas 
of the head and neck (80-100%) (Salomon et al., 1995; Grandis et al., 1996), Non-
small cell lung cancer (40-80%) (Rusch et al., 1997; Fontanini et al., 1998), 
glioblastomas (40-60%) (Ekstrand et al., 1991; Rieske et al., 1998), as well as in 
pancreatic carcinomas (30-50%) (Uegaki et al., 1997) and ovarian cancer (35-70%) 
(Bartlett et al., 1996; Fischer-Colbrie et al., 1997). Several studies correlate EGFR 
expression with reduced survival of patients (Veale et al., 1993; Resnick et al., 
2004), the same correlation has also been observed for tumor expression of TGFα 
and EGF (Hirai et al., 1998; Tateishi et al., 1990). 
Another mechanism of EGFR-mediated cancerogenesis is transactivation of the 
receptor through non-classical mechanisms. This includes transactivation of EGF 
receptor by GPCRs through metalloprotease-mediated EGF-like ligand shedding 
(Fischer et al., 2003). Furthermore, cross-talk between other RTKs, integrins, 
cytokine-receptors, ion-channels and EGFR have been described (Prenzel et al., 
2000; Gschwind et al., 2001). 
Deregulated EGFR-mediated signaling may also be triggered through mutations of 
ErbB genes. The most common mutation is a deletion of EGFR, encompassing 
residues 6-273, called EGFRvIII (de2-7 EGFR). Even though EGFRvIII is unable to 
bind EGF-like ligands, it is constitutively phosphorylated and elicits downstream 
signaling pathways qualitatively and quantitatively slightly different from ligand-
activated wild-type EGFR (Pedersen et al., 2001). In xenograft models EGFRvIII can 
confer enhanced tumorigenicity (Damstrup et al., 2002; Feldkamp et al., 1999) and 
clinically this mutation has been detected for example in NSCLC (5-39%) and glioma 
(57-86%) biopsies (Moscatello et al., 1995; Frederick et al., 2000; Okamato et al., 
2003; Ji et al., 2006). Recently, EGFR ectodomain mutations have found to occur 
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frequently in glioblastoma patients (13,6%), however their clinical impact has not yet 
been studied (Lee et al., 2006b). In contrast, activating EGFR kinase domain 
mutations that were found in NSCLC patients have been subject of enormous 
research activities.    
 
1.2.3 EGFR kinase domain mutations 
In May 2004 two groups independently reported on EGFR kinase domain mutations 
found in NSCLC patients with clinical response to the EGFR-targeting cancer drug 
gefitinib (Lynch et al., 2004a; Paez et al., 2004). Gefitinib is a tyrosine kinase 
inhibitor (TKI), which is in clinical use for lung cancer and that is discussed in detail 
in section 1.3.1. More than 15 mutations at different sites in or close to the EGFR 
kinase domain have been described so far, small deletions in exon 19 encompassing 
the LREA motive (~48% of mutations), point mutations, such as L858R (~38%), in-
frame deletion/insertions in exon 20 (~6%) being the most abundant ones (Janne et 
al., 2005; Pao and Miller, 2005) (figure 5).  
The first two mutations are also referred to as classical EGFR kinase domain 
mutations, to underline that they confer sensitivity for gefitinib to NSCLC patients and 
cell lines. Up to now, EGFR kinase domain mutations have only been sporadically 
described in other tumors, such as colorectal (<0.3%) and head and neck cancer (0-
7%) (Barber et al., 2004; Lee et al., 2005; Sihto et al., 2005). 
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Figure 5   EGFR kinase domain mutations found in NSCLC patients with relevance for clinical response 
to gefitinib therapy. Structural organization of EGFR and localization of clinically relevant mutations in the 
kinase domain of NSCLC patients. Mutations are highlighted in yellow boxes and their proportional frequencies 
are indicated for the most abundant clinical mutations. Mutations that may confer resistance to EGFR-directed 
TKIs are highlighted in orange boxes (from Irmer et al., 2007a). 
 
The initial observation that EGFR mutations on their own do not affect binding 
affinities of gefitinib (Fabian et al., 2005) triggered a variety of non-clinical analyses 
using different in vitro and animal models with the aim to better understand the 
molecular and cellular mechanisms of the EGFR mutations in tumor homeostasis. 
Clinical investigations showed that EGFR mutations appear to be more frequent in 
females, never-smokers and in patients with adenocarcinomas. Furthermore, Asians 
show a much higher prevalence for EGFR mutations (20–40%) than Caucasians 
(<10%) (Pao and Miller, 2005; Calvo and Baselga, 2006). Many retrospective studies 
have been performed on NSCLC patients, all correlating expression of mutated 
receptor with sensitivity to gefitinib (Irmer et al., 2007a). Furthermore, encouraging 
data on gefitinib monotherapy as first-line regimen in chemonaive NSCLC patients 
have been reported: pre-selection of patients based on EGFR mutations increased 
gefitinib or erlotinib response rates from 22.7–30 to 75–90% (Asahina et al., 2006; 
Giaccone et al., 2006; Niho et al., 2006). In contrast, a secondary mutation (T790M, 
discussed in section 1.3.3.1) may occur in NSCLC patients who carry classical 
kinase mutations, which reverts hypersensitivity and causes resistance to EGFR-
targeting TKIs (Pao et al., 2005a). Additionally, it was proposed that occurrence of 
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the EGFR mutation E884K dominantly renders tumors resistant to erlotinib, another 
TKI, but not to gefitinib in NSCLC patients (Choong et al., 2006). 
Laboratory studies with cells expressing transfected or endogenous EGFR revealed 
that mutated receptors are constitutively activated. This is often reflected by a high 
basal activation of signaling components downstream from EGFR, including 
phosphorylation of Akt and STAT3/5. Compared with this, phosphorylation of MAPK 
seems to be exclusively affected in stably transfected cells or in those expressing 
endogenous receptors. Activation of mutated EGFR or downstream signaling can be 
very effectively inhibited by gefitinib treatment in most in vitro models (Sordella et al., 
2004; Amann et al., 2005; Greulich et al., 2005).  
Only very limited data are available for the impact of these mutations on NSCLC 
therapy with EGFR-targeting monoclonal antibodies, such as cetuximab, which are 
also in clinical use as cancer therapeutics (see section 1.3.1 for detailed 
information). However, initial examinations indicate that clinical response to 
cetuximab in NSCLC does not seem to correlate with the presence of EGFR 
mutations (Lynch et al., 2004b; Mukohara et al., 2005, Tsuchihashi et al., 2005). This 
impression is supported by studies with cell lines and examinations on murine 
xenograft models (Amann et al., 2005; Perez-Torres et al., 2006).  
 
1.2.4 The role of Epithelial-mesenchymal transition (EMT) for metastasis and 
EGFR 
The conversion of epithelial cells to mesenchymal cells is a critical event in 
embryogenesis and organ development that was first observed in 1908 (Lillie, 1908). 
Epithelial cells are normally part of a thin epithelium, where cell-cell junctions and 
adhesions closely interconnect them, which confers mechanical rigidity and a 
polarized structural organization to tissues. In contrast, mesenchymal cells have a 
non-uniform morphology with elongated shapes, do not build tight cell-cell contacts, 
lack polarity and display an increased migratory capacity (Shook and Keller, 2003). 
The process that transduces a cell with epithelial morphology to a state with 
mesenchymal morphology has been designated EMT (epithelial-mesenchymal 
transition) and was shown to be regulated by a complex interplay of various factors 
(Thiery, 2002). EMT is a fundamental event of epithelial remodeling during 
development in many metazoan organisms (Gilbert, 1997) and is essential e.g. for 
gastrulation during embryogenesis in vertebrates (Shook and Keller, 2003).  
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Furthermore, EMT is a crucial prerequisite for the mobilization of cancer cells, 
leading to invasive growth, triggering cellular intravasation into the endothelium and 
finally metastazation over the body (Thompson et al., 2005). EMT is reversible and 
can be reversed by a process called mesenchymal-epithelial transition (MET).    
 
 
Figure 6   Modes and sites of EMT and MET in the emergence and propagation of carcinoma. Regular cells 
from polarized epithelium may proliferate upon transformation and give rise to adenoma. Further genetic 
alterations or the presence of paracrine ligands elicit further outgrowth into carcinoma in situ. EMT then leads to 
disintegration of the basal layer that permits passage of cancer cells into the endothelium, where they are 
shuttled to other sites. Micrometastases may form after extravasation in distant tissues, where finally 
macrometastases can arise after a mesenchymal-epithelial transition (MET) of cells (from Thiery, 2002).     
 
Proteins indicating the progress of EMT have been identified to serve as markers 
permitting categorization of clinical samples and cancer cell lines. The phenotypic 
markers of EMT are: elongated morphology, as well as an increased scattering, 
migration and invasion of originally epithelial cells. The most important molecular 
hallmarks are loss of E-Cadherin expression, increase of vimentin and N-Cadherin 
expression and nuclear localization of β-Catenin (Lee et al. 2006a). However, 
typically not all of these features are strictly observed when studying EMT in cell 
cultures. E-Cadherin is the key component of intercellular junction complexes, where 
it forms tight connections in between cells through their endodomains, while their 
intracellular domains bind to the actin microfilaments (Gumbiner, 2005). Cell-cell 
contacts formed by N-Cadherin, however, are much weaker (Lee et al., 2006a). 
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The action of RTKs has been found to play a central role in triggering EMT. 
Hepatocyte growth factor receptor (HGFR), together with its natural ligand 
hepatocyte growth factor/scatter factor (HGF/SF), was the first RTK proven to 
mediate EMT (Sonnenberg et al., 1993). EGF-mediated activation of EGFR has also 
been shown to induce EMT in epithelial breast cancer cells (Lee et al., 2006a). The 
postulated mode of EGFR-mediated EMT induction includes interaction of activated 
EGFR with the transcription factor STAT3 (signal transducer and activator of 
transcription 3) and subsequent shuttling into the nucleus (Lo et al., 2005). It has 
been reported earlier that EGFR may induce EMT through a STAT3-dependent 
mechanism, which causes a Liv1-mediated activation of the transcription factor Snail 
(Yamashita et al., 2004). Snail is a zinc finger transcription factor, which centrally 
controls the transcription of genes involved in EMT, including repression of E-
Cadherin (Cano et al., 2000; Batle et al., 2000). Interestingly, recent reports point 
towards a role of EMT for determining response of cancer cell lines to treatment with 
EGFR-targeting TKIs. According to these examinations, cells that have undergone 
EMT are resistant to this regimen (Yauch et al., 2005; Thomson et al., 2005).  
 
1.3 EGFR-targeting cancer therapy 
Since cancer treatment via EGFR inhibition was suggested for the first time in the 
1980’s (Sato et al., 1983), a variety of EGFR-directed therapeutics have been 
developed and some of them already came into clinical use. These drugs belong to 
two major classes: monoclonal antibodies and tyrosine kinase inhibitors (TKIs). 
Currently, there are five EGFR-directed drugs, which are approved for cancer 
treatment: two TKIs and three antibodies. Clinically approved EGFR inhibitors 
usually show favourable tolerability with manageable adverse events and preclinical 
as well as clinical studies have shown beneficial anti-tumor effects in combination 
with radiation or chemotherapy. Moreover, innovative combination therapies 
targeting other oncogenic factors, such as mTOR (mammalian target of rapamycin) 
or VEGFR (vascular endothelial growth factor receptor) are currently in the focus of 
refined EGFR-directed therapy concepts (Adjei et al., 2006). A variety of other 
EGFR-directed drugs are currently in clinical phase II and III. These include 
reversible bi-specific EGFR/ErbB2 and EGFR/VEGFR inhibitors, as well as 
irreversible bi-specific EGFR/ErbB2 TKIs and additional EGFR-directed monoclonal 
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antibodies (Heymach et al., 2006). Common effects of EGFR inhibition include 
inhibition of cell proliferation, induction of apoptosis, delay in cell cycle progression, 
anti-angiogenic effects, inhibition of invasion and metastasis and sensitizing of 
tumors to chemotherapy or radiation (Normanno et al., 2003). 
 
1.3.1 Tyrosine kinase inhibitors 
TKIs are designed to fit into specific binding pockets of their target structures usually 
located close to the kinase domain, comprising amino acids of the ATP binding 
pocket of EGFR (Noble et al. 2004). Binding of the TKI to EGFR blocks its capacity 
for autophosphorylation and thereby inhibits activation. Due to their small size and 
formulation, TKIs can infiltrate tumors and enter into cells quite efficiently, where they 
display a direct and rapid onset of action. 
Two EGFR-directed TKIs, gefitinib (ZD1839/Iressa from Astra Zeneca) and erlotinib 
(CP-358,774/Tarceva/OSI-774 from OSI Pharmaceuticals/Genentech/ Roche) have 
already been approved for clinical use in NSCLC after failure of standard treatment. 
Both are reversible, pharmacologically similar drugs (de Bono and Rowinsky, 2002; 
Laskin and Sandler, 2004).  
 
Adenosinetriphosphate Gefitinib
 
 
Figure 8   Chemical structures of adenosinetriphosphate (ATP) and gefitinib. Gefitinib (N-(3-chloro-4-fluoro-
phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine) is a low molecular weight quinazolin derivate 
that functions as an ATP competitive inhibitor of the EGFR kinase.   
 
Phase II studies further revealed single-agent activity of gefitinib in squamous cell 
carcinoma of head and neck (Cohen et al., 2003; Caponigro et al., 2004) and 
promising activity of gefitinib in colorectal cancer in combination with standard radio- 
or chemotherapy (Williams et al., 2004; Douglass et al., 2003).  On the other hand, 
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phase II trials with gefitinib in breast cancer have been overall unsatisfactory 
(Baselga et al., 2004). 
Even though gefitinib is quite specific for EGFR, dose-limiting side effects and 
occasionally severe complications (e.g. intestinal lung disease) are observed in the 
clinic (Dancey and Sausville, 2003; Cohen et al., 2004). Affinity chromatography with 
a gefitinib derivative and subsequent analyses of bound proteins by 2D gel 
electrophoresis revealed a number of cellular targets for this drug, in addition to 
EGFR (IC50<0,014µM). In vitro kinase assays determined low IC50 values of gefitinib 
e.g. for EphB4, BRK and Lyn (IC50<1µM), as well as medium activity of gefitinib 
against HGFR (IC50=3,2µM) (Brehmer et al., 2005). Together with the notion that 
gefitinib concentrations in breast tumors can be as high as 5 to 25µM (Baselga et al., 
2002; Albanell et al., 2002; Ranson et al., 2002), this allows the conclusion that the 
observed side effects are not exclusively due to inhibition of EGFR. On the other 
hand, this facet could also yield chances for therapy since the effects against other 
tyrosine kinases might extend therapeutic utility of the drug.  
 
1.3.2 EGFR-targeting monoclonal antibodies 
In comparison to TKIs, monoclonal antibodies may elicit different modes of action, 
which include competition for ligand binding and induction of receptor internalization 
(Ono et al., 2006). Another important aspect of antibodies is their interaction with the 
host immune system that may for instance lead to complement-dependent (CDC) 
and antibody-dependent cellular cytotoxicity (ADCC) (Mellstedt, 2003). Further 
advantages of monoclonal antibodies over TKIs are their prolonged half-life 
(associated with decreased drug administrations) and low toxicities.  
Three EGFR-directed antibodies are in clinical use: Cetuximab (C225/Erbitux from 
ImClone Systems/Bristol-Myers Squibb/Merck KGaA) is a 152kDa human-mouse 
chimeric anti-EGFR monoclonal antibody containing the human IgG1 constant region 
that is approved for the treatment of advanced colon rectal cancer (CRC) and 
squamous cell carcinoma of the head and neck (SCCHN) (Janmaat and Giaccone, 
2003; Harding and Burtness, 2005). Nimotuzumab (TheraCim/hR-3 from YM 
BioSciences/Oncoscience) is a humanized monoclonal antibody that was originally 
developed by a Cuban research institute and is clinically used in certain Asian and 
South American countries (Allan, 2005). Lastly, panitumumab (ABX-EGF/Vectibix 
from Abgenix/Amgen), a fully human anti-EGFR antibody generated using the 
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XenoMouse technology was approved by the FDA for the treatment of 
chemotherapy-resistant CRC (Davis et al., 1999).  
 
 
 
Figure 9   Schematic illustration of EGFR in the EGF or cetuximab bound state. Figure A shows the 
ectodomain of EGFR (domain I is colored in light green, domain II in light purple, domain III in dark green and 
domain IV in dark purple) in the autoinhibited (tethered) state (A). Figure B shows structure of the 1:1 EGF:EGFR 
ectodomain (dimerization-competent state; EGF is colored in orange) (B), while figure C displays the structure of 
the 2:2 EGF:EGFR ectodomain (dimerized, activated state) (C). Figure D shows the ectodomain of EGFR in the 
cetuximab bound state, where domain III of EGFR is tethered to the antibody causing receptor arrest in the 
autoinhibited state (the cetuximab Fab Cα light chain is colored in yellow and the Cα heavy chain is colored in 
cyan) (D) (from Hubbard, 2005). 
 
Co-crystallization of the EGFR ectodomain with the antigen binding fragment (Fab) 
of cetuximab revealed that the antibody binds exclusively to domain III of the 
receptor. This epitope overlaps with the binding site of EGF, however, binding 
studies show that affinity of cetuximab to EGFR is 50 fold higher than the receptor’s 
affinity to EGF. Through its mode of receptor binding, the antibody sterically inhibits 
juxtaposition of domains I and III and could thereby prevent a putative spontaneous 
(ligand independent) formation of the dimerization competent receptor conformation 
(Li et al., 2005b).      
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1.3.3 Mechanisms of cellular and clinical resistance and sensitivity to EGFR-
directed cancer therapy 
Clinical resistance against monoclonal antibodies and TKIs is common and may 
either be intrinsic (primary resistance) or can be acquired during drug treatment 
(secondary resistance). An impressive examination of TKI resistance has been 
published for the Bcr-Abl (Breaking Cluster Region - Abelson Murine Leukemia) 
kinase in chronic myeloid leukemia (CML) where mutations conferring resistance to 
the Bcr-Abl-targeting TKI imatinib can arise during treatment, but may also be 
detected at low frequency in patients that had not received the drug before (Roche-
Lestienne et al., 2002). 
 
1.3.3.1 Biomarkers for resistance to EGFR-directed cancer therapy 
Biomarkers are products of organisms that are indicative for the biological response 
of the organisms to drug exposure or other environmental conditions. Extensive 
efforts are made to identify tumor biomarkers that allow prognosis of response of 
cancer patients to EGFR-tagreting drugs. Recently, a mechanism that may at least 
account for some cases of resistance to gefitinib was revealed in NSCLC patients. 
Clinical and laboratory examinations showed that an EGFR-T790M mutation, which 
confers resistance to gefitinib treatment, may occur additionally to EGFR kinase 
domain mutations L858R and deletion mutations of the LREA motive within the 
kinase domain of EGFR (Gow et al., 2005; Kobayashi et al., 2005, Pao et al., 
2005a). The presence of this particular resistance conferring mutation in NSCLC 
patients appears to be independent from TKI treatment, but subpopulations of tumor 
cells expressing this EGFR variant might be enriched during the TKI regimen 
(Toyooka et al., 2005, Inukai et al., 2006). Yet, cetuximab treatment of mouse 
xenografts carrying subcutaneously transplanted cells that endogenously express 
EGFR-L858R-T790M causes marked tumor regression, while gefitinib treatment had 
only marginal effects (Perez-Torres et al., 2006). In contrast, cell lines expressing the 
EGFRvIII mutation are rather growth resistant against treatment with gefitinib (Learn 
et al., 2004) and cetuximab (Li et al. 2007). 
Another, principal cause for resistance to EGFR-directed therapy - concerning TKIs 
and therapeutic antibodies - is aberrant activation or overexpression of other RTKs. 
Since cancerogenesis generally involves genetic alteration of various factors, it is 
unlikely that inhibition of a single oncogene like EGFR will lead to a complete stasis 
1. Introduction    
   
19
or death of tumor cells. Constitutive activation or amplification of e.g. insulin-like 
growth factor-1 receptor (IGF1R) (Laban et al., 2003), HGFR (Ma et al. 2003; 
Christensen, et al.  2005) or FGFR family members (Adnane et al., 1991) is common 
in various cancers and might compensate for blockage of EGFR. Exemplarily, it was 
observed that a breast cancer cell line with sensitivity to the ErbB2-targeting 
antibody herceptin was rendered resistant to this drug by transfection with IGF1R (Lu 
et al., 2001). Furthermore, the ligands FGF and IGF1 were found to block the 
inhibitory effects of cetuximab on cellular survival and activation of downstream 
signaling in colon cancer and glioblastoma cell lines (Liu et al., 2001; Chakravarti et 
al., 2002). 
Since EGFR-directed drugs act at an early point of the signal transduction cascade, 
they cannot affect tumorigenic alterations in downstream signaling pathways. 
Inhibition of EGFR-mediated signaling through PI3K/Akt and Ras/Raf/MEK/MAPK 
pathways is thought to be crucial for sensitivity to EGFR-targeting tumor drugs. 
Tumorigenic activation of the Ras/Raf/MAPK pathway may be responsible for 
causing resistance to EGFR-directed therapy. Gain-of-function mutations of KRAS 
are described in various cancers, including NSCLC and may confer resistance to 
EGFR-targeting TKIs (Pao et al., 2005b). By the same token, persistent activation of 
PI3K/Akt signaling paralleled by cellular resistance to gefitinib can be caused by loss 
of the phosphatase PTEN (phosphatase and tensin homolog), a negative regulator 
of PI3K (She et al., 2003; Bianco et al., 2003). Amplification of PI3K or Akt 
expression (Robertson, 2005), as well as growth advantage conferring genetic 
alterations in the PI3KCA gene (Samuels et al., 2004) might also cause a clinically 
relevant activation of the pathway. 
 
1.3.3.2 Biomarkers for sensitivity to EGFR-directed cancer therapy 
Facing the multitude of putative and known mechanisms leading to resistance 
against EGFR-directed tumor therapy, the question if there are any factors, which 
alone allow a robust prediction of response to this regimen is at hand. Such 
biomarkers for sensitivity can either be dominant over certain resistance causing 
alterations discussed above, or they can be subordinate to them, gaining relevance 
in absence of resistance conferring factors. This scenario makes it practically very 
difficult to decipher the relative value of putative biomarkers for sensitivity. As 
discussed in section 1.2.3, EGFR kinase domain mutations appear to be a rare 
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exception in biomarker research, for they represent one of the few quite dominant 
sensitivity markers known. 
EGFR gene amplification has been positively correlated with tumor response to TKI 
regimen (Takano et al., 2005; Cappuzzo et al., 2005). However it is not clear 
whether this translates to increased EGFR protein levels detectable by 
immunohistochemistry (IHC) (Hirsch et al., 2006). A similar picture arises for 
cetuximab, where EGFR expression assessed by IHC did not correlate with 
response to the antibody in colorectal cancer (Saltz et al., 2004; Cunningham et al., 
2004); however amplification of gene copy number as assessed by FISH 
(fluorescence in-situ hybridization) did (Moroni et al., 2005). 
Conflicting results exist also for the relevance of high levels of phosphorylated Akt or 
STAT3/5 for predicting gefitinib sensitivity in patients. Most probably this depends on 
the simultaneous activation of EGFR in the same tissue, indicating dependence of 
these downstream signaling components on a paralleled EGFR phosphorylation 
(Cappuzzo et al., 2004; Haura et al., 2005). High expression of ErbB2, ErbB3 or 
ErbB ligands was also postulated to be predictive for gefitinib response. However 
forced expression of e.g. ErbB3 in gefitinib-resistant cells did not render them 
sensitive, indicating that this candidate is only of subordinate value for response 
prediction (Amann et al., 2005; Engelman et al., 2005). 
Whole genome expression profiling analyses was used to compare candidate gene 
expression in gefitinib sensitive and resistant cell lines. Detection of differential 
expression patterns within sensitive or resistant groups may thus reveal biomarkers 
for response prognosis. Microarray profiling of a panel of NSCLC cells independently 
identified increased ErbB3, E-cadherin and tumor-associated calcium signal 
transducer 2 (TACSTD2) levels as potential indicators for cellular response to 
gefitinib (Coldren et al., 2006). Another expression analyses with tumor samples 
from gefitinib-treated NSCLC patients identified amphiregulin (AREG) as a potential 
biomarker expressed high in non-responders to this TKI (Kakiuchi et al., 2004). 
Another study from Yauch and colleagues also found E-Cadherin expression as a 
marker for sensitivity for erlotinib (Yauch et al., 2005). A proteomics study on two 
colorectal cancer cell lines with variable responses towards cetuximab has been 
published where different patterns of proteins primarily associated with metabolic 
functions have been identified (Skvortsov et al., 2004). 
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1.3.3.3 Cellular resistance models 
Systematic laboratory studies to approach the problem of relapse of cancer patients 
that first responded efficiently to EGFR inhibitor therapy are rare. To address this 
problem, in vitro experiments have been conducted with primary sensitive cancer cell 
lines, which were made resistant against a specific drug by long-term exposure and 
dose escalation. Various cellular alterations that might be responsible for resistance 
of these cells towards the therapeutic have been identified by comparisons with 
untreated cells of the same origin and similar passage number. 
The first such approach was performed with erlotinib, applying the human squamous 
cancer cell lines HN5 and A431, which are sensitive to EGFR-targeting drugs. 
Erlotinib-resistant cells expressed significantly lower levels of EGFR than medium-
treated control cells. Furthermore, total levels and activation of Akt was increased 
and mRNA expression analyses revealed up-regulation of FGFR, PDGFR (platelet-
derived growth factor receptor) and fibronectin levels (Perez-Soler et al., 2003) 
Equivalent approaches with gefitinib were undertaken with different NSCLC cell lines 
that carry EGFR kinase domain mutations that sensitize cells to gefitinib or erlotinib 
treatment. The changes observed in resistant cells include: increased ligand- 
induced internalization of EGFR, down regulation of EGFR expression, loss of the 
EGFR kinase domain mutation, gain of the resistance conferring EGFR-T790M 
mutation, decreased EGFR-dependent Akt/NFkB signaling, loss of PTEN, as well as 
increased activation of Akt and increased sensitivity towards TNFα induced 
apoptosis (Kwak et al., 2005; Ando et al., 2005; Kokubo et al., 2005; Engelman et 
al., 2006). 
Two studies focusing on a long-term exposure of cells to EGFR-targeting therapeutic 
antibodies have been published so far. In one study, two pancreatic carcinoma cells 
with either primary sensitivity or resistance to cetuximab were exposed to the drug 
for 6 weeks under cell culture conditions. A relative decrease of EGFR surface levels 
as well as an up-regulation of the pro-apoptotic protein BAX (BCL2-associated X 
protein) (as compared to untreated control) was seen for the sensitive but not for the 
resistant cell lines. Interestingly transactivation of EGFR through FGF in the 
presence of cetuximab was observed for the primary resistant, but not for the 
sensitive cell lines (Huang et al., 2003). The latter finding could be indicative for a 
compensatory activation of FGFR upon EGFR blockage in pancreas carcinoma as 
possible mode of resistance to cetuximab (Liu et al., 2001).    
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In another study, cetuximab-resistant A431 cells from relapsed xenograft tumors 
were isolated after 280 days of treatment with the antibody. Interestingly, total EGFR 
expression was unaltered and long-term-treated cells retained normal in vitro 
sensitivity to cetuximab as compared to the parental cell line. Yet, cells isolated from 
the relapsed xenograft showed increased in vivo resistance to cetuximab and 
expressed increased levels of VEGF (vascular endothelial growth factor), paralleled 
with higher levels of angiogenesis in vivo (Viloria-Petit et al., 2001).  
 
1.4 Aim of this study 
The aim of this study was to investigate the action of EGFR-targeting compounds, 
exemplified by the TKI gefitinib and the monoclonal antibody cetuximab in cellular 
model systems. The ultimate goal of the work was to identify possible modes of 
sensitivity and resistance of model cell lines to these two classes of EGFR-specific 
cancer drugs.  
One approach utilized stably transfected cells or NSCLC cell lines endogenously 
expressing EGFR kinase domain mutations. The first model aimed to study the 
impact of EGFR mutations have on gefitinib or cetuximab therapy in a cellular 
system with a consistent genetic background. Furthermore, a panel of NSCLC cell 
lines was characterized in order to study the relevance of factors suggested to be 
involved in determining sensitivity or resistance to EGFR-targeting compounds. In 
addition, expression profiling of NSCLC cells was performed to identify novel 
candidate genes predictive for cellular response to gefitinib or cetuximab.   
In another approach, a panel of cancer cell lines was long-term exposed to gefitinib 
or cetuximab in order to monitor cellular alterations and to identify cellular factors 
that confer resistance to cancer cells upon treatment with these therapeutics. Two 
primary sensitive and two cell lines with primary resistance to EGFR-targeting 
therapeutics included in this examination were characterized in terms of sensitivity to 
cetuximab and gefitinib. Furthermore, a primary sensitive cell line was examined in 
detail in regard to the biological and molecular alterations conferred by long-term 
treatments. Finally, a candidate based expression analyses was carried out to 
identify genes that are differentially expressed in primary sensitive and resistant cell 
lines after long-term cultivation.  
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2. Material and Methods 
2.1 Material 
2.1.1 Laboratory instruments 
Agarose gel chambers (Mini-/ Wide Mini- SUB Cell - GT) BioRad 
Bacteria shaking incubator      New Brunswick 
Bioanalyzer (3100)       Applied Biosystems 
Blotting chamber       BioRad  
Cell counting chamber (Neubauer chamber)   Zeiss 
Cell culture incubator      Heraeus 
Centrifuges, table (5417R)      Eppendorf 
Centrifuge, cell culture (Omnifuge 2.0 RS)   Haereus 
Centrifuge, laboratory (RC5C)     Sorvall 
DNA Sequencer (3100 Genetic Analyser)   Applied Biosystems  
Electronic Pipet (Accujet)      Brand 
Heating thermostat       Haereus 
Immunoblot documentation system (Versa DocTM)  BioRad 
Laboratory shaker (ST5)      Hecht-Assistent  
Light microscope (Axiovert 25, Axiostar Plus)   Zeiss 
Magnet stirrer (MR3001K)      Heidolph 
Microwave        Neff  
Multipette        Eppendorf 
Nanodrop        Peqlab 
PCR apparatus (Gene Amp PCR System 9700)  Applied Biosystems 
pH-meter (pH211)       Hanna 
Pipettes (Reference)      Eppendorf 
Plate reader spectroscope (Mithras LB940)   Berthold 
Power supply, agarose gels (EPS601)    Amersham Pharmacia  
Power supply, SDS-PAGE (Power Pac 200)   BioRad 
Precellys apperatus       Peqlab 
Precision balances       Mettler 
         Satorius   
Real-time PCR system (ABI Prism 7900 HT)   Perkin Elmer  
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Sonification ultrasound-homogenizator (HD2070)  Bandelin 
SDS-PAGE chambers (Criterion)     BioRad 
UV documentation system      Syngene  
Vortex apparatus (VFC)      Janke & Kunkel 
Water treatment apparatus (Mili Q UF plus)   Milipore 
 
2.1.2 Software 
Agarose gel documentation (GeneSnapTM)   Syngene 
Cell QuestTM, FACSComp TM     Becton Dickinson 
Design of oligonucleotides (PrimerSelectTM)    DNASTAR 
DNA/protein sequence analyses  
(EditSeqTM, MegAlignTM, SeqManTMII)    DNASTAR 
Immunoblot documentation (Quantity One®)   BioRad  
Pharmacology data processing (GraphPad Prism®)  Graph Pad 
Plate reader spectrometer software (MicroWin 2000TM) Berthold 
SDS 2.1 real time data analyses software   Applied Biosystems 
Text processing, data processing and graphic software Microsoft Office 
 
2.1.3 Laboratory chemicals 
Acetic acid        Merck 
Agar-agar        Merck  
Agarose        Invitrogen 
Ampicilin        Applichem 
Aprotonin        Sigma-Aldrich 
Bovine serum albumin (BSA), fraction V    Applichem 
Bromphenol blue       Merck  
Calcium chloride       Merck 
Di-sodium hydrogen phosphate     Merck 
DMSO         Applichem 
dNTP mix (10mM ea. dNTP)     New England Biolabs  
Ethanol         Merck 
Ethidium bromide       Sigma-Aldrich 
Glycin         Merck 
Isopropanol        Merck 
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Kanamycin        Applichem 
LipofectamineTM2000 reagent     Invitrogen  
Loading dye solution for nucleotides (6x)   Fermentas 
LumiLight Western blotting substrate    Roche 
Magnesiumchloride-hexahydrate     Merck 
Methanol        Merck 
Mercaptoethanol       Merck 
Nonidet P40        Roche 
Nuclease-free water      Promega 
Peptone (from Casein pancreatic digestion)   Merck 
Phosphatase inhibitor cocktail set II    Calbiochem   
Ponceau S        Merck 
Protease inhibitor cocktail set III     Calbiochem  
Potassiumchlorid-dihydrate     Merck 
Propidium Iodide       Molecular Probes 
S.O.C.S. medium       Invitrogen 
Sodium acide       Merck 
Sodium acetate       Merck 
Sodium chloride       Merck 
Sodium dihydrogenphosphate     Merck 
Sodium dodecylsulfate (SDS)     Sigma-Aldrich 
Starting BlockTM (PBS) buffer     Pierce 
TAE buffer (50x)       Invitrogen 
Tris         Merck 
Triton X-100        Merck 
Tween-20        Merck  
XT MOPS running buffer (20x)     BioRad   
XT reducing agent (20x)      BioRad 
XT sample buffer (4x)      BioRad 
Yeast extract        Applichem  
Zeocin         Invitrogen   
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2.1.4 Consumables 
7900 HT Micro Fluidic Card (Real Time PCR; LDA)  Applied Biosystems 
Acrodiscs® PF syringe filter (Supor membrane)   Pall 
Blotting fiber pads       BioRad 
Blotting sandwiches (nitrocellulose membrane)   BioRad 
Cell culture dishes, plates & flasks  (NuncleonTM Surface) NUNC  
FACS tubes        Becton Dickinson 
Laboratory tubes (15ml/ 50ml)     Becton Dickinson 
Multipette CombiTips      Eppendorf 
PCR tubes, MicroAmp® tubes (Real Time PCR; LDA)  Applied Biosystems 
PCR tubes, standard      Biozyyme 
Petridishes for microbiology     Greiner 
Pipett tips        Eppendorf 
Plastic pipettes       Costar 
Precellys ceramic bead columns (1,4mm beads)  Peqlab 
Reaction tubes (1,5ml/ 2ml)     Eppendorf 
RNAeasy solution   Invitrogen 
RNAse-free pipett tips (Safeseal Premium)   Biozyme  
Sterile filtration units (SFCA)     Nalgene 
Steriflip® sterile filtration units (ExpressPlus membrane) Milipore 
Syringes for sterile filtration      Terumo  
 
2.1.5 Enzymes 
Anarctic phosphatase (5U/µl)     New England Biolabs 
DNA-polymerase I (Klenow) (5U/µl)    New England Biolabs 
Pwo polymerase (1U/µl)      PeqLab 
Restriction enzymes (listed in section 2.2.1.7.1)  New England Biolabs 
T4-DNA-ligase (400U/µl)      New England Biolabs 
 
 
 
 
 
 
2. Material and Methods    
   
27 
2.1.6 Antibodies 
Primary Antibodies 
Antigen  
 
Dilution Source Catalog number Supplier 
Cofilin 1:500 in 
TBST/BSA 
rabbit #3312 Cell Signaling 
E-Cadherin 
(clone 67A4) 
1:200 in 
TBST/Skim Milk 
rabbit #SC-21791 Santa Cruz 
EGFR 
(clone 1005) 
1:250 in 
TBST/Starting Block 
rabbit #SC-03 Santa Cruz 
EGFR, PE-labeled  10mg/ml rat #MCA 1784-PE Serotec 
ErbB2 
(clone 44E7) 
1:500 in 
TBST/Starting Block 
mouse #2248 Cell Signaling 
ErbB3 
(clone 66219) 
1:500 in 
TBST/BSA 
mouse #Mab-348 R&D 
Systems 
ErbB4 1:200 in 
TBST/BSA 
rabbit #SC-283 Santa Cruz 
HGFR 1:500 in 
TBST/BSA 
rabbit #SC-161 Santa Cruz 
N-Cadherin 
(clone 13A9) 
1:750 in 
TBST/Skim Milk 
mouse #05-915 Upstate 
Phospho-Akt (Ser473) 1:750 in 
TBST/Starting Block 
rabbit #9271 Cell Signaling 
Phospho-EGFR 
(Tyr1068) 
1:1000 in 
TBST/BSA 
rabbit #2234 Upstate 
Phospho-MAPK 
(Ser217/Ser221) 
1:1000 in 
TBST/BSA 
rabbit #9122 Cell Signaling 
Phospho-HGFR 
(Tyr1234/Tyr1235) 
1:150 in 
TBST/BSA 
rabbit #3126 Cell Signaling 
Vimentin 
(clone LN6) 
1:200 in 
TBST/Starting Block 
mouse #IF01 Calbiochem 
 
Secondary Antibodies 
Mouse-IgG 1:2000 horse #7076 Cell Signaling 
Rabbit-IgG 1:2000 goat #7074 Cell Signaling 
Mouse-IgG - FITC 10µg/ml goat #349031 Becton-
Dickinson 
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2.1.7 “Kits”  
BigDye® Terminator v3.1 cycle sequencing kit   Applied Biosystems 
First strand cDNA synthesis kit for RT-PCR   Roche 
HiSpeed plasmid Maxi kit      Quiagen 
Jetquick gel extraction spin kit     Genomed 
One cycle target labeling assay      Affymetrix 
Plasmid mini purification kit     Quiagen 
Proteome ProfilerTM array (Human phospho-RTK array kit) R&D Systems 
Quik Change® II XL site-directed mutagenesis kit  Stratagene 
RNeasy® Mini kit       Quiagen 
Sigma Spin™Post reaction clean up columns   Sigma 
Spectral calibration reagent kit     Applied Biosystems 
TaqMan® Universal PCR master mix    Applied Biosystems 
 
2.1.8 Vectors and oligonucleotides 
2.1.8.1 Oligonucleotides 
All oligonucleotides were purchased from Operon Biotechnologies. 
 
1) Oligonucleotides for site-specific mutagenesis: 
EGFR_T790M_fdw 
GTG CAA CTC ATC ATG CAG CTC ATG CCC 
EGFR_T790M_rev 
GGG CAT GAG CTG CAT GAT GAG TTG CAC 
 
2)  Oligonucleotides for EGFR sequencing: 
cEGFRS4  
CAA CAT GTC GAT GGA CTT CCA 
cEGFRS5 
GCA AAG TGT GTA ACG GAA TAG G 
cEGFRS6 
GTG AAA ACA GCT GCA AGG CC 
cEGFRS7 
GCC TAA GAT CCC GTC CAT CG 
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cEGFRS8 
AAT CCT CGA TGA AGC CTA CG 
cEGFRS9 
AGA GTG ATG TCT GGA GCT ACG GGG TGA C 
cEGFRS10 
CCA GCG CTA CCT TGT CAT TC 
cEGFRAS2  
GGC AGT TCT CCT CTC CTG C 
cEGFRAS3 
CTG TGG ATC CAG AGG AGG AGT AT 
cEGFRAS5 
AGA GTT CTC CAC AAA CTC CC 
cEGFRAS6 
TTC GCA TGA AGA GGC CGA TCC 
cEGFRAS7 
CCA GTT GAG CAG GTA CTG GGA 
cEGFRAS8 
GGG TTC AGA GGC TGA TTG TGA T 
 
2.1.8.2 Starting vectors 
Vector name/designation cloned by person/  
  sold by company 
EGFR-pcDNA3.1/v5-His Pia Stroh, Merck KGaA 
EGFR-del747-753-pcDNA3.1/v5-His Yvonne Wilhelm, Merck KGaA 
EGFR-L858R-pcDNA3.1/v5-His Yvonne Wilhelm, Merck KGaA 
pEF5/FRT/v5-D-TOPO® (Cat.# K6035-01) Invitrogen 
pcDNA3.1/v5-His© TOPO® (Cat.# K4800-01) Invitrogen   
 
2.1.8.3 Vectors constructed in this work 
EGFR- pEF5/FRT/v5  
EGFR was cut out via KpnI/PmeI restriction site from EGFR-pcDNA3.1/v5-His and 
was cloned via KpnI/EcoRV restriction sites into to the pEF5/FRT/v5 vector plasmid.  
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EGFR-L858R - pEF5/FRT/v5  
EGFR-L858R was cut out via KpnI/PmeI restriction site from EGFR-pcDNA3.1/v5-
His and was cloned via KpnI/EcoRV restriction sites into to the pEF5/FRT/v5 vector 
plasmid. 
 
EGFR-del747-753 - pEF5/FRT/v5 
EGFR- del747-753 was cut out via KpnI/PmeI restriction site from EGFR-
pcDNA3.1/v5-His and was cloned via KpnI/EcoRV restriction sites into to the 
pEF5/FRT/v5 vector plasmid. 
 
EGFR-del747-753/T790M - pEF5/FRT/v5 
Amino acid exchange mutation T790M was introduced into EGFR-del747-753 - 
pEF5/FRT/v5 plasmid by the Quick Change® II XL site directed mutagenesis kit 
under use of oligonucleotide primers EGFR_T790M_fdw and EGFR_T790M_rev. 
 
EGFR-L858R/T790M - pEF5/FRT/v5 
Amino acid exchange mutation T790M was introduced into EGFR-L858R - 
pEF5/FRT/v5 plasmid by the Quick Change® II XL site-directed mutagenesis kit 
under use of oligonucleotide primers EGFR_T790M_fdw and EGFR_T790M_rev. 
 
All constructs were validated via DNA seuquencing (sequencing primers are noted in 
section 2.1.8.1). 
 
2.1.9 DNA- and protein size standards 
1kb Plus DNA ladder       Invitrogen 
MagicMark® XP Western standard    Invitrogen  
SeeBlue® Plus2 prestained protein standard Invitrogen 
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2.1.10  Media and buffers  
 
Acid stripping solution 
NaCl                                                    0,5M 
Acetic acid                                           0,2M 
Filled up with sterile MiliQ water and adjusted pH 2,8 
 
 
Blocking buffer, immunoblot 
Bovine serum albumine (BSA)           5% (w/v) 
Filled up with TBST 
 
 
 
Basal agar, soft-agar assay 
Agar-agar                                           1,0% (w/v) 
Filled up with sterile water, autoclaved  
LB agar 
LB medium 
Agar-agar                                          1,5% (w/v) 
Filled up with sterile water, autoclaved  
LB medium 
Peptone (trypsine digested)               1% (w/v) 
Yeast extract                                      0,5% (w/v) 
NaCl                                0,5% (w/v) 
Filled up with sterile water, autoclaved  
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Lysis buffer, Laemmli 
Glycerol                                              192mM 
SDS                                                    0,1% (v/w)  
Tris, pH 6,8                                        25mM 
Bromphenol blue                                0,005% (v/w) 
Filled up with sterile MiliQ water 
Added freshly: 
XT reducing agent (20x)                   5% (v/w) 
Phosphate inhibitor mix (100x)         1% (v/w) 
Protease inhibitor mix (100x)            1% (v/w) 
 
Lysis buffer, RIPA (4x) 
NaCl                                                   600 mM 
Tris, pH 7,4                                        200 mM 
Nonidet P-40                                      4% (w/v) 
SDS                                                    2% (w/v) 
EGTA                                                 4mM 
Filled up with sterile MiliQ water 
Diluted with water and added freshly: 
XT reducing agent (20x)                    5% (v/w) 
Phosphate inhibitor mix (100x)          1% (v/w) 
Protease inhibitor mix (100x)             1% (v/w) 
 
MEM medium (2x), soft-agar assays 
Fetal calf serum (FCS)                       20% (v/v) 
L-glutamine (200mM)                         2% (v/v) 
Sodium pyruvate (100mM)                 2% (v/v) 
Sodium bicarbonate (7,5%)                6% (v/v) 
Filled up with sterile MiliQ water 
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Ponceau staining solution 
Ponceau S                                          0,25% (w/v) 
Acetic acid                                         10% (v/v) 
Filled up with MiliQ water 
 
 
Top agar, soft-agar assay 
Agar-agar                                           0,8% (w/v) 
Filled up with sterile water, autoclaved, stored at 4°C  
 
Transfer buffer, Electroblotting 
Tris, pH 8,3                                        12mM 
Glycine                                               96mM 
Methanol                                            20% (v/v) 
Filled up with MiliQ water, adjusted to pH 8,0 
 
Tris-buffered saline (TBS), 20x   
Tris, pH 7,4                                         500mM              
NaCl                                                    3M 
Filled up with MiliQ water and adjusted to pH 7,4 
 
Wash buffer, FACS 
BSA           1% (w/v) 
Sodium azid                                        0,03% (w/v) 
Filled up with TBST 
 
TBST   
TBS (20x)                                           5% (v/v) 
Tween-20 (20%)                                 0,25% (v/v)                     
Filled up with MiliQ water  
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Wash buffer, immunoblot 
BSA           1% (w/v) 
Filled up with TBST 
 
2.1.11 Cell culture media and supplements 
Mammalian cell lines were cultured in specific medium as designated in section 
2.1.13. All cell cultivation media were purchased from GIBCO. Human cancer cell 
lines were treated long term with cetuximab or gefitinib in medium supplemented 
with FCS purchased from Pan Biotech and tested in cell culture before use. 
 
Cell dissociation solution (1x)     Sigma  
EDTA-Trypsine (2,5%)      Invitrogen 
Hygromycin (50mg/ml)      Invitrogen 
L-glutamine (200nM)      Invitrogen 
MEM alpha powder        Invitrogen 
Sodium pyruvate (200nM)   Invitrogen 
Sodium bicarbonate (200nM)     Invitrogen 
 
2.1.12 Growth factors and cancer therapeutics 
Cetuximab (Erbitux)       Merck  
Gefitinib (Iressa)       Astra Zeneca 
Matuzumab (EMD72000), FITC labeled Merck 
      (labeled by Mr. Jürgen  
      Schmidt, TA Oncology) 
Paclitaxel       Sigma 
EGF, human recombinant      Upstate 
HGF       R&D Systems 
125I–Cetuximab       Merck 
       (labeled by Biotrend) 
PMA (phorbol 12-myristate 13-acetate)    Calbiochem 
TNFα       R&D Systems 
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2.1.13 Bacterial strains 
DH5α, chemically competent (transformation)   Invitrogen 
XL Blue, chemically competent (site-directed mutagenesis) Stratagene 
 
2.1.14 Mammalian cell lines 
A431 (ATCC Cat.# CRL-1555) 
DMEM + 10% FCS                                               Humane epidermoid cancer cell line 
 
A549 (ATCC Cat. # CCL-185)    
Calu-3 (ATCC Cat. # HTB-55)    
Calu-6 (ATCC Cat. # HTB-56) 
H1650 (ATCC Cat. # CRL-5853) 
H1781 (ATCC Cat. #CRL-5894) 
H1975 (ATCC Cat. #CRL-5908)  
H292 (ATCC Cat. #CRL-1848)    
H322 (Dr. Christa Burger, Merck)          
H4006 (kind gift from Dr. Jon Kurie, MD Anderson Cancer Center, Houston, USA) 
H460 (ATCC Cat. # HTB-177)    
HCC2279 (kind gift from Dr. Jon Kurie, MD Anderson Cancer Center, Houston, USA) 
HCC-827 (ATCC Cat. #CRL-2868)    
 
RPMI + 10% FCS  
+ 2mM L-glutamine + 1mM sodium pyruvate                        Human NSCLC cell lines 
 
Difi  (Dr. Christa Burger, Merck)                        
DMEM/F12 (1:1) + 10% FCS                                    Human colorectal cancer cell line    
 
Hela (Dr. Christa Burger, Merck)                        
DMEM + 10% FCS                                                       Human cervical cancer cell line 
 
MCF-7 (ATCC Cat.# HTB-22)                                                    
DMEM + 10% FCS                                                         Human breast cancer cell line 
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MDA-MB-231 (ATCC Cat.# HTB-26)                             Human breast cancer cell line 
DMEM + 10% FCS 
 
NIH3T3 (Cat.# F-2900, Invitrogen)                           
DMEM + 10% FCS + 100µg/ml zeocin                Murine embryonic fibroblast cell line 
 
NIH3T3                                                                           
stably transfected with EGFR variants (see section 2.2.2.5) 
DMEM + 10% FCS + 200µg/ml hygromycin        Murine embryonic fibroblast cell line 
 
SCOV-3 (Dr. Christa Burger, Merck)                                        
DMEM + 10% FCS                                                       Human ovarian cancer cell line 
 
SW707 (Dr. Christa Burger, Merck)                                      
DMEM + 10% FCS                                                    Human colorectal cancer cell line 
 
 
2.2 Methods 
2.2.1 Methods in molecular biology 
2.2.1.1 Introduction of plasmid DNA into bacteria 
Bacterial plasmid DNA was introduced into an E. coli strain via transformation of 
commercially available competent cells. Aliquots (50µl) of chemically competent 
E.coli DH5α (Invitrogen) were thawed on ice and then incubated with 10-50ng 
plasmid DNA. After 15 min incubation on ice, cells were subjected to a 1-minute heat 
shock at 42°C and directly chilled on ice for 5 min. A volume of 200µl SOCS medium 
was added to the 1,5ml tube, which was then incubated at 37°C for 40 min. When 
the plasmid DNA was for re-transformation, a volume of 50µl cell suspension was 
plated on LB-agar dishes containing the respective selection antibiotic (50µg/ml for 
ampicilin and kanamycin, 40µg/ml for zeocin). When plasmid DNA was from a 
ligation reaction, one volume of 50µl and one volume of 200µl were plated on the 
respective LB-agar dishes. Agar plates were incubated overnight at 37°C. 
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2.2.1.2 Plasmid preparation from bacteria  
Overnight cultures of E. coli cells carrying the plasmid of choice were inoculated with 
one colony from an agar plate transferred in flasks containing LB-medium and a 
selective antibiotic. The cell suspension was centrifuged and the bacterial plasmid 
DNA was isolated from the pellet with a kit according to the recommendations in the 
manufacturers manual (HiSpeed Plasmid Maxi kit or Mini Preparation kit). 
 
2.2.1.3 Agarose gel electrophoresis  
Nucleic acids were fractionated by size through horizontal agarose gel 
electrophoresis. This method has been used to analyse and purify specific DNA 
molecules from total DNA and RNA in a complex mixture. Agarose gels (containing 
0,7-1,5% agarose) were poured after mixing agarose with TAE buffer, heating in a 
microwave and addition of ethidium bromide (0,01%). After solidification of the gel, 
samples were mixed with 1/5-volume loading buffer (5x) and loaded into the 
respective wells. A current of 100 Volt was applied for 20-100 min. After completion 
of the run, DNA was visualized under UV light, photos were taken and documented 
with an integrated gel documentation system (Syngene). The size and mass of 
specific DNA molecules was estimated by the usage of size markers separated on 
gel in parallel to the loaded samples.   
 
2.2.1.4 Eluation of plasmid DNA from agarose gels 
Specific DNA molecules were cut out from the agarose gel and subsequently purified 
from agarose by the help of a kit (Jetquick Gel Extraction Spin kit). Agarose slices 
were transferred to 1,5ml tubes and DNA was purified according to the 
manufacturers guidelines in the manual. 
 
2.2.1.5 Nucleic acid quantification and determination of purification quality 
The exact quantification and quality determination of isolated DNA and RNA was 
performed by UV/Vis spectroscopy with a Nano-Drop 1000 UV/Vis spectrometer 
(Nanodrop). This apparatus measures the absorption at 260nm (for the nucleic acid 
content) and 280nm (for the protein content) in the test solution. The ratio (r) 
260nm/280nm is therefore indicative or the purity of the sample, with 1,8<r<2 as the 
optimal range. The concentrations of nucleic acids can be determined according to 
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their OD260nm, where an OD260nm=1 correlates to 50µg/ml double-strand DNA and 
40µg/ml RNA, respectively. For RNA isolations, integrity of RNA molecules was 
tested determining the ratio of 28S and 18S RNA by the help of a kit (mRNA Pico 
Kit) and analyses via a spectrometer (Bioanalyzer 3100). Intact RNA has a 28S/18S 
RNA ratio of 2,0 and here ratios between 1,8 and 2,0 were considered as 
acceptable. 
 
2.2.1.6 Polymerase chain reaction (PCR) 
PCR allows the rapid amplification of specific DNA fragments from complex mixtures 
of DNA molecules. The applications of the PCR are numerous, since it has been 
refined and can be used for various methods that base on the classical PCR 
technique. The methods used in this work that relate to the classical PCR reactions 
include the detection of DNA fragments in biological isolates, directed mutagenesis 
and quantitative real-time PCR.   
 
The reaction mixture for DNA fragment detection is: 
 1µl template DNA (10-20ng) 
 5µl buffer (10x) 
 1µl dNTP mixture (10mM ea.)  
 0,5µl oligonucleotide I (100µM) 
 0,5µl oligonucleotide II (100µM) 
1µl Pwo polymerase (1U/µl) 
 
The employed PCR program was dependent on the length of the template fragment, 
on the used oligonucleotides and on the purpose of the PCR reaction. This is 
reflected by variable elongation times and variable annealing temperatures. The 
variable annealing temperatures for the oligonucleotides are indicted in the material 
section of this work. The variable elongation times are dependent on the length of 
the fragment to be amplified. An elongation time of 1 min per 1kb template was 
calculated for reactions with the proofreading Pwo DNA-polymerase. The terminating 
elongation step was run for the cycle elongation time multiplied by four. Steps 2) to 
4) were repeated over 30 cycles. 
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The standard protocol used for the PCR reaction was: 
1) 2 min at 95°C (initial denaturation) 
2) 45 sec at 95°C (denaturation) 
3) 30 sec at variable temperature [60°C to 68°C] (annealing) 
4) Variable time [30 sec to 4 min] at 72°C (elongation) 
5) Variable time [2 to 16 min] at 72°C (terminating elongation) 
 
2.2.1.7 Automated fluorescence DNA sequencing 
For the determination of the sequence of defined stretches of DNA molecules, an 
automated fluorescence DNA-sequencing reaction, which emerges from the Sanger 
DNA sequencing method, has been used (Sanger et al., 1977). A PCR reaction with 
the DNA template of interest and a single primer is performed with a high molar 
amount of desoxynucleotides and a low molar amount of fluorescence tagged 
didesoxynucleotides (using different dyes for each of the four nucleotides). The 
catalyzed integration of didesoxynucleotides into the amplified DNA molecules leads 
to termination of the amplification reaction, which causes the generation of a 
heterogeneous mixture of DNA molecules with different lengths. These are 
separated via a capillary electrophoresis and subsequently the fluorescence tags 
can be detected with a laser, which allows the identification of the DNA sequence 
over length of approximately 400 nucleotides. 
 
The PCR reaction has been performed with the following reaction mixture: 
 1µl  DNA (c.a. 20ng) 
 1µl  oligonucleotide primer (5pmol) (see section 2.1.8.1 for sequences) 
 2µl  reaction buffer (5x) 
 4µl  Big Dye reaction mix (includes dNTPs, ddNTPs, Ampli-Taq FS) 
 12µl  nuclease-free water 
 
The reaction was performed with the following PCR protocol (25 cycles): 
 10 sec at 96°C 
 10 sec at 62°C 
 4 min at 60°C 
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2.2.1.8 Enzymatic manipulation of DNA 
2.2.1.8.1 Restriction digestion of plasmid DNA 
Enzymatic digestion of purified DNA molecules was performed with specific 
restriction enzymes under optimal temperature and buffer conditions, as indicated in 
the following table. All restriction enzymes and buffers were received from New 
England Biolabs. 
 
Restriction enzyme Reaction buffer  Temperature optimum 
EcoRV 3 37°C 
KpnI 1 37°C 
PmeI 4 37°C 
KpnI/EcoRV 2 37°C 
KpnI/PmeI 2 37°C 
  
Different reaction conditions were used for analytic (reaction time: 2 h) or preparative 
digestions (reaction time: overnight). 
 
Reaction mixture (total volume 20µl) for analytic digestions: 
 1µl DNA (50-200 ng) 
 2µl reaction buffer (10x) 
 0,5µl restriction enzyme I 
 (0,5µl restriction enzyme II - optional) 
 16,5µl (16,0µl) nuclease-free water 
 
Reaction mixture (total volume 50µl) for preparative digestions: 
 2µl DNA (1-2 µg) 
 5µl reaction buffer (10x) 
 1,5µl restriction enzyme I 
 (1,5µl restriction enzyme II - optional) 
 41,5µl (40,0µl) nuclease-free water 
 
2.2.1.8.2 Dephosphorylation of vector DNA at 5’ strand ends  
Target vector DNA was enzymatically dephosphorylated at its 5’ end to prevent self- 
ligation in the ligation reaction. Anarctic phosphatase catalyzes the hydrolysis of the 
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phosphate group at the 5’ end of nucleic acid strands and at desoxynucleotides and 
thereby generates 5’ OH ends at its substrates. The reaction was performed for 15 
min at 37°C and the following reaction mixture has been used. 
 
Reaction mixture for the 5’ end dephosphorylation of vector DNA by Antarctic 
phosphatase 
 2µl Antarctic phosphatase buffer 
 1µl Antarctic phosphatase (5 units) 
 10µl DNA (<1µg) 
 7µl H2O 
 
The reaction was stopped via heat inactivation (5 min at 65°C). 
 
2.2.1.8.3 Preparation of DNA for ligation  
Restriction digested and 5’ end dephosphorylated DNA was purified by centrifugation 
in Sigma Spin™Post Reaction Clean Up Columns as recommended by the 
manufacturer. 
 
2.2.1.8.4 Ligation of manipulated DNA with T4 Ligase  
The enzyme T4 ligase catalyzes the formation of phosphodiester bonds between 
juxtaposed 3’ OH and 5’ phosphate DNA strand ends in an ATP dependent reaction. 
T4 ligase is capable to ligate double-stranded DNA with blunt or cohesive ends and 
therefore e.g. allows the integration of DNA inserts into DNA target vector plasmids. 
The reaction was performed at 16°C overnight and subsequently the whole ligation 
reaction mixture was subjected to bacterial transformation as described. 
 
The reaction was set up in the following mixture (total volume 10µl) in PCR tubes: 
 
 1µl digested, dephosphorylated and purified vector DNA (5-10ng) 
 5µl digested and purified insert DNA (c.a. 25 ng) 
 1µl ligase buffer (10x) 
 1,5µl T4 ligase (400U/µl) 
 1,5µl nuclease-free water  
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To estimate the ligation efficacy, control ligations were performed with the reaction 
mixture without insert DNA (ratio of self-ligated vector) or with the reaction mixture 
without T4 Ligase (ratio of uncut vector/insert DNA) and also subjected to bacterial 
transformation. The calculation of the ratio of colonies on the agar plates from control 
reactions to colonies from bacteria with plasmids from the complete reaction mixture, 
allows estimating the ratio of colonies with correctly ligated vectors.  
 
2.2.1.8.5 Site-directed mutagenesis of vector constructs 
For the introduction of site-specific nucleotide exchanges into DNA vector plasmids 
the Quik Change® II XL site-directed mutagenesis kit has been applied. Two 
complementary oligonucleotides containing the mutation of choice were used 
together with PfuTurbo proofreading DNA-polymerase to amplify the template vector 
plasmid, which produces plasmids with the mutation. Plasmids were incubated with 
DpnI enzyme, which specifically degrades methylated template DNA isolated from E. 
coli while DNA amplified with Pfu-polymerase in vitro remained intact and was 
transformed into XL1-Blue competent cells. All steps were performed as 
recommended by the manufacturer of the kit. 
 
The sample mix for the PCR reaction was: 
 
5µl reaction buffer (5x) 
1µl DNA template (10ng) 
1µl Primer 1 (125ng) 
1µl Primer 2 (125ng) 
2µl dNTP mix (10mM each) 
1,5µl PfuTurbo DNA polymerase (2,5U/µl) 
Filled up to 50µl with nuclease-free water.   
 
The PCR program was run with the following parameters: 
1) 30 sec at 95°C (initial denaturation) 
2) 30 sec at 95°C (denaturation) 
3) 1 min at 55°C (annealing) 
4) 1 min/kb of plasmid length at 68°C (elongation) 
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For introduction of the T790M mutation into pEF5/FRT/V5-EGFR vector plasmids 
(see section 2.1.8.1), elongation time was 10 min per cycle and 16 cycles (of steps 
2-4) were performed. All steps were carried out as recommended by the 
manufacturer of the kit. 
 
2.2.1.9 RNA expression analyses 
Analyses of the mRNA expression in differentially treated cells has been used to 
display the biological differences caused by specified treatment condition within one 
or more cell lines. 
 
2.2.1.9.1 Isolation of total RNA from mammalian cells   
Total cellular RNA was isolated from human cancer cell lines with the help of a 
commercially available kit according to manufacturer’s recommendations (Rneasy 
Mini Kit). The preparation process was conducted carefully with RNAse-free pipette 
tips and reaction tubes. Working gloves were changed frequently and working 
surfaces were rinsed with RNAse Away solution.    
 
2.2.1.9.2 Reverse transcription of mRNA for cDNA synthesis 
Isolated total RNA that was used for quantitative mRNA expression analyses via 
Taqman® Low Density Arrays (LDA; micro fluidic cards) was transcribed into 
complementary DNA (cDNA) with the First strand cDNA synthesis kit for RT-PCR. 
The initial template concentration of total RNA was 1µg per 20µl reaction mixture. 
The cDNA synthesis was performed by using a hexamerix (“random”) primer 
mixture. 
 
Synthesis of cDNA was carried out with the following reaction mixture: 
 
2µl reaction buffer (10x) 
4µl MgCl2 (25mM) 
2µl random hexameric primer mixture 
1µl RNAse inhibitor (1000U/µl) 
0,8µl AMV reverse transcriptase (~ 500 U/µl) 
2µl total RNA (1µg) 
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Filled up to 20µl with nucelase-free water. 
 
The following steps followed the manufacturer’s guidelines. Samples were frozen at 
80°C, if not used directly for cDNA analyses with Real-time PCR. 
 
Reverse transcription and sample processing of the RNA which was analysed by  
Affymetrix Whole Genome DNA chips is described in section 2.2.1.7.6.4. 
 
2.2.1.9.3 Quantitative real-time PCR analyses with Taqman® Low Density 
Arrays (LDA) 
Real-time PCR allows an online documentation of the quantitative increase of the 
amplification product during the running PCR. This allows determination of the 
relative starting amount of cDNA in the sample and thus enables comparisons of 
mRNA expression in between samples from different sources. In this work Taqman® 
Low-density arrays (LDAs; micro fluidic cards) were employed to compare the mRNA 
expression levels from long-term gefitinib or cetuximab treated A431 cell in 
comparison to medium-treated control cells.  
Real-time PCR with LDAs allow parallel probing with 12 to 380 probes for different 
candidate genes on one single chip system. Fluorescence-tagged oligonucleotides 
with specificity for respective candidate genes are used as probes. They are 
covalently linked with a rhodamine-derivate (TAMRA) as a reporter dye at their 5’ 
end and with a fluorescein-derivate (FAM) as a signal quencher at their 3’ end. 
During the PCR reaction, probes are hybridizing with the cDNA templates. This 
triggers Ampli-Taq polymerase binding to the 5’ end of the oligonucleotides and 
release of the TAMRA dye through the 5’-3’ exonuclease activity of the polymerase. 
Free TAMRA dye produces fluorescence signals (emission at 530nm), whose 
intensity is correlated with the amount of amplification product, which were detected 
by an ABI Prism 7900 HT apparatus. A signal threshold (Ct) is defined for every 
probe, which is reached after variable cycle numbers by every sample under 
examination. A high Ct value therefore corresponds to a low amount of cDNA 
template in the respective sample. To determine efficiencies (Eff) of PCR reaction 
with the different probes, variable concentrations of reference cDNA were loaded i) 
on a LDA chip carrying probes for endogenous control genes (“housekeeper” genes; 
Effcontrol) and ii) on a LDA chip carrying probes for candidate genes (Effcandidate). 
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Concentrations of cDNA from different samples were determined via capillary 
electrophoresis and adjusted via dilution before starting PCR reactions. 
 
The reaction mixture for Taqman-PCR was: 
 
25µl H20 
25µl cDNA (200ng/µl) 
50µl Universal Master Mix (Cat.# 4304437; Applied Biosystems) 
 
Relative quantification of candidate gene mRNA was performed by normalization 
against a mean value calculated from a panel of household genes, whose 
expression has been shown to constant under treatment of cells with EGFR-directed 
cancer therapeutics (Radonić et al. 2004). Relative expression of candidate genes in 
drug treated (dt) in relation to untreated cells (ut) has been calculated by the 
following formula: 
 
Relative Expression of candidate gene =  
Effcandidate 
(Ctdt - Ctut) x Effcontrol 
(Ctdt - Ctut) 
 
Ctdt = Threshold cycle in drug treated cells 
Ctut = Threshold cycle in untreated control cells 
Effcandidate = Efficacy of specific candidate gene 
Effcontrol = Efficacy of control gene 
 
A relative expression value >1 means that the corresponding candidate gene 
expressed higher in cells treated with the respective drug than in untreated control 
cells. All measurements with probes for candidate genes were performed as 
triplicates, measurements with probes for endogenous control genes as duplicates. 
The evaluation of data probed via Taqman® LDAs (micro fluidic cards) was kindly 
performed by Mr. Jens Baumgärtner in the laboratory of Mr. Tobias Haas, LSA, 
Merck KGaA.    
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2.2.1.9.4 Quantification of the genome-wide mRNA expression with Affymetrix 
whole genome DNA chip arrays 
Transcription of cDNA, sample labeling, clean up and hybridization control was 
accomplished with the Affmetrics Gene Chip One Cycle Target Labeling and Control 
Reagents kit as described in the manufacturer’s protocol and analysed on an 
Affymetrix Gene Chip Array Station. Whole genome expression analyses was kindly 
performed by Mrs. Melanie Kühnl in the laboratory of Dr. Detlef Güssow, TAR, Merck 
KGaA.    
 
2.2.1.9.5 Statistical methods for evaluation and interpretation of the whole 
genome expression analyses 
Preprocessing of the probe-level Affymetrix data was conducted using VSN 
(variance stabilization and calibration) (Huber et al., 2002), followed by computing 
probe set summaries with the median polish algorithm of RMA (Irizarry et al., 2003). 
In a global prefiltering step, only probe sets with a) intensity values above 100 in at 
least two cell lines, b) a standard deviation above 0,5 on the logarithmic scale (base 
2), and c) matches to RefSeq transcripts of unique human genes, where chosen for 
the analyses. For the analyses of NSCLC cell lines, differentially expressed genes in 
the comparison of sensitive and resistant cell lines were identified using a moderated 
t-test. All microarray analyses were performed using Bioconductor software 
(Gentleman et al., 2004). Statistic data prefiltering and processing was kindly 
performed by Dr. Anja von Heydebreck, Bioinformatics, Merck. 
 
2.2.2 Methods in mammalian cell culture and pharmacology 
2.2.2.1 General cell culture conditions and techniques 
All adherent mammalian cells lines used for this work, were cultured in cell line 
specific full medium, as indicated in section 2.1.13. Incubation of cell lines was at 
37°C and 5% CO2. For passaging, cells were washed once with D-PBS and 
detached from the plate by incubation with 1,5ml Trypsin/EDTA (2,5%) for 1-5 min at 
37°C. Detached cells were resuspended in 20ml full medium, the suspension was 
centrifuged for 3 min at 1200rpm and 4°C and the cell pellet was again carefully 
resuspended in a defined volume of full medium. Depending on the specific 
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experimental purpose, the cell suspension was then transferred to variable formats 
of cell culture dishes. 
 
2.2.2.2 Calculation of cell numbers 
A small volume of a cell suspension (50-200µl) was mixed with an equivalent volume 
of trypane blue solution (0,4%) and transferred to a Neubauer counting chamber. 
Only unstained (viable) cells are counted under the microscope, since trypane blue 
can penetrate only dead cells. To calculate the number of viable cells per millilitre of 
the suspension, the number of cells counted in one big square (which is subdivided 
into 9 small squares) gets multiplied by factor 1x104 (counting chamber dilution 
factor) and by factor 2 (dilution factor for trypane blue). Cell numbers of four big 
squares were determined and their mean value was used for calculation.  
 
2.2.2.3 Freezing and thawing of cell lines 
Cell lines were frozen in liquid nitrogen for long-term storage purposes. After 
trypsinizing, centrifugation and resuspension of cells in full medium, aliquots of the 
suspension (500µl) were transferred to cryo vials. An equivalent volume of freezing 
medium (full medium + 20% FCS + 20% DMSO) was added to the cryo vials, the cell 
suspension was carefully mixed and chilled stepwise (2 h at –20°C, 2 days at –80°) 
an finally stored in liquid nitrogen.  
 
2.2.2.4 Light microscopy  
Phase contrast microscopy has been used for documentation of cellular morphology. 
Cells were seeded in variable densities on 6-well cell culture dishes and morphology 
was observed under a light microscope at 40x and 400x magnifications. Microscope 
was adjusted according to the guidelines of Köhler (Köhler, 1893) before use. Photos 
were taken and processed by an integrated photo documentation system. 
 
2.2.2.5 Generation of stably transfected NIH3T3 cell lines 
For the generation of murine NIH3T3 cells stably transfected with variants of EGFR, 
genetically manipulated NIH3T3 cells, which are part of the Flp-In™ transfection 
system, have been used (Cat.# R761-07, Invitrogen). These cells possess a genome 
wide unique Flp recombination target (FRT) site, which is located in the coding 
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sequence of a zeocin resistance gene. For generation of stably EGFR expressing 
Flp-In cell lines, NIH3T3 cells were co-transfected with the pEF5/FRT/v5 expression 
vector transferring resistance to hygromycin and coding for EGFR and the Flp 
recombinase expression plasmid pOG44. Flp recombinase catalyses site-specific 
DNA recombination and therefore allows integration of EGFR into to the FRT locus. 
Upon integration of the plasmid, cells lose zeocin resistance, but gain resistance to 
hygromycine, allowing specific selection of stably transfected cells. 
For transfection 5x105 cells per well were seeded in a 6-well culture plate and 
allowed to attach on the surface overnight. Transfection of cells was performed with 
Lipofectamine™2000 reagent according to the manufacturer’s recommendations. 
Transfected cells were incubated under standard cell culture conditions and medium 
was changed 6 h post transfection. After incubation for two days, selective medium 
containing hygromycin (200µg/ml) was added to the cells. This step was repeated 
once each day for 4 days and plates were checked every day for viable cells. One 
well with untransfected cells was as well treated with selection medium. No viable 
cells could be observed after two days of selection with hygromycin in this control 
well. Surviving cells from the transfections were permanently propagated in selective 
medium, expanded, frozen and used or experiments. Since the integration locus of 
EGFR is constant in every case, subcloning of colonies was not necessary. Stable 
expression of EGFR in the respective cell lines has been validated via FACS 
analyses (see section 2.2.2.10).  
 
2.2.2.6 Generation of long-term gefitinib or cetuximab-treated human cancer 
cell lines 
Human cancer cell lines were treated for 8-15 months with gefitinib or cetuximab to 
examine the effects of long-term exposure to these drugs in vitro. Cells were thawed 
from low passage cryo stocks and cultured with their specific medium in 75T cell 
culture flasks. Treatment medium containing gefitinib or cetuximab was sterile 
filtrated and changed every 3-4 days. When necessary, cells were passaged and 
seeded in low density on fresh flasks with treatment medium. Biological activity of 
therapeutics after sterile filtration was shown once and activity after storage at 4°C 
was shown periodically by monolayer growth assays with Difi cells, which are 
hypersensitive to gefitinib and cetuximab. 
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The starting concentrations of the therapeutics correspond to the EC50 concentration 
of the therapeutic in the respective cell line and are indicated in the table below. 
Concentrations of gefitinib were stepwise escalated once the cells resumed growth 
under the current doses. To reduce the bias through off-target effects, maximum 
concentration for dosis escalation with gefitinib was 10µM. 
With the exception of Difi cells, no EC50value could be determined for cetuximab in a 
monolayer growth-inhibition assay. Therefore A431, H460 and SW707 cells were 
treated with constant concentrations of cetuximab, while Difi cells were also doses 
escalated with cetuximab. 
 
            Starting Concentration                Final Concentration 
Cell line 
           Gefitinib           Cetuximab            Gefitinib         Cetuximab 
A431 0,5µM 33µg/ml (150nM) 10µM 33µg/ml (150nM) 
Difi 0,05µM 0,22µg/ml (1nM) 1µM 5µg/ml (25nM) 
H460 5µM 33µg/ml (150nM) 10µM 33µg/ml (150nM) 
SW707 5µM 33µg/ml (150nM) 10µM 33µg/ml (150nM) 
 
2.2.2.7 Monolayer growth inhibition assays with Wst-1 reagent 
Monolayer growth assays were performed to study the growth inhibitory effect of 
gefitinib and cetuximab on human cancer cells. Cells were counted, centrifuged, 
resuspended in full medium, seeded in flat bottom 96-well plates (50µl per well) and 
allowed to attach to the plate. The number of cells seeded on per well varied by the 
cell line (1x103 cells per well for SW707 and H460, 3x103 cells per well for Calu3 and 
Difi and 2x103 cells per well for all other cell lines). After full attachment to plates, 
50µl starvation medium (without serum) containing the therapeutics in variable 
concentrations was given to the wells. Cells were incubated under standard cell 
culture conditions for five days. For evaluation 10µl of Wst1 reagent were added to 
each well and incubated for 2 h. Wst1 is a tetrazolium salt, which is cleaved to 
produce formazan by viable cells. Finally, absorbance at 440 nm was determined via 
a spectrometer (Mithras plate reader). To determine the pharmacological 
background for each cell line, cells were treated with 100µM Paclitaxel, which 
effectively kills all cells in the respective well. EC50 values were calculated by the 
Graph Pad Prism software, after subtraction of the pharmacological background, 
normalization to the mean value of medium-treated control cells, log-transformation 
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of the x-axis and sigmoidal dose-response (variable slope) regression. Quantification 
of every data point was carried out at least as triplicate. 
 
2.2.2.8 Colony formation assay in a soft-agar matrix 
Colony formation assays were performed to study the growth inhibitory effect of 
gefitinib and cetuximab on human cancer cells in an agar matrix format. In this assay 
cells cannot attach to a culture plate surface, but are exposed to contact-free growth 
conditions. This assay therefore requires special tumorigenic capabilities, other than 
those displayed under cellular adherence at culture plate surfaces. 
For assay preparation, equal volumes of 2x MEM-full medium (warmed to room 
temperature) and basal agar (warmed to ~ 52°C) were mixed and 750µl of this 
mixture is transferred to each well on 24-well plates. These plates were either used 
directly for soft-agar assays or stored at 4°C. Cells were trypsinized, resuspended 
and counted, then centrifuged and resuspended in a defined volume of 2x MEM-full 
medium. The cell number per well was variable, depending on the cell line (a cell 
number of 5x103 cells per well was used for the H460 cell line; 1,5x104 cells per well 
for stably transfected NIH3T3 cells; 5x104 cells per well for Calu3 and H1781 cell 
lines and 3x104 cells per well for all other cell lines). Top agar solution (warmed to ~ 
52°C) was carefully mixed with cell suspension and 750µl of this mixture is 
transferred on top of the solidified basal agar layer. Plates are incubated overnight 
under standard cell culture conditions. 
Treatment solutions were prepared from serum-free medium supplemented with 
variable doses of EGF or therapeutics and added on top of the agar layers. 
Treatment solutions were 5x concentrated, sterile filtrated and added in a volume of 
375µl per well (total volume of assay is 1875 µl). Plates were cultured under 
standard conditions for 6-10 days. For evaluation 200µl of Cell Titer Blue solution are 
added to the wells and incubated for 2-8 h. Cell titer blue solution contains resazurin, 
which is processed by respiratory chain components of viable cells to produce the 
fluorescent product resorufin. The fluorescence signal was quantified with a plate 
reader (excitation: 540nm, emission: 600nm). The EC50 values were determined as 
described for the monolayer growth assays. Quantification for every data point was 
carried out at least as triplicate. 
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2.2.2.9 Short-term treatment of cell lines with EGF and cancer therapeutics for 
protein lysate preparation 
Mammalian cell lines were subjected to a short-term ligand stimulation and treatment 
with cancer therapeutics to study the dynamics of marker protein activation and 
inactivation in their protein lysates. A total cell number of 7,5x105 cells per well were 
seeded on 6-well plates, allowed to attach to the plate surface, washed once in 
serum-free medium and serum starved overnight. The next day cells were exposed 
45 min to serum-free medium containing variable doses of gefitinib and cetuximab 
under standard culturing conditions. Then cells were stimulated by directly adding 
EGF to the wells and again incubated for 10 min. Thereafter cells were harvested as 
described in section 2.2.3.1.1. 
 
2.2.2.10 Detection of EGFR surface expression via fluorescence assisted cell 
sorting (FACS) 
FACS was employed to analyse the presence and determine the relative quantity of 
EGFR on the surface of mammalian cells. Cells were harvested from culture flasks, 
counted, pelleted by centrifugation, washed once with cold D-PBS and resuspended 
in a defined volume of ice-cold FACS wash buffer (1% BSA, 0,03% sodium azide in 
D-PBS) to adjust cell density in the suspension (1x106 cells/ml). A volume of 1 ml 
suspension was transferred to FACS tubes and washed again with FACS wash 
buffer. Cells were centrifuged and incubated with 10µg/ml FITC-conjugated 
matuzumab (e.g. for EGFR expression analyses in NIH3T3 cells) or with 10µg/ml 
PE-conjugated rat-anti-human EGFR antibody (e.g. for EGFR expression analyses 
in long-term-treated A431 cells) for 15 min on ice with repeated mixing. Cell pellets 
were washed three times with FACS wash buffer and resuspended in FACS wash 
buffer containing 100µg/ml propidium iodide (PI) to discriminate dead from viable 
cells. When carrying out indirect stainings, cells were incubated with FITC-
conjugated secondary antibody for 15 min on ice, washed three times and 
resuspended in FACS buffer containing PI. Cells were analyzed on a Becton 
Dickinson FACScalibur flow cytometer. For evaluation and quantification of the 
assay the median channel signal from every population was transformed by the help 
of Cell Quest software into absolute arbitrary units, in order to compare the signal 
intensity between distinct cell populations. 
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2.2.2.11 Internalization of radioactively labeled 125I-cetuximab in A431 cell 
lines 
To study differences of A431 cells that long-term-treated with cancer therapeutics in 
the capacity internalize cetuximab, radioactively labeled cetuximab was used to track 
cellular uptake of this antibody. Cells were seeded in 24-well cell culture dishes and 
starved overnight in serum free medium. On the next day cells were washed in ice-
cold serum free medium and incubated in ice-cold serum free medium containing 
2nM 125I-cetuximab for 2 h to label surface EGFR. To start internalization the 
temparature was shifted to 37°C for variable durations (5 to 60 min) and thereafter 
cells were washed with ice-cold serum-free medium to remove unbound ligands. 
Bound ligands were dissociated from the cells by adding ice-cold stripping buffer and 
cells were again washed with ice-cold serum-free medium. The washing fraction was 
then combined with the stripping fraction to obtain all not-internalized ligands. Cells 
were lysed in 1M NaOH, wells were washed with medium and again both fractions 
were combined to obtain all internalized ligands. All quantifications of 125I-cetuximab 
were carried out as triplicates with a LKB Wallac 1277 Gammamaster counter. 
 
2.2.2.12 In vivo pharmacology with murine tumor xenografts upon treatment 
with cancer therapeutics 
Drug sensitivity of certain cell lines to gefitinib and cetuximab was examined via 
xeno-transplantation of cells into mouse models, which were subsequently subjected 
to treatment. These in vivo studies are of particular interest since they may closely 
resemble the situation in human cancer patients. Female CD1 nu/nu mice (e.g. used 
for H292 and H1650 cell line xenografts) and BalbC nu/nu mice (e.g. used for H1975 
and Calu6 cell line xenografts) were 4-5 weeks old when obtained from Charles 
River and allowed to accustom to the mouse facility for 1-2 weeks. NSCLC were 
harvested, resuspended in PBS and an equal volume of Matrigel and concomitantly 
injected subcutaneously into the left or right flank of the mice (5x106 cells in 100µl). 
At a tumor size of 70-80mm3 mice were randomized and then treated twice per week 
i.p. with 15mg/kg cetuximab in 0,5 ml sterile PBS (0,5ml PBS vehicle) or daily p.o. 
with 40mg/kg gefitinib (1ml 0.5% Tween-80/physiol. NaCl). Each treatment group 
consisted of 10 mice and treatment periods varied depending on tumor growth as 
noted in the results section. Tumor sizes were determined via measurement of tumor 
width (w) and length (l) followed by calculation of the tumor volumes (length [mm] x 
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width [mm2]/2 = tumor volume [mm3]). After sacrification of the mice, the tumors were 
carefully resected, directly frozen in liquid nitrogen and stored at -80°C. Mouse 
husbandry and conduction of xenograft experiments was kindly performed by Mr. 
Gerhard Schuster and Mrs. Monika Schaefer in the laboratory of Dr. Christiane 
Amendt, TA Oncology, Merck.    
 
2.2.3 Methods in protein analyses and biochemistry 
2.2.3.1 Preparation of protein lysates 
2.2.3.1.1 Protein extraction from cell lines 
Protein lysates were prepared from cell lines grown on variable cell culture dish 
formats, depending on the experimental context. Two different buffers have been 
used or lysate preparation: RIPA buffer and Laemmli buffer (compositions are noted 
in section 2.1.9). The use of non-denaturating RIPA buffer allows quantification of 
the protein content in the lysate, which is of importance when the relative protein 
expression between different cell lines is examined. Denaturating Laemmli buffer 
was used for cell lysis when protein modification by phosphorylation was studied.  
Prior to lysis cells were treated with growth factors or tumor therapeutics as indicated 
in the figure legends of the results section. Cells were transferred from the incubator 
on ice and immediately washed with ice-cold D-PBS. Cells were harvested after 
addition of lysate buffer (freshly supplemented with phosphatase inhibitor and 
protease inhibitor cocktails). Lysates were sonified on ice with a ultrasound 
homogenizator (permanent; 15 sec; 40% power) to shear genomic DNA and improve 
solubilization of proteins from subcellular membrane fractions. Centrifugation (30 
min; 14000rpm; 4°C) helped to clear lysates. The supernatant from RIPA lysates 
was subsequently subjected to quantification, while Laemmli buffer lysates were 
denaturated by boiling (10 min; 95°C). 
 
2.2.3.1.2 Protein extraction from murine xenograft tumors 
Murine tumors from xenografts were carefully dissected on ice and representative 
pieces from the middle of the tumor were transferred to Precellys ceramic bead 
columns (1,4mm beads). An adequate volume of RIPA buffer (3x) was added and 
tumor tissue was destroyed by subjection to a Precellys 24 homogenizator (30 sec; 
12000rpm; 4°C). The ceramic beads were washed twice with cold sterile water and 
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combined with the 3x concentrated RIPA buffer. The combined lysate was 
subsequently treated as described for standard RIPA lysates.  
 
2.2.3.2 Determination of protein concentrations 
Protein concentrations in RIPA buffer lysates were determined via the BCA 
(bicinchoninic acid) Protein Assay kit. To generate a standard curve dilutions of a 
BSA stock solution were made (concentrations were from 0 to 1000µg/ml). To 
determine the protein concentrations from a sample, two different dilutions were 
generated (1:4 and 1:12) and spotted on a flat bottom 96-well plate together with the 
standard samples (every data point was determined as duplicate). The assay was 
then performed as recommended by the manufacturer and evaluated via detection of 
the absorption at 550nm with a plate reader spectrometer. The concentration of 
RIPA lysates was adjusted according to the experimental purpose by diluting the 
samples with RIPA buffer, then XT reducing agent (20x) and XT loading buffer (4x) 
were added and samples were denatured as described above.  
 
2.2.3.3 SDS-polyacrylamide-gelelectrophoresis (SDS-PAGE)  
Separation of proteins by their molecular weight was accomplished via sodium 
dodecyl sulphate polyacrylamide gelectrophoresis (principle described in Laemmli et 
al., 1970). Criterion precast gels, MOPS running buffer (20x) and the Criterion 
Running Chamber system were used for SDS-PAGE separations as recommended 
by the manufacturer. Magic Mark and Sea Blue markers were loaded together with 
the protein samples as molecular size standards. The separation was performed at 
100 to 150 Volt for variable durations, depending on the experimental context.   
 
2.2.3.4 Transfer of proteins on nitrocellulose membranes  
Transfer and immobilization of proteins from gels onto nitrocellulose membranes was 
accomplished via electroblotting using a Criterion Blotter (principle described in 
Towbin et al., 1979). Transfer buffer was prepared freshly and it was used to 
generously soak all components of the blotting sandwich during assembly. Blotting 
was performed with a frigistor under stirring for 90 min at 0,8mA per cm2 gel. 
Nitrocellulose membranes were stained with Ponceau Red solution and scanned 
after blotting to check and document proper transfer of proteins. 
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2.2.3.5 Immunoblot detection of proteins  
Immunodetection of nitrocellulose bound proteins was performed after membrane 
blocking with immunoblot blocking buffer or Starting Block™ (PBS) blocking buffer 
for 30 min at RT on a shaker. Membranes were probed shaking with primary 
antibody overnight at 4°C, washed three times for 15 min with immunoblot washing 
buffer and incubated with horseradish-peroxidase (HRP)-coupled secondary 
antibody diluted in immunoblot washing buffer for 2 h at RT on a shaker. 
Immunoblots were again washed as described above before antigen-antibody 
complexes were detected by adding LumiLight® or LumiLight® Plus Western blotting 
substrate that produce chemoluminescence upon conversion by HRP. 
Luminescence was visualized via the Vers Doc immunoblot visualization and 
documentation system, pictures were processed with Quantity One software. All 
used antibodies and their dilution factors are listed in section 2.1.6. 
 
2.2.3.6 Examination of receptor tyrosine kinase (RTK) activation levels using 
immunoblot arrays 
Use of membrane arrays spotted with immobilized antibodies allows a paralleled 
identification of multiple antigens present in a single lysate. In this work a Proteome 
ProfilerTM Array for human phospho-RTK detection was used to probe relative 
activation of 42 RTKs in long-term gefitinib or cetuximab-treated A431 cells. 
A membrane spotted with duplicates of 42 RTK capture antibodies and 6 control 
antibodies is incubated with cell lysate which allows formation of specific antigen-
antibody complexes. Unbound material is washed away and membranes are 
incubated with an HRP-coupled pan anti-phospho-tyrosine antibody and subsequent 
of activated receptors with detection of chemiluminescence by the Versa Doc 
documentation apparatus. 
 
Preparation of lysis buffer was performed by the following protocol (in MiliQ water): 
 
NP-40   1% 
Tris, pH 8,0   20mM 
NaCl   135mM 
EDTA   2mM 
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Added freshly: 
Sodium vanadate  1mM 
Aprotinin   10µg/ml 
Leupeptin   10µg/ml 
 
Cells were harvested, lysates solubilized by rotation (30 min, 4°C) cleared by 
centrifugation (10 min, 14000rpm, 4°C) and protein content was quantified by BCA 
assay. After adjustment of protein concentrations, lysates were incubated with the 
array membranes overnight at 4°C and assay was developed as recommended by 
the manufacturer. Data analyses was performed with QuantityOne software by 
background substraction, determination of average signal density from duplicates 
and normalization of values from long-term gefitinib or cetuximab-treated cell lysates 
against values from untreated control cell lysates of similar passage number, which 
were set 1. Assay development was kindly carried out by Mrs. Irina Onofrei in the 
laboratory of Dr. Andree Blaukat, TA Oncology, Merck. 
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3.  Results 
3.1 Impact of clinically relevant mutations in the EGFR kinase 
domain for EGFR-directed tumor therapy 
3.1.1 Studies on stably transfected NIH3T3 cells 
It was described earlier that stable transfection of murine fibroblastic NIH3T3 cells 
with human EGFR and parallel EGF supplementation of growth medium is sufficient 
to transform this cell line (Di Fiore et al., 1987). Due to this fact and the low 
endogenous expression of mouse EGFR in these cells (Velu et al., 1989; Helin and 
Beguinot, 1991), an unbiased and well-defined cellular model was available for 
studying the impact of EGFR kinase domain mutations.   
 
3.1.1.1 Validation of the cellular model system 
After transfection and selection of stably transfected NIH3T3 cells, surface levels of 
human EGFR were assessed by FACS analyses with a human EGFR-specific 
antibody. EGFR is expressed in all tested cell lines, while no human EGFR could be 
detected on the surface of mock-transfected NIH3T3 cells (figure 10). 
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Figure 10   Validation of EGFR expression in NIH3T3 cells stably transfected with EGFR variants. NIH3T3 
cells were stably transfected with plasmids coding for wild-type EGFR and kinase domain mutants as described in 
material and methods. Receptor surface expression was analyzed by FACS after staining of the cells with FITC-
labeled cetuximab for 15 min. Median signal intensity from the fluorescence channel was calculated for every cell 
line and transformed to arbitrary units to compare relative expression levels between cell lines. Cells were 
analyzed on a Becton Dickinson FACScalibur flow cytometer. 
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The analyses showed above-average surface levels in the wild-type EGFR 
transfected cell line and comparable strong levels in the other five cell lines. As 
explained in the methods section, transfected plasmid DNA may only be integrated at 
an unique site in the genome of the used NIH3T3 cell line. Together with the 
observation from the FACS analyses (figure 10), this means that the effects observed 
for these cell lines are exclusively due to the respective EGFR mutation and are not 
caused by collateral genomic integration influences or variable expression levels 
between cell lines. On the other hand, the high EGFR levels in the cell line 
expressing wild type receptor need to be taken into consideration when comparing 
those data with these form the mutant cell lines.  
 
3.1.1.2 Examination of cellular signal transduction in NIH3T3 cells 
To study the effects the mutations have on EGFR-mediated signaling, cells were 
treated with EGF after serum starvation and exposure to either cetuximab or gefitinib 
and examined for activation of EGFR and downstream signaling cascades (figure 
11).   
Basal activation of EGFR and the downstream signaling marker Akt was high in cells 
expressing mutated receptor, but could hardly be detected in the cell line transfected 
with the wild-type receptor. Some activation of the Ras/Raf/Mek/MAPK signaling 
cascade, reflected by phosphorylation of MAPK, could be found in most cell lines, 
however a high activation was only seen in NIH3T3 cells expressing EGFR-del747-
753-T790M.  
Efficient blockage of EGF-induced activation of EGFR and downstream components 
by gefitinib was seen in NIH3T3 cells transfected with the classical EGFR kinase 
domain mutations, EGFR-del747-753 and EGFR-L858R. Some, less effective 
phosphorylation blockage of marker proteins by the TKI could be observed in cells 
with wild-type receptor. Yet, no significant signaling inhibition could be detected in 
cells expressing EGFR with a T790M amino-acid exchange mutation, either alone or 
in combination with one of the classical mutations. 
Upon treatment of cells with the monoclonal antibody cetuximab, only moderate 
inhibition of protein phosphorylation was seen for all marker proteins in nearly all 
NIH3T3 cell lines, with the exception of NIH3T3-EGFR-del747-753-T790M cells. 
These did not show any change in this phosphoprotein analyses after challenge with 
cetuximab. 
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Figure 11   Ligand activated NIH3T3 cells expressing EGFR mutants showed variable signaling responses 
upon treatment with cetuximab and gefitinib. NIH3T3 cells were treated with variable doses of cetuximab 
[µg/ml] or gefitinib [µM] (45min) and stimulated with EGF (30ng/ml, 10min) after serum starvation. After lysis, total 
EGFR, phosphorylated EGFR (Tyr1068), phosphorylated MAPK (Tyr202/Tyr204) and phosphorylated Akt (Ser 
473) were detected as marker proteins for EGFR-mediated signaling by immunoblotting. Membranes were probed 
with an anti-cofilin antibody as loading control. (a) Lysates of mock transfected NIH3T3 cells and A431 cells were 
probed for total EGFR content as negative and positive controls. 
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3.1.1.3 Cellular transformation by EGFR mutants 
To test the paradigm that increased signaling activity correlates with cellular 
transformation, the colony formation capacity under external EGF supplementation 
was studied in a 3D soft-agar assay.  
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Figure 12   NIH3T3 cells expressing EGFR mutants displayed variable growth patterns upon EGF 
stimulation in a soft-agar colony formation assay. Stably transfected NIH3T3 cells, exogenously expressing 
wild-type and different variants of mutated receptor, were seeded in a soft agar matrix as described in material 
and methods and treated with serum-free medium containing variable doses of human EGF for 8 days. 
Fluorescence was detected after addition of Cell Titer Blue reagent, incubation (2 h) and concomitant detection of 
signals with a plate reader.  Intensity of fluorescence is linearly correlated to the relative number of viable cells per 
well. Each bar is the average from triplicate values (mean +/- standard deviation).   
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As expected, wild-type (wt) EGFR transformed NIH3T3 cells only upon external 
supplementation with EGF. Figure 12 assembles data from two independent 
experiments with NIH3T3-EGFRwt cells as reference for the cell lines expressing 
mutated EGFR. Maximal saturation of wild-type receptor expressing cells is observed 
at a ligand concentration of 33ng/ml.  
On the other hand, ligand independent growth was seen for all cell lines expressing 
mutant receptor, with NIH3T3-EGFR-del747-753 cells as an exception, which, like 
EGFRwt cells were strictly dependent on EGF supplementation. Yet, colony 
formation for all cells with mutated receptors, apart from NIH3T3-EGFR-del747-753-
T790M, could further be increased by addition of external EGF. This cell line’s ligand 
independent growth was paralleled by constitutive activation of EGFR, Akt and MAPK 
proteins as detected by immunoblot analyses (figure 11). Interestingly, the colony 
formation capacity of NHI3T3-EGFR-del747-753 cells, even under EGF stimulation, 
was lower than the growth potential of wild-type EGFR transfected cells, despite the 
basal activation of mutant receptor (figure 11). 
 
3.1.1.4 Growth inhibition of NIH3T3 cells under drug treatment in a 3D soft-
agar matrix 
To examine the influence of EGFR mutations on gefitinib- or cetuximab-mediated 
growth inhibition of NIH3T3 cells, 3D soft-agar assays were performed under 
concomitant stimulation with 10ng/ml EGF. Ligand induced growth of NIH3T3 cells 
expressing wild-type EGFR is readily inhibited by concentrations higher than 0,1µM 
of gefitinib (figure 13). Compared with this, NIH3T3 expressing EGFR with classical 
mutations were hypersensitive to the TKI. As expected, colony formation of cells with 
EGFR variants containing a T790M amino-acid exchange mutation, did not respond 
to gefitinib. Growth inhibition at high concentrations (3,3 or 10 µM) is probably due to 
off-target effects (Brehmer et al., 2005).    
In contrast to this, cetuximab was capable of inhibiting colony formation in all cell 
lines, apart from NIH3T3-EGFR-del747-753-T790M. Notably, all other NIH3T3 cells 
with the T790M mutation were sensitive to cetuximab. The maximal inhibitory activity 
of the antibody, however, was not as marked as that observed for gefitinib (figure 13).  
These findings showed that the inhibitory effect of cetuximab is rather unaffected 
form mutations in the intracellular kinase domain of EGFR, while the T790M mutation 
confers resistance to gefitinib to otherwise sensitive cell lines.  
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Figure 13   NIH3T3 cells expressing EGFR mutants showed variable growth responses upon treatment 
with gefitinib and cetuximab. Stably transfected NIH3T3 cells, exogenously expressing wild-type and different 
variants of mutated receptor, were seeded in a soft agar matrix and treated in EGF supplemented (10 ng/ml) 
serum-free medium containing variable doses of cetuximab [0,003 - 3,3 µg/ml] or gefitinib [0,01 - 3,3 µM] for 8 
days. Fluorescence intensity was detected by Cell Titer Blue reagent and read out with a plate reader.  Relative 
cell numbers under treatment were calculated by signal normalization to medium-treated control cells. Each bar is 
the average from triplicate values. Bars for medium-treated control cells were determined as sextuplets (mean +/- 
standard deviation).   
 
3.1.2 Examination of NSCLC cell lines endogenously expressing EGFR 
3.1.2.1 ErbB receptor and ligand expression levels in NSCLC cell lines 
Studies in NSCLC cells that carry endogenous mutations can in general be 
considered of higher value than the analyses of the transfected NIH3T3 cell lines, 
since they should more closely reflect the pathological situation. In order to 
investigate the relevance of EGFR kinase domain mutations for determining 
response to cetuximab therapy a panel of twelve NSCLC cell lines was analyzed, 
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including all cell lines with mutant EGFR openly available for the scientific 
community. Previous work suggests that the levels of ErbB family members conjoint 
with the expression of their ligands may be important indicators for cellular response 
to gefitinib (Amann et al., 2005; Engelman et al., 2005; Fujimoto et al., 2005). 
Furthermore, it has been proposed that activating KRAS mutations are associated 
with resistance to TKIs (Pao et al., 2005b; Eberhard et al., 2005).  
Table 1 summarizes the EGFR and KRAS mutation status in the NSCLC cell lines 
used in this thesis. Furthermore, mRNA expression levels of ErbB receptors and 
ErbB ligands in the respective cell lines were determined by Affymetrix cDNA 
expression profiling. The data show that the panel includes five cell lines with EGFR 
kinase domain mutations and eight cell lines with wild-type receptor. One of the cell 
lines (H1975) contains a T790M mutation, which has been shown to confer 
resistance to gefitinib (Pao et al., 2005a), in combination with a classical L858R 
mutation. Three cell lines carry mutated KRAS, which also was postulated to be 
responsible for non-response to EGFR-directed TKIs (Pao et al., 2005b). The 
frequency of KRAS mutations in this cell panel of 23% (3/13) is a little lower than the 
frequency of KRAS mutations observed in the clinic, where it was found to range 
from 26% to 39% in NSCLC patients (Jassem et al., 2004; Chong et al., 2007; Hirsch 
et al., 2007). Only the H1650 cell line is known to lack PTEN (8%; 1/13), yet not all 
cell lines in the panel have been profiled in this respect. This ratio is lower than the 
20% to 46% patients with loss of PTEN observed in NSCLC patients (Tang et al., 
2006; Capuzzo et al., 2006). Interstingly only two cell lines (H1781 and H460) have 
no or very low EGFR expression levels, while two cell lines over express EGFR 
(HCC2279 and HCC827). The other nine cell lines display medium EGFR mRNA 
expression levels. Expression of moderate and high levels of EGFR and its natural 
ligands is frequently observed in NSCLC and has been correlated with response to 
EGFR-targeting cancer therapy (Rusch et al., 1997; Fujimoto et al., 2005). 
Congruently, EGFR ligand expression was found in many NSCLC cell lines in the 
panel (table 1). 
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Cell line EGFR 
expression 
level and 
mutation 
status * 
KRAS 
status 
No/low 
expression 
** 
Medium 
expression 
** 
High 
expression 
** 
Additional 
characteristics 
H1781  Wild type Wild type AREG, BTC, 
EGF, ErbB4, 
EREG, HB-
EGF, NRG1, 
NRG2 
TGFα  ErbB2, ErbB3 ErbB2-G776V 
mutation 
(Shigematsu et 
al., 2005) 
H460 
 
N
o
/L
o
w
 
Wild type  Q61H 
mutation 
AREG, BTC, 
ErbB2, ErbB3, 
ErbB4, EREG, 
NRG2, TGFα 
EGF, HB-EGF, 
NRG1 
  
A549 
 
Wild type G12S 
mutation 
BTC, EGF, 
ErbB2, ErbB3 
ErbB4, HB-
EGF, NRG2 
TGFα AREG, EREG, 
NRG1  
 
Calu-3 Wild type Wild type BTC, EGF, 
ErbB4, NRG2 
HB-EGF AREG, ErbB2, 
ErbB3, EREG, 
TGFα, NRG1 
 
Calu6 Wild type Q61K AREG, BTC, 
EGF, ErbB2, 
ErbB3, ErbB4, 
NRG1, NRG2 
EREG, HB-
EGF, TGFα 
  
H1650 
 
delE746- 
A750  
mutation 
Wild type AREG, BTC, 
EGF, ErbB4, 
EREG, HB-
EGF, NRG1, 
NRG2 
ErbB2, ErbB3, TGFα Lack of PTEN 
(Janmaat et al., 
2006) 
H1666 
 
Wild type Wild type BTC, EGF, 
ErbB2, ErbB3, 
ErbB4, NRG1, 
NRG2, TGFa 
EREG, HB-
EGF 
AREG BRAF-V470F 
mutation (Toyooka 
et al., 2007) 
H1975 L858R +  
T790M  
mutations 
Wild type BTC, EGF, 
ErbB4, NRG2 
AREG, ErbB2 
ErbB3, EREG, 
NRG1, TGFα 
HB-EGF APC-T1556 
frameshift 
(COSMIC 
database) 
H292 
 
Wild type Wild type BTC, EGF, 
ErbB4, EREG, 
NRG1, NRG2 
AREG, ErbB2, 
ErbB3, TGFα 
HB-EGF  
H322 Wild type Wild type BTC, EGF, 
ErbB4, HB-
EGF, NRG1, 
NRG2 
AREG, ErbB2, 
ErbB3, EREG, 
TGFα 
 p53 mutation 
(Zhang et al., 
1994) 
H4006 
 
M
e
d
iu
m
 
 
del746- 
750,  
S752V  
mutations 
Wild type BTC, ErbB4, 
EREG, NRG1, 
NRG2 
AREG, EGF, 
ErbB2, HB-
EGF, TGFα 
ErbB3  
HCC2279 
 
del746-750  
mutations 
Wild type BTC, EGF, 
ErbB2, ErbB3, 
ErbB4, NRG1, 
NRG2 
AREG, EREG, 
TGFα 
HB-EGF  
HCC-827 
 
H
ig
h
 
 
delE746- 
A750  
mutations 
Wild type BTC, EGF, 
ErbB4, HB-
EGF, NRG2, 
TGFα 
AREG, ErbB2, 
ErbB3, 
EREG, NRG1  
 
 
Table 1   NSCLC cell lines characterized in this thesis and mRNA expression status of ErbB receptors and 
ligands. (*) EGFR mRNA, as well as (**) ErbB receptor and ligand mRNA expression status has been determined 
with Affymetrics whole genome DNA chips as described in material and methods. Expression levels are indicated 
by grey scales (light grey = no/low expression, medium grey = medium expression, dark grey = high expression) 
and additional characteristics worth mentioning are noted.  
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3.1.2.2 Growth inhibition of NSCLC cells under drug treatment 
The ability of gefitinib to cause growth inhibition in a pre-characterized panel of 
NSCLC cell lines was examined in order to confirm and extend current data available 
from the literature. In addition, the capacity of cetuximab to inhibit growth in this 
heterogeneous cell panel was determined, since not much is known about cellular 
sensitivity parameters for this therapeutic antibody.  
 
 
  
Gefitinib   Cetuximab   Cell line   
IC 50 [µM]   IC 50 [µg/ml]   Max. Inhibition  
[%]   
A549   9, 8   n.d.   0   
Calu - 3   1,9   0,27   21   
Calu - 6   26,4   n.d.   0   
H1650   2, 8   n.d.   0   
H1666   11, 1   0,39   23   
H1781   10, 9   n.d.   0   
H1975   13,5   n.d.   0   
H292   0, 5   0,07   45   
H322   4, 9   0,72   73   
H4006   0,02   n.d.   0   
HCC2279   14,3   n.d.   0   
HCC - 827   0,00 3   0,084   25   
 
Table 2   Growth Inhibition of human NSCLC cell lines by gefitinib and cetuximab. Monolayer growth -
inhibition assays were performed as described in material and methods and evaluated using the Wst1 reagent by 
absorbance determination with a Mithras plate reader. EC50 values were calculated as mean values from 
triplicates with Graph Pad Prism software. “Max. Inhibition” means growth inhibition in % at a maximal cetuximab 
concentration of 100µg/ml. Growth inhibition by gefitinib was 100% for all tested cell lines at the maximal 
treatment doses of 100µM. “n.d.” means not determinable. 
 
In monolayer growth assays, treatment with gefitinib showed variable effects on 
NSCLC cells expressing wild-type EGFR, e.g. H292 cells were sensitive to the TKI, 
while Calu6 and H1781 cells did not respond well, reflected by EC50 values above 
10µM (table 2). As reported earlier, H4006, HCC-827 and H1650 cell lines, which all 
carry EGFR mutations, responded well to gefitinib treatment with EC50 values below 
3µM. Interestingly, HCC2279 cells that do express mutant EGFR turned out to be 
rather resistant to gefitinib even at high doses resulting in an EC50 of 14,3µM.  
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Cetuximab had only minor effects on the wild-type EGFR cells H1666, H292 and 
Calu3, except H322 that were particularly sensitive to cetuximab with an efficacy of 
73% and an EC50 of 0,72µg/ml (table 2). Similarly, only one cell line expressing 
mutated EGF receptor (HCC827) was moderately inhibited by cetuximab. 
To better reflect the pathophysiological situation, three-dimensional growth of the 
NSCLC cells in a soft-agar matrix was assessed. All cells in the panel were 
subsequently classified based on the EC50 value and efficacy of growth inhibition 
caused by gefitinib or cetuximab. The response to gefitinib in soft-agar assays was 
largely equivalent to that observed in monolayer assays (figure 14). In line with 
published results with EGFR-del746-750 expressing PC9 cells (Perez-Torres et al., 
2006), an augmented response to gefitinib was seen in cell lines expressing mutant 
EGFR, such as H1650, H4006 or HCC827. While H1650 cells were classified 
sensitive, H4006 and HCC827 were classified very sensitive according to the 
categorization key specified in legend of figure 14. Contrary data were observed only 
for H1975, which carry the resistance conferring T790M mutation, as well as for the 
HCC2279 cell line. These cell lines were rated non-responsive (H1975) or 
moderately sensitive (H2279) reflected by efficacy values below 50% or 25%, 
respectively. The non-responsiveness of the latter cell line had been described earlier 
in a monolayer growth assay; however the underlying mechanism is still unclear 
(Fujimoto et al., 2005).  
For cetuximab a different picture arose from three-dimensional growth assays, in 
contrast to the observations made in monolayer growth assays. The effects of 
cetuximab on several cell lines were more pronounced in the soft agar assay. While 
the growth of three cell lines expressing wild-type EGFR was efficiently inhibited by 
cetuximab (H292, H322 and A549), three others were not significantly affected 
(H1781, Calu3 and Calu6) (figure 14). Out of four NSCLC cell lines that express 
gefitinib-sensitizing EGFR mutations, colony formation of two was marginally 
impaired by cetuximab (H4006, H1650) and growth of one was strongly inhibited by 
cetuximab (HCC827). Interestingly, three-dimensional growth of the gefitinib-resistant 
cell line H1975 was inhibited by cetuximab while it was not affected in the monolayer 
assay. The same is true for A549 cells that carry an activating KRAS mutation. 
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Figure 14   Inhibition of colony formation in human NSCLC cell lines by gefitinib and cetuximab. For soft-
agar colony formation assays, cells were treated with variable doses of cetuximab and gefitinib in serum free 
medium for 8 days. Cell lines were categorized in relation to their sensitivity to either gefitinib or cetuximab. Cell 
lines were classified “very sensitive” (dark green) for an EC50<0,01µM (Gefitinib) or an EC50<0,1µg/ml 
(Cetuximab), respectively, and for an efficacy >75%. “Sensitive” (bright green) for 0,01µM< EC50<0,1µM 
(Gefitinib) or 0,1µg/ml<EC50<1µg/ml (Cetuximab), respectively, and for 50%<efficacy<75%. “Moderately 
sensitive” (orange) for 0,1µM< EC50<1µM (Gefitinib) or 1µg/ml< EC50<10µg/ml (Cetuximab), respectively, and for 
25%<efficacy<50%. “Non-responsive” (red) for an EC50>1µM (Gefitinib) or EC50>10µg/ml (Cetuximab), 
respectively, and for an efficacy<25%. 
1
 1Efficacy corresponds to % of cell number reduction at a concentration of 
1µM gefitinib or 10µg/ml cetuximab as compared to untreated control. 
 
From these data it appeared that colony formation assays were more appropriate to 
study the effects of cetuximab on cell growth than monolayer growth tests. 
Furthermore, with a single exception (HCC2279), a higher degree of sensitivity to 
gefitinib, reflected by lower EC50 values, was observed in NSCLC carrying EGFR 
mutations. Cetuximab was able to inhibit growth of NSCLC cells expressing mutated 
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EGFR as well as of those expressing wild-type receptor. These data suggest that 
EGFR mutations do not have the same predictive value for cetuximab sensitivity as 
they do have for TKI. Based on the soft-agar assays growth responses gained, 
sensitivity categories were developed, which also refer to in the following sections 
(figure 14). 
 
3.1.2.3 Examination of cellular signal transduction in NSCLC cells 
To better understand the observed growth responses to gefitinib and cetuximab, 
signaling cascades in the different NSCLC cell lines were extensively studied. All 
data sets are summarized in a heat plot graph in figure 15a and exemplary data for 
some cell lines are shown in figures 15b-d. The effect of the drugs on the 
phosphorylation of EGFR and on the EGF-induced activation of Akt and MAPK within 
the cell panel was compared with their inhibitory potential in the soft-agar assay. 
In many cases an inhibition of EGFR phosphorylation by cetuximab was associated 
with sensitivity of the respective cell line in the three-dimensional growth assay. 
However, Calu6 and H1650 cells were non-responsive to cetuximab in the soft-agar 
assay, while EGFR phosphorylation was effectively inhibited by the antibody. On the 
other hand, phosphorylation of EGFR and downstream signaling in HCC-827 cells 
was not abolished by cetuximab, but the growth of cells was still very responsive to 
this drug.  
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Figure 15a   Ligand activated NSCLC cells expressing wild-type and mutated EGFR showed variable 
signaling responses upon treatment with cetuximab and gefitinib. Cells were treated with variable doses of 
cetuximab [µg/ml] or gefitinib [µM] (45min) and stimulated with EGF (30ng/ml, 10min) after serum starvation. After 
lysis, phosphorylated EGFR (Y1068), phosphorylated MAPK (Tyr202/Tyr204) and phosphorylated Akt (Ser 473) 
were detected as marker proteins for EGFR-mediated signaling by immunoblotting. Membranes were probed with 
a cofilin antibody as protein loading control. Cell lines were categorized with respect to the capability of gefitinib or 
cetuximab to inhibit EGF-mediated phosphorylation of target proteins. Cell lines were classified “Very sensitive” 
(dark green) for a 50% reduction of the phosphorylation signal at a concentration of 0,1µM (gefitinib) or 1µg/ml 
(cetuximab), respectively. “Sensitive” (bright green) for a 50% reduction of the phosphorylation signal at a 
concentration of 1µM (gefitinib) or 10µg/ml (cetuximab). “Moderately sensitive” (orange) for a 50% reduction of the 
phosphorylation signal at a concentration of 10µM (gefitinib) or 100µg/ml (cetuximab). “Non-responsive” (red) for 
a reduction of the phosphorylation signal at a concentration of 10µM (gefitinib) or 100µg/ml (cetuximab) that was 
lower than 50%.  
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b) c)
d) e)
 
 
Figure 15 b-d Ligand activated NSCLC cells expressing wild-type and mutated EGFR showed variable 
signaling responses upon treatment with cetuximab and gefitinib. Exemplary immunoblots for (b) H292, (c) 
H1650, (d) H1975 and (e) HCC2279 cell lines are shown. 
 
In summary, neither EGFR phosphorylation nor interference with MAPK or Akt 
activation appeared to be robust prognostic indicators for cetuximab induced growth 
inhibition in an agar matrix. Similar observations, e.g. only partial correlation of 
signaling and growth inhibition, were made for gefitinib, even in a cell line (H1650) 
bearing an EGFR mutation, which is particularly responsive to this TKI (figure 14). 
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3.1.2.4 Tumor regression of NSCLC cells under drug treatment in murine 
xenografts 
To substantiate the data obtained in the three-dimensional growth assays and the 
signal transduction studies, murine tumor xenograft experiments in athymic mice with 
the panel of those NSCLC cell lines that developed subcutaneous tumors were 
applied. In perfect agreement with the in vitro data from soft-agar assays, H292 
tumors responded very well to either i.p. to 15mg/kg or 50mg/kg cetuximab (twice a 
week) or  p.o. to gefitinib (daily) leading to 95% (cetuximab) and 79% (gefitinib) 
reduction in tumor burden, respectively (figure 16c). A similar match of in vitro and in 
vivo response data was seen for H1975 tumors that were non-responsive to gefitinib 
but responsive to cetuximab resulting in 79% tumor burden decrease (figure16b). 
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Figure 16 Inhibitory effects of cetuximab or gefitinib on tumor formation of NSCLC cell lines in murine 
xenografts. Murine xenograft experiments were performed with (a) H1650, (b) H1975, (c) H292 and (d) Calu6 
cell lines as described in material and methods. Mice were treated daily with gefitinib (40mg/kg/d), twice a week 
with cetuximab (C225) (15mg/kg or 50mg/kg) or vehicle controls, after subcutaneous injection of cells, 
randomization and scheduling of treatment groups (n=10). Mouse husbandry and conduction of xenograft 
experiments was done by Mr. Schuster and Mrs. Schaefer in the laboratory of Dr. Amendt, Merck KGaA.    
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A discrepancy between in vivo and in vitro data was seen for H1650 cells that were 
effectively inhibited by both drugs in vivo (67% and 89% tumor burden decrease for 
cetuximab and gefitinib, respectively) (figure 16a), but were non-responsive to 
cetuximab in the colony formation assay (cf. figure 14). This finding is of particular 
interest, since H1650 lack expression of PTEN. Similarly, Calu-6 cells that carry an 
activating KRAS mutation were moderately affected by cetuximab and gefitinib in 
mouse xenografts (44% and 57% tumor burden reduction, respectively) (figure 16d), 
but completely resistant in vitro (cf. figure 14). These examinations showed that 
cetuximab displays in vivo efficacy in NSCLC cells with any genetic background, 
while expression of EGFR-T790M confers resistance to gefitinib. 
 
To analyze whether the two drugs inhibited their target in vivo tumor tissues at the 
end of the treatment period was collected and EGFR phosphorylation, as well as 
MAPK and Akt activation was determined by immunobloting using phospho-specific 
antibodies. A marked decrease of phospho-EGFR, phospho-Akt and phospho-MAPK 
signals was found after cetuximab treatment in H1650 xenografts (figure 17a), while 
only a slight (pEGFR, pAkt) and no pharmacodynamic effect (pMAPK) was observed 
in H1975 xenografts (figure 17b). Congruent with the lack of xenograft growth 
inhibition of H1975 cells upon gefitinib treatment, corresponding tumors showed only 
modestly reduced levels of phospho-EGFR and phosphoMAPK and no reduction of 
pAkt (figure 17b). Yet a clear reduction of phospho-EGFR, phospho-Akt and 
phospho-MAPK was observed in H1650 xenografts upon gefitinib treatment (figure 
17a).  
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Figure 17   Inhibitory effects of cetuximab or gefitinib on EGFR-mediated signaling of NSCLC cell lines in 
murine xenografts. At the day of scarifice, mice from xenograft experiments were treated with the respective 
drug concentrations two h prior to resection. Tumors were removed, processed and protein lysates were analyzed 
for phosphorylation levels of EGFR, MAPK and Akt with immunoblots. Chemiluminescence signals were detected 
and quantified with BioRad Quantity One® software. Each bar is the average from five to ten tumor lysates (mean 
+/- standard deviation).   
 
A modest reduction of Akt activation was observed for cetuximab-treated H292 
tumors, but interestingly no decrease in phosphorylation of EGFR or MAPK was seen 
in the same tumors. However, a minor gefitinib-mediated decrease in phospho-EGFR 
and phospho-Akt, was found in H292 tumors (figure 17c). This is striking, as H292 
tumors respond well to either drug (cf. figure 16c). For murine tumors originating from 
transplanted Calu6 cells, neither phospho-EGFR, nor phospho-Akt could be detected 
via immunoblotting. Activated MAPK could be detected in these tissues; however, for 
this marker no alteration was found (figure 17d). It can be inferred from these 
examinations that inhibition of neither EGFR nor Akt or MAPK activation with 
cetuximab or gefitinib is clearly correlated to tumor sensitivity to either drug.  
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3.1.2.5 Identification of response predicting marker genes through gene 
expression profiling in drug sensitive and resistant NSCLC cell lines 
Because interference with EGFR signaling pathways in vitro did not correlate well 
with cellular growth inhibition in response to gefitinib or cetuximab, an unbiased 
global gene expression profiling approach was carried out to identify candidate genes 
or a signature associated with response of NSCLC cell line to EGFR inhibitors. 
Based on the in vitro sensitivity classification in the colony formation assay (cf. figure 
14) cell lines were classified for each drug into a “resistant” and a “sensitive” group. 
Due to the intermediate and therefore not clearly classifiable responses gained for 
A549 and H1781 cells upon gefitinib treatment, these were not included in the 
analyses for gefitinib. 
A statistical comparison between gefitinib-resistant and sensitive cell lines was 
performed for 9002 Affymetrix probe sets fulfilling global filtering criteria (see 
Materials and Methods). Based on this analyses 56 probe sets representing 46 
known genes showed significantly differential expression with an unadjusted 
p<0,001, corresponding to a false discovery rate of 0,16 (table 3). Interestingly, from 
these 46 candidates, 17 (37%) had been identified in a recently published study that 
also examined expression profiling with NSCLC cell lines based on their response to 
gefitinib in a monolayer assay. This includes tumor-associated calcium signal 
transducer 2 (TACSTD2) and E-cadherin (CDH1), whose overexpression in gefitinib 
sensitive NSCLC cells has already been validated on the protein level (Coldren et al., 
2006). Furthermore, the analyses confirmed 8 (17%) candidate genes that were 
identified in an examination with NSCLC cells profiled for their sensitivity against 
erlotinib (Yauch et al., 2005). Seven of these genes were also identified in the 
gefitinib response analyses from Coldren and two of them (TACSTD2 and CDS1) 
were additionally found in another expression profiling study with NSCLC cells and 
tumor samples to identify response predictors for erlotinib (Balko et al., 2006).  
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GeneSymbol Gene Name ratio ** p.value FDR Literature 
ELOVL7 ELOVL family member 7, elongation of long chain fatty acids   9,52 1,3E-06 0,01152   
ALDH1A3 aldehyde dehydrogenase 1 family, member A3    16,5 1,2E-05 0,04607 1,3 
C1orf106 chromosome 1 open reading frame 106    9,81 1,8E-05 0,04607   
C20orf100 chromosome 20 open reading frame 100    0,11 2,2E-05 0,04607   
MOBKL2B Mps One Binder kinase activator-like 2B 5,81 2,6E-05 0,04607   
FGFBP1 Fibroblast growth factor-binding protein 1 4,57 6,7E-05 0,08249   
TSPAN1 tetraspanin 1   9,02 0,00007 0,08249 1,3,6 
KCNK1 * potassium channel, subfamily K, member 1 5,96 7,3E-05 0,08249 1 
TACSTD2 tumor-associated calcium signal transducer 2    38,5 8,4E-05 0,08416 1 
ST14 * suppression of tumorigenicity 14  8,37 0,00011 0,0911 1,3 
DMKN dermokine  6,92 0,00011 0,0911   
CLDN7 Claudin-7  7,94 0,00013 0,0911 1,3 
ELF3 E74-like factor 3 7,66 0,00014 0,0911 1 
RAB25 RAB25, member RAS oncogene family 16,1 0,00016 0,0911   
RBM35A * RNA binding motif protein 35A 14,3 0,00019 0,0911   
VGLL1 vestigial like 1 21,9 0,00019 0,0911   
VGLL3 vestigial like 3 10,8 0,00019 0,0911   
MAL2 T-cell differentiation protein 2    26,6 0,0002 0,0911 1,3 
CDH1 * E-cadherin 26,3 0,0002 0,0911 1 
TRIM22 tripartite motif-containing 22    12,4 0,00025 0,1016   
MOBKL2B MOB1, Mps One Binder kinase activator-like 2B 3,78 0,00026 0,1016   
GPR110 G protein-coupled receptor 110    9,05 0,00027 0,1016 1 
SPINT1 serine peptidase inhibitor, Kunitz type 1    9,36 0,00031 0,1016 1,3 
HPCAL1 * Hippocalcin-like protein 1 0,24 0,00027 0,1016   
COL6A1 Collagen alpha-1(VI) chain 0,14 0,00029 0,1016   
HERC6 HECT domain and RCC1-like domain-containing protein 6 4,91 0,00034 0,10451   
SAMD9 sterile alpha motif domain containing 9    6,54 0,00035 0,1048   
FXYD3 FXYD domain containing ion transport regulator 3   12,1 0,00036 0,1048 1 
ANXA6 Annexin A6 0,27 0,00042 0,11189 3 
CENTD1 Centaurin-delta 1 3,77 0,00042 0,11189 1 
KLF5 Kruppel-like factor 5 5,13 0,00044 0,11189   
FKBP11 * FK506-binding protein 11 0,16 0,00043 0,11189   
EPS8L2 Epidermal growth factor receptor kinase substrate 8-like protein 2 3,88 0,00045 0,11323 1 
EDG2 Lysophosphatidic acid receptor 1 4,84 0,00048 0,11425   
LIMA1 LIM domain and actin-binding protein 1 3,53 0,00054 0,12181   
TNNC1 troponin C type 1 (slow)    6 0,00055 0,12181   
SLC44A3 Choline transporter-like protein 3 3,82 0,00062 0,13273   
TIMP4 Metalloproteinase inhibitor 4 0,3 0,0008 0,15761   
SH2B3 SH2B adapter protein 3 0,22 0,00082 0,15761   
CA12 * Carbonic anhydrase 12 0,21 0,00084 0,15761   
TMEM30B transmembrane protein 30B   11,7 0,00087 0,15761   
ECHDC2  Enoyl coenzyme A hydratase domain-containing protein 2 3,1 0,0009 0,15761   
CXCL16 chemokine (C-X-C motif) ligand 16    4,4 0,00093 0,15761   
SHROOM3 Shroom3 4,08 0,00095 0,15761   
STARD10 START domain containing 10 4,07 0,00095 0,15761 1 
FLJ20920  hypothetical protein FLJ20920    3,26 0,00096 0,15761   
CDH11 Cadherin-11 (Osteoblast-cadherin) 0,06 0,00096 0,15761   
 
Table 3   Gene expression profiling for the identification of candidates predicting growth response to 
gefitinib. Whole genome expression profiling was performed as described in section material and methods. (*) 
Indicates that the respective gene found to be differentially regulated (p-value <0,001) by more than one probe in 
a panel of ten NSCLC cell lines. The figure lists the probe with the lowest p-value. (**) Depicts the quotient 
between mean Affymetrix signals of the cells that were classified sensitive and signal of cells classified resistant 
to gefitinib (mean signalsensitive / mean signalresistant). “Literature” Indicates that the corresponding gene has 
been found to be putatively predictive by other authors (Coldren et al., 2006 (1); Balko et al., 2006 (2); Yauch et 
al., 2005 (3).  
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Among the new identified candidates associated with gefitinib response, were genes 
that are possibly involved in controlling expression of distinct target mRNAs 
(C20orf100, RBM35A, VGLL1, KLF5), in regulating activity of specific signal 
transduction components (MOBKL2B, ZD52F10, EDG2, SH2B3, CXCL16), as well 
as in managing cellular invasion or tumor homeostasis (COL6A, LIMA1, TNNC1, 
CA12, TIMP4, SHROOM3, CDH11), cellular proliferation (TRIM22, SAMD9) or 
balancing of calcium or other ion levels (KCNK1, HPCAL1, CA12, CXCL16).  
 
A similar analyses for the identification of genes predictive for in vitro response to 
cetuximab revealed only one candidate (TRIM6) with an unadjusted p<0,001 (table 
4). However, choosing a p-value cutoff of 0,02 leads to 33 genes that could be 
associated with response to cetuximab (table 4). Several of these candidates have 
been linked with cellular signal transduction processes (SDC2, RGS20, TMEM46, 
AMFR, JAG2, TSPAN8, TGFB1, SOCS2, DUSP6, CD109), with cellular adhesion 
and migration (SDC2, RGMB, AMFR, SRGAP1, MMP2) and protein trafficking 
(TMEM46, LPHN1, CPNE3, SPG20, ANXA8), but the list also includes transcription 
factors (TRIM6, PLAGL1) and proteins associated with balancing of calcium levels 
(STOM, ANXA8, CADPS2). Though statistically questionable the identified gene 
candidates promise potential biological significance and warrant further examination.  
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GeneSymbol Gene Name ratio ** p.value 
TRIM6 tripartite motif-containing 6   4,4 0,00096 
ALDH3B1 * aldehyde dehydrogenase 3 family, member B1 3,24 0,0026 
SUSD2 sushi domain containing 2 2,43 0,0035 
SDC2 * syndecan 2  0,16 0,0036 
RGS20 regulator of G-protein signalling 20    3,3 0,0042 
KIAA1609 KIAA1609    2,42 0,0044 
PLAGL1 * pleiomorphic adenoma gene-like 1 0,29 0,0053 
RGMB RGM domain family, member B    0,39 0,0068 
STOM stomatin    2,83 0,007 
LOC400566 hypothetical gene supported by AK128660    2,29 0,009 
TMEM46 transmembrane protein 46    0,26 0,01 
GPR172A G- protein coupled receptor 172A 0,43 0,011 
TACC2 * transforming, acidic coiled-coil containing protein 2    2,12 0,012 
AMFR autocrine motility factor receptor    0,46 0,012 
CCT5 chaperonin containing TCP1, subunit 5 0,44 0,013 
PLAGL1 pleiomorphic adenoma gene-like 1   0,36 0,013 
HYLS1 hydrolethalus syndrome 1 2,31 0,014 
JAG2 * jagged 2    2,09 0,014 
TGFB1 transforming growth factor, beta 1  0,4 0,014 
TSPAN8 tetraspanin 8    0,16 0,014 
LPHN1 latrophilin 1    0,44 0,015 
CPNE3 copine III    2,03 0,015 
SOCS2 * suppressor of cytokine signaling 2 2,72 0,017 
C16orf74 chromosome 16 open reading frame 74   1,83 0,017 
MMP2 matrix metallopeptidase 2 0,3 0,017 
SRGAP1 SLIT-ROBO Rho GTPase activating protein 1    1,99 0,017 
CADPS2 Ca2+-dependent activator protein for secretion 2    0,31 0,017 
DUSP6 * dual specificity phosphatase 6    0,34 0,017 
BRP44L brain protein 44-like   0,49 0,018 
ANXA8 Annexin A8 (Annexin VIII) 3,93 0,018 
AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1   0,53 0,018 
SEZ6L2 seizure related 6 homolog (mouse)-like 2    0,41 0,018 
SLC1A4 solute carrier family 1, member 4    0,46 0,019 
SPG20 spastic paraplegia 20, spartin  3,63 0,02 
H2AFX H2A histone family, member X    2,08 0,02 
RNF144 Ring finger protein 144  0,45 0,02 
C5orf13 chromosome 5 open reading frame 13    0,34 0,02 
H2AFX H2A histone family, member X     2,06 0,02 
BTBD11  BTB (POZ) domain containing 11   2,91 0,02 
  
Table 4   Gene expression profiling for the identification of candidates predicting growth response to 
cetuximab. Whole genome expression profiling was performed as described. (*) Indicates that the respective 
gene was found to be differentially regulated (p-value <0,02) by more than one probe in a panel of twelve NSCLC 
cell lines. The figure lists the probe with the lowest p-value. (**) Depicts the quotient between mean Affymetrix 
signals of the cells that were classified sensitive and these classified resistant to gefitinib (mean signalsensitive / 
mean signalresistant).  
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3.2 Establishment and characterization of cancer cell lines treated 
long-term with EGFR-directed cancer drugs 
An appropriate pre-selection of cancer patients for EGFR-directed cancer therapy is 
important in order to achieve significant clinical outcomes. Aside from EGFR kinase 
domain mutations, which are highly predictive for clinical and in vitro response to 
gefitinib, but not for antibody therapy, reliable biomarkers with prognostic value for 
cetuximab have not yet been identified. Furthermore, as can be seen from clinical 
and laboratory studies, mutations in kinase domain are neither exclusive nor 
stringently predictive for sensitivity to gefitinib (Irmer et al., 2007a). In addition, 
tumors with primary sensitivity to gefitinib do often relapse and gain resistance 
against TKI treatment. The same holds also true for therapy with therapeutic 
antibodies, such as cetuximab (Italiano, 2006).  
Thus, four cancer cell lines, two with primary sensitivity and two with primary 
resistance, were exposed to either cetuximab or gefitinib for a period of several 
months in order to study long-term effects of different EGFR-directed therapies in a 
cell culture model. 
 
3.2.1 Identification and selection of cancer cell lines with primary drug 
resistance and sensitivity 
Four cell lines were selected on the basis of preceding examinations. Difi is a 
colorectal cancer cell line that was derived from a familial adenomatous polyposis 
patient (Gross et al. 1991). A431 is an epidermoid carcinoma cell line (Krupp et al., 
1982). Both cell lines express high levels of EGFR and are sensitive to EGFR-
targeting cancer therapeutics (Wu et al., 1995; Janmaat et al., 2003). In contrast, the 
lung cancer cell line H460 and colorectal cell line SW707 express moderate or very 
low levels of EGFR and are not responsive to gefitinib or cetuximab. In order to 
substantiate these observations and to directly compare cellular responsitivity, the 
four cell lines were subjected to growth inhibition by cetuximab and gefitinib. 
Difi cells were highly sensitive to cetuximab in a monolayer growth assay (EC50 <0,1 
µg/ml) and moderate effects were observed for A431 cells, while H460 as well as 
SW707 cell lines did not show any growth inhibition, even at high doses of 
cetuximab.   
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Figure 18   Difi cells were found to be sensitive to cetuximab in a monolayer growth assay. Monolayer 
growth inhibition assays with A431, Difi, H460 and SW707 cells were performed under treatment with variable 
doses of cetuximab. Assay evaluation with Wst1 reagent by absorbance measurement on a plate reader and data 
processing with Graph Pad Prism software were performed as described. 
 
As expected from the studies with NSCLC cell lines (table 2 and figure 14), 3D 
growth in softagar was more sensitive to EGFR inhibition. Under these conditions 
growth of A431 cells was markedly inhibited by cetuximab (EC50 <1µg/ml). Difi cells 
again responded very well (EC50 <1µg/ml), while colony formation of H460 and 
SW707 cells was not influenced by cetuximab (figure 19).     
Human Cancer cell lines under Cetuximab treatment
 
Figure 19 Difi and A431 cells were found to be sensitive to cetuximab in a soft agar colony formation 
assay. Soft-agar assays with A431, Difi, H460 and SW707 cells were performed under treatment with variable 
doses of cetuximab, evaluated with Cell Titer Blue reagent by fluorescence measurement on a plate reader and 
data were processed with Graph Pad Prism software. 
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The sensitivity profiles of the four cell lines towards gefitinib were validated likewise. 
In a monolayer growth assay Difi cells were hypersensitive to gefitinib (EC50 
<0,1µg/ml) and also A431 (EC50 <1µg/ml) are responsive to this drug. As expected 
from the preceding screens H460 and SW707 cells were found to be resistant to the 
TKI (EC50 >10µg/ml) (figure 20). Growth effects observed at higher doses were 
probably due to off-target effects of the TKI.  
 
Figure 20   Difi and A431 cells were found to be sensitive to gefitinib in a monolayer growth assay. 
Monolayer growth inhibition assays with A431, Difi, H460 and SW707 cells were performed under treatment with 
variable doses of gefitinib, evaluated with Wst1 reagent by absorbance measurement on a plate reader and 
processed with Graph Pad Prism software. 
 
3.2.2 Examination of sensitivity and cross-sensitivity of long-term-treated 
A431 cells 
In order to examine A431 cells that had been treated for fifteen months with either 
gefitinib or cetuximab for acquisition of resistance to the respective drug, growth 
properties in soft-agar assays were studied. Further it was investigated, if long-term 
exposure of cells to either drug led to cross-resistance against the other drug. This 
question is of special interest, since it may have implications for the therapy of cancer 
patients that e.g. relapse from gefitinib therapy. In this case frequently observed in 
the clinic, it would be important to know if these patients could profit from subsequent 
cetuximab regimen.  
 
Before being able to address this question, it was important to remove the drugs from 
A431 cells after long-term exposure to ensure comparability between the different 
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populations. Cetuximab exposed A431 cells were washed for variable time points 
with full medium lacking the antibody and were subjected to FACS analyses to 
determine residual antibodies on cell surfaces.   
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Figure 21   Washing cetuximab long-term treated A431 cells with medium for three days cleared the  
cellular surface from antibody. A431 cells long-term-treated with cetuximab were washed for variable durations 
(0-4 days) with full medium three times per day. Cetuximab remaining at the cellular surface was detected with a 
mouse IgG specific FITC conjugated antibody followed by analyses on a Becton Dickinson FACScalibur flow 
cytometer. Median signal intensity from the fluorescence channel was calculated for every condition and 
transformed to arbitrary units. Median signal intensities from washed cells were normalized to median signal 
intensity for unwashed cells (0 days), which were fully covered with cetuximab. Medium-treated A431 cells of 
similar passage number were used as negative control. 
 
Washing long-term cetuximab-treated A431 cells for three days (three times per day) 
removed the majority of the antibody from the system (figure 21). A431 cells treated 
long-term with gefitinib were also washed for three days (three times per day) before 
they were used for further experiments. 
 
A431 cells that were long-term incubated with gefitinib displayed a significant 
resistance against this drug in monolayer growth assays, as compared to A431 cells 
of similar passage number that were cultured in parallel in regular growth medium 
(untreated control) (figure 22). This was reflected by an EC50 value that is roughly 20 
fold higher as the value of the reference population (45µM vs. 2µM). Interestingly, 
A431 cells that were exposed to cetuximab for 15 months (long-term cetuximab) also 
displayed a significantly reduced response towards the TKI (EC50 = 24µM). However 
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this gain is lower than the resistance observed for A431 cells long-term exposed to 
gefitinib. 
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Figure 22   A431 cells long-term treated with gefitinib or cetuximab showed reduced growth inhibition by 
gefitinib in a monolayer assay. A431 cells that were long-term treated with gefitinib or cetuximab were washed 
for two or three days (three times per day), respectively, with full medium before start of experiment. Together 
with medium-treated A431 cells of similar passage (untreated control), they were subjected to a monolayer growth 
assay and treated with variable doses of gefitinib. EC50 values were calculated as mean values from triplicates 
using the Graph Pad Prism software. Relative cell numbers under treatment were calculated by signal 
normalization to medium-treated cells. Each data point is the average from quadruplet values (mean +/- standard 
deviation).  
 
In addition, soft agar colony formation assays were applied to confirm the data 
generated with the monolayer growth assays (figure 23).  
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Figure 23   A431 cells long-term treated with gefitinib or cetuximab showed reduced growth inhibition by 
gefitinib in a soft-agar assay. A431 cells that were long-term treated with gefitinib or cetuximab were washed for 
two or three days (three times per day), respectively, with full medium before start of experiment. Together with 
medium-treated A431 cells of similar passage (untreated control), they were subjected to a soft-agar colony 
formation assay and treated with variable doses of gefitinib. EC50 values were calculated as mean values from 
triplicates with Graph Pad Prism software. Relative cell numbers under treatment were calculated by signal 
normalization to medium-treated cells. Each data point is the average from triplicate values (mean +/- standard 
deviation).  
 
Gefitinib resistance of A431 cells that were long-term exposed to this drug was 
confirmed in soft-agar assays. Resitance of these cells was refelected by an EC50 
value that was roughly 700 fold higher than the EC50 value from medium cultured 
cells of similar passage number (control - high passage) and roughly 200 fold higher 
than the EC50 measured for the A431 starting population (control - low passage) 
(figure 23). A431 cells that were long-term exposed to cetuximab displayed only a 
moderate gain of resistance to gefitinib, reflected by an EC50 value that was roughly 4 
fold increased over the value of control cells with similar passage number (figure 23). 
This finding for cetuximab was in contrast to the observation from monolayer growth 
assays, where A431 cells displayed significant resistance to gefitinib after long-term 
treatment with cetuximab (figure 22).  
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The analysis was also performed to test cetuximab-mediated growth inhibition in the 
long-term cultured A431 cells. As expected from previous analyses growth inhibitory 
effects of the antibody were only very moderate in a monolayer growth assay.  
As figure 24 shows there was still a decent inhibition of the medium-treated control 
cells of high passage number. However, cell numbers were only very moderately 
reduced by cetuximab in A431 cells after long-term exposure to cetuximab or 
gefitinib. Yet, inhibitory effects were too weak to allow calculation of EC50 values for 
any of the tested populations. 
 
 
Figure 24   A431 cells long-term treated with gefitinib or cetuximab showed poor growth inhibition by 
cetuximab in a monolayer assay. A431 cells that were long-term treated with gefitinib or cetuximab were 
washed for two or three days (three times per day), respectively, with full medium before start of experiment. 
Together with medium-treated A431 cells of similar passage (untreated control), they were subjected to a 
monolayer growth assay and treated with variable doses of cetuximab. EC50 values were calculated as mean 
values from triplicates with Graph Pad Prism software. Relative cell numbers under treatment were calculated by 
signal normalization to medium-treated cells. Each data point is the average from quadruplet values (mean +/- 
standard deviation).  
 
Due to the relative resistance of monolayer cell growth to cetuximab, soft-agar colony 
formation assays were carried out to determine the sensitivity and cross-sensitivity of 
long-term-treated A431 cell populations. 
Interestingly, long-term exposure of A431 cells to cetuximab under standard cell 
culture condition did not appear to render these cells resistant to the antibody in a 
soft-agar growth assay (figure 25). In contrast, it even appeared that this population 
was rather sensitized, when comparing the EC50 value to those of medium-treated 
control cells (0,008µg/ml vs. 0,04µg/ml and 0,054µg/ml, respectively). Yet, the 
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efficacy of growth-inhibition for cetuximab long-term treated cells by cetuximab was 
somewhat lower than for medium-treated A431 cells with similar passage number 
(high passage) (67% vs. 87%).  
Surprisingly, A431 cells resistant to gefitinib after long-term exposure to this drug still 
responded very well to cetuximab. The extent of cetuximab caused growth inhibition 
was comparable to medium-treated control cells (EC50 0,014µg/ml vs. 0,04µg/ml and 
0,054µg/ml, respectively) and the same was true for the efficacies of growth inhibition 
(76% vs. 87% and 78%, respectively). 
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Figure 25   A431 cells long-term treated with gefitinib or cetuximab did not show reduced growth 
inhibition by cetuximab in a soft-agar assay. A431 cells that were long-term treated with gefitinib or cetuximab 
were washed for two or three days (three times per day), respectively, with full medium before start of experiment. 
Together with medium-treated A431 cells of similar passage (untreated control), they were subjected to a soft-
agar colony formation assay and treated with variable doses of cetuximab. EC50 values were calculated as mean 
values from triplicates with Graph Pad Prism software. Relative cell numbers under treatment were calculated by 
signal normalization to medium-treated cells. Each data point is the average from triplicate values (mean +/- 
standard deviation).  
 
3.2.3 Morphological changes in cell lines with primary drug sensitivity 
During the cultivation of the different A431 cells, it became obvious that the 
populations were subject to significant morphological changes. Phenotypical 
alterations were first observed after two to three months of cetuximab treatment. 
While the concentration of cetuximab was kept constant (33µg/ml), doses were 
steadily increased in the gefitinib-treated population. Here, the starting concentration 
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was 0,5µM (corresponding to the EC50 in a monolayer growth assay), which 
significantly reduced cell numbers in culture and caused a longer period of growth 
stasis in the viable cells. After two to three months cells resumed growth and from 
this point, gefitinib concentrations were increased in steps of dose doublings (0,5µM; 
1µM; 2µM; 5µM; 10 µM). The morphology of A431 was documented fifteen months 
after the start of treatments (figure 26). 
 
 
CetuximabMedium control  
(low passage)
GefitinibMedium control  
(high passage)
 
 
Figure 26  A431 cells showed distinct morphological alterations upon long-term treatment with 
cetuximab, gefitinib or long-term cultivation in full medium. A431 cells treated with cetuximab or gefitinib for 
15 months, as well as medium-treated control cells of similar passage number (high passage) and medium-
treated cells from the starting population (low passage) were seeded and photographed under 40 fold (up) and 
400 fold (down) magnifications with a light microscope. 
 
The A431 cell line is widely used as a model for cancer cells that display typical 
epithelial features. Epithelial cells are closely attached to each other through tight 
cell-cell contacts and are mainly assembled in compact colonies in cell culture. The 
A431 starting population (medium control, low passage) was a classic example for 
that (figure 26).  In contrast, A431 cells showed a completely different morphology 
after a long-term cultivation in regular growth medium (medium control - high 
passage). In this population most cells had a longitudinal cell shape and a fibroblastic 
morphology with many cell extensions. Cell-cell contacts were loose and colonies 
were mainly broken up with single cells or small aggregates spreaded over the 
surface of the culture dish. This population displayed typical features of 
mesenchymal cell lines. Obviously, cultivation of A431 cells under standard cell 
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culture conditions for a period of fifteen months provoked morphological changes, 
which have been described as epithelial-mesenchymal transition (EMT).   
The population that had been long-term exposed to cetuximab also showed 
morphological alterations in comparison to the starting population (low passage). In 
proportion, cells from the cetuximab-treated population were slightly bigger, appeared 
flattened and contained a more prominent nucleus than cells from the starting 
population. Also these features pointed towards a more mesenchymal phenotype. 
However, the cetuximab-treated population still displayed fundamental epithelial 
characteristics, including tight cell-cell contacts and development of organized, 
defined colonies.    
In contrast, the morphology of A431 cells that were treated with gefitinib appeared 
very similar to that from long-term untreated A431 cells with similar passage number 
(medium control – high passage). Cell extensions protruding from gefitinib-resistant 
A431 cells were even a little more pronounced than in the high passage reference 
cells, possibly indicating an increased migratory activity within this population (figure 
26).  
 
In parallel to A431 cells, Difi cells were as well long-term exposed to cetuximab and 
gefitinib. Since these cells are hypersensitive to either drug under monolayer growth 
conditions, treatment doses were increased for cetuximab (from a starting 
concentration of 0,2µg/ml to a maximal dose of 5µg/ml) and gefitinib (from a starting 
concentration of 75nM to a maximal dose of 1,5µM). The starting doses were chosen 
to be close to the calculated EC50 value for each drug. Both therapeutics significantly 
reduced cell numbers in culture and caused a long period of growth stasis in the 
living cells. Even after 15 months of drug exposure, cetuximab and gefitinib-treated 
Difi cells still growed slowly as compared to medium-treated reference cells.  
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Figure 27   Difi cells showed distinct morphological alterations upon long-term treatment with cetuximab 
and gefitinib. Difi cells treated with cetuximab or gefitinib for 15 months, as well as medium-treated control cells 
of similar passage number (high passage) and medium-treated cells from the starting population (low passage) 
were seeded and photographed under 40 fold (up) and 400 fold (down) magnifications with a light microscope.  
 
Plain cultivation of Difi cells under standard cell culture conditions did not confer any 
significant change with regard to the cell population’s morphology, as it had been 
observed for A431 cells (figures 26 and 27). On the other hand, higher magnifications 
of Difi populations that were exposed to gefitinib or cetuximab revealed considerable 
alterations. Especially cetuximab-treated cells showing a diffuse morphology and 
unorganized colony formation and some cells show an enlarged hyperchromatic 
nucleus (figure 27). Notably, gefitinib-treated Difi cells displayed an unusual colony 
formation pattern and single cell morphology. Figure 27 exemplarily highlights one 
gefitinib-treated cell with five nuclei. Along with multinucleated cells in the gefitinib-
treated population, a high ratio of Difi cells with two nuclei was found after exposure 
to either drug. This may point towards impaired cellular cytokinesis. 
 
Similarly, H460 lung cancer and SW707 colon cancer cell lines were long-term 
treated with cetuximab and gefitinib for 12 months and 8 months, respectively. Drug 
concentrations were kept constant for cetuximab (33µg/ml) and gefitinib (10µM), 
since no growth inhibition was seen for cetuximab at variable doses and the EC50 for 
monolayer growth inhibition by gefitinib was around 10µM in these cell lines. 
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In contrast to the cell lines with primary sensitivity for gefitinib and cetuximab, A431 
and Difi, no morphological changes were observed between medium-treated control 
populations and cells that were exposed for several months to either drug (figure 28). 
This implied that the morphological changes seen for A431 and Difi cells upon drug 
exposure were primarily due to effects of both drugs on EGFR and not on cellular off-
targets. 
 
Cetuximab GefitinibMedium control 
high passage
Cetuximab GefitinibMedium control 
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H460
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Figure 28   H460 and SW707 cells did not show morphological alterations upon long-term treatment with 
cetuximab or gefitinib. H460 and SW707 cells treated with cetuximab or gefitinib for 12 months or 8 months, 
respectively, as well as medium-treated control cells of similar passage number (high passage) were seeded and 
photographed under 40 fold magnification with a light microscope. 
 
3.2.4 Characterization of biological and biochemical changes in long-term-
treated A431 cells 
3.2.4.1 Examination of EGFR levels and dynamics in A431 cells 
The significant morphological changes observed for A431 cells implied major 
molecular alterations underlying and causing the rendered phenotypes. To start with 
a detailed examination of biochemical and biological changes in A431 cells, the 
surface levels of EGFR were determined via FACS analyses.   
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Figure 29   A431 cells showed reduced EGFR surface levels after long-term treatment with cetuximab and 
gefitinib.  A431 cells long-term treated with cetuximab or gefitinib were washed for two or three days, 
respectively, with full medium three times per day. EGFR on these and medium-treated control cells of similar 
passage number (high passage) was detected with an EGFR-specific FITC conjugated antibody, which has been 
shown to bind another epitope than cetuximab (Jürgen Schmidt, TA Oncology, Merck KGaA, personal 
communication), followed by analyses on a Becton Dickinson FACScalibur flow cytometer. Median signal intensity 
from the fluorescence channel was calculated for every condition and transformed to arbitrary units. Median 
signal intensities from cells treated with cancer therapeutics were normalized against median signal intensity of 
medium-treated control cells of similar passage number. 
 
Long-term exposure of A431 cells to cetuximab, led to a fourfold reduction of the 
surface EGFR. As also apparent from figure 29, gefitinib-resistant A431 cells 
displayed twofold reduced surface levels of EGFR, as compared to medium-treated 
control cells of similar passage number.    
 
It has been reported that pancreas cancer cells, which are resistant to cetuximab in 
murine xenografts, displayed reduced cetuximab-mediated receptor internalization, 
as compared to pancreas cancer cells that are sensitive to the antibody (Arnoletti et 
al., 2005). This finding could also be reproduced for six NSCLC cell lines selected 
from the panel characterized above (Irmer et al., 2007b). To access the cetuximab 
associated dynamics of EGFR in long-term-treated A431 cells, they were incubated 
with radioactively labeled antibody for 30 min followed by measuring intracellular and 
extracellular portions of radiation.   
As evident from figure 30, medium-treated control cells of high or low passage 
number showed efficient cetuximab induced EGFR internalization after a 30-min 
exposure to 125I-labeled cetuximab (41% and 46% internalization, respectively). On 
the other hand A431 cells that were long-term treated with cetuximab and cleared 
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from the antibody prior to the experiment (cf. figure 21), showed a slightly reduced 
capacity for cetuximab induced receptor turnover. Gefitinib-resistant A431 cells, 
however, had a markedly decreased ability for EGFR internalization upon exposure 
with cetuximab. Noteworthy, these gefitinib-resistant A431 cells do show a slightly 
decreased response to cetuximab in a soft-agar colony formation assay, in regard to 
their EC50 value, as compared to medium-treated control cell lines (figure 25). 
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Figure 30   A431 cells showed reduced EGFR internalization after long-term treatment with cetuximab or 
gefitinib. Internalization of 125I-cetuximab was examined 30 min after incubation of A431 cells with 2nM 
radioactively labeled antibody under serum starving conditions. The internalization rate is indicated as fraction of 
125I-cetuximab that was found in cell lysates in relation to total 125I-cetuximab deployed in the experiment. 
Antibody internalization of A431 cells long-term treated with cetuximab or gefitinib and washed with medium for 
three or two days, was compared with internalization of medium-treated control cells of similar passage number 
(high passage) or from the starting population (low passage). 
 
In the next step, total expression of EGFR and other ErbB receptors in the different 
A431 populations was determined via immunoblot analyses of cell lysates. As 
depicted in figure 31, expression of EGFR was comparable between the long-term 
cultured populations, yet gefitinib-resistant A431 cells showed a roughly two-fold 
decreased expression of the receptor. In contrast A431 cells from the starting 
population showed moderately higher levels of total EGFR. Together with the results 
from the FACS analyses (figure 29) this indicated that gefitinib-resistant A431 cells 
had a roughly two fold reduced level of total cellular EGFR, as compared to medium-
treated control cells of similar passage number (medium control; fifteen months). On 
the other hand, A431 cells that were exposed long-term to cetuximab had markedly 
reduced surface levels of receptor; however, cellular levels of total EGFR were 
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comparable to the levels in medium-treated control cells of similar passage. This 
would mean that in long-term cetuximab-treated cells roughly fourfold more EGFR 
was localized within the cell as compared to medium-treated cells of similar passage 
number.  
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Figure 31   Expression of ErbB receptors moderately differed between long-term gefitinib or cetuximab-
treated A431 cells and reference A431 cells. ErbB receptor expression in A431 cells treated 15 months with 
gefitinib or cetuximab was compared with expression in medium-treated controls cells of similar passage number 
and expression in the starting population. Cellular lysates were normalized after protein quantification by BCA 
assay and probed by immunoblotting. Expression of cofilin has been determined as a loading control.  
 
While ErbB2 could not be detected in either population, ErbB3 expression was similar 
in all populations and slightly higher in cetuximab-treated cells. Expression of the 
ErbB4 receptor was moderately higher in A431 cells from the starting population and 
cetuximab-exposed cells as compared to the gefitinib-resistant population and 
medium-treated cells of similar passage number. 
 
3.2.4.2 Analyses of molecular markers for epithelial-mesenchymal transition 
(EMT) in A431 cells 
In order to further characterize the morphological changes observed within the 
different A431 cell populations, cellular lysates were probed for the expression of 
EMT marker proteins (figure 32).  
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Figure 32   Long-term incubation of epithelial A431 cells with cetuximab or gefitinib, but not long-term 
cultivation in medium, prevented expression of mesenchymal cell-like marker proteins. EMT marker 
protein expression in A431 cells long-term treated with gefitinib or cetuximab and in medium-treated control cells 
of similar passage number was determined and compared with EMT marker expression in typically epithelial 
(MCF7, A431 starting population) and mesenchymal (MDA-MB-231, Skov-3, Hela) reference cell lines. Cellular 
lysates were normalized after protein quantification by BCA assay and probed by immunoblotting. Expression of 
cofilin has been determined as a loading control. 
 
MCF-7 and A431 cells from the starting population are typical epithelial cells and 
served as references. On the other hand, MDA-MB-231, Skov-3 and Hela cells were 
included as typical mesenchymal references. Other controls were MCF-7 cells, 
treated with Phorbol 12-myristate 13-acetate (PMA) (8 h; 0,1 µM or 1 µM, 
respectively) or with tumor necrosis factor alpha (TNFα) (48 h; 5ng/nl or 20ng/ml, 
respectively). It was expected that treatment of MCF cells with PMA would reduce 
cellular levels of E-Cadherin (Kuroda et al., 1998; Li et al., 2005a); yet this could not 
be reproduced here. Treatment with TNFα has been shown to initiate EMT in MCF-7 
cells (Dong et al., 2007), which was reflected by a moderate decrease in E-Cadherin 
expression (figure 32). 
 
3. Results    
   
94
The expression profile of untreated MCF-7 and A431 cells from the start population 
was typically epithelial (figure 32): these cells showed a high expression of E-
cadherin, but lacked expression of mesenchymal markers N-cadherin and vimentin. 
This expression profile was also shared by A431 cells after long-term exposure to 
cetuximab or gefitinib. In contrast, medium-treated A431 of similar passage number 
lost E-cadherin expression and had high levels of vimentin. This profile was also 
shared by the mesenchymal reference cell lines MDA-MB-231, Skov-3 and Hela. The 
latter two cell lines also expressed low or high levels of N-cadherin, respectively. 
While TNFa treatment moderately diminished the E-cadherin levels of MCF-7 cells, 
exposure with PMA did not have any effect on the expression of EMT marker 
proteins. Interestingly, gefitinib-resistant cells did express markedly less E-cadherin 
than A431 cells that were long-term exposed to cetuximab, which correlated with the 
reduction of cell-cell contacts (cf. figure 26).  
 
3.2.4.3 Identification of scavenger pathways compensating for EGFR 
blockade in A431 cells 
It has been reported that gefitinib or cetuximab mediated blockage of EGFR may be 
compensated by an increased action of other RTK-mediated signaling pathways (Liu 
et al., 2001; Chakravarti et al., 2002). In order to identify RTKs, which are turn on 
upon long-term treatment of A431 cells with EGFR-directed drugs, lysates from the 
different populations were probed with a human phospho-RTK array. This array 
allowed simultaneous assessment of the relative activation of 42 different RTKs.  
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Figure 33   Differential activation of RTKs in A431 cells under long-term treatment with cetuximab or 
gefitinib. Proteome ProfilerTM Array membranes spotted with capture antibodies for human RTKs were probed 
with cellular lysates from A431 long-term treated with cancer therapeutics and medium-treated control cells of 
similar passage number (high passage) or from starting population (low passage) as described in material and 
methods. Phosphorylation of captured RTKs was visualized with a HRP-coupled anti-phospho-tyrosine antibody 
followed by chemiluminscence detection with the Versa Doc documentation system. Kinases with significant 
differences of activation between cell lines are highlighted in color. The array used for lysates from the starting 
population (low passage), was from another production charge as the other arrays. 
 
The signal intensities from the immunoblots were quantified and relative 
phosphorylation levels of significant differently regulated RTKs were summarized 
(figure 34). There was a high activation of HGFR and Axl in A431 cells long-term 
treated with cetuximab as compared to medium-treated cells of similar passage 
number. Axl phosphorylation was also markedly upregulated in gefitinib-resistant 
A431 cells, which was also true for EphA4. On the other hand, phosphorylation of 
ErbB2 and ErbB3 was significantly downregulated in gefitinib-resistant A431 cells, 
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but not in cells that were long-term exposed to cetuximab. Further, phosphorylation of 
EGFR was fivefold downregulated in gefitinib-resistant cells, but only moderately 
decreased in A431 cells after a fifteen months exposure to cetuximab. In addition, a 
moderate decrease of EphA2 phosphorylation was observed in the latter cell 
population, which could be a secondary effect caused by EGFR inhibition through 
cetuximab (Larsen et al., 2007).   
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Figure 34    Differntial activation of Axl, HGFR, EphA4, EGFR, ErbB2, ErbB3 and EphA2 was observed in 
A431 cells after long-term incubation with cetuximab or gefitinib. Chemiluminscence signals were quantified 
and data processing with QuantityOne software was done by background substraction, determination of average 
signal density from duplicate values and normalization of values from long-term cetuximab or gefitinib-treated cell 
lysates against values from untreated control cell lysates of similar passage number (high passage), which were 
set 1.  
 
To verify HGFR activation in long-term cetuximab-treated cells further immunoblot 
analyses with specific phospho-HGFR antibodies were carried out. A549 lung cancer 
cells treated with 20ng/ml HGF for 5 min were used as a positive control. Cetuximab 
long-term treated A431 cells showed markedly increased levels of activated HGFR 
and moderately increased levels of total HGFR as compared to medium treated cells 
with a similar passage number (medium control; fifteen months) (figure 35). Gefitinib-
resistant A431 cells showed only moderately increased levels of activated HGFR and 
markedly increased expression of total HGFR. Interestingly, A431 cells from the 
starting population showed a comparable expression of HGFR as cells from the long-
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term medium-treated population, but a significantly increased activation of this 
receptor. 
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Figure 35   High activation of HGFR was seen  in long-term cetuximab-treated A431 cells. Activation and 
expression of HGFR in A431 cells long-term treated with gefitinib or cetuximab and in medium-treated control 
cells of similar passage number was determined and compared an compared with levels in A431 cells from the 
starting population. Cellular lysates were normalized after protein quantification by BCA assay and probed by 
immunoblotting. Expression of cofilin has been determined as a loading control. 
 
Thus, the ratio of activated receptor over total receptor was the highest in A431 cells 
from the starting population, followed by cetuximab long-term treated A431 cells. 
Gefitinib-resistant A431 cells displayed an increased HGFR expression, but a low 
ratio of activated receptor. In contrast, medium-treated control cells of high passage 
number showed a low expression combined with a low activation of HGFR, which 
may imply a decreased importance of this signaling component for cellular growth.  
 
To test whether high activation of HGFR in long-term cetuximab-treated cells and 
cells from the start population correlated with increased sensitivity of these 
populations to HGFR-directed TKIs, soft-agar colony formation assays under 
treatment with cetuximab and/or HGFR-TKIs were performed. PHA-665752 
(SUGEN/Pfizer) (Christensen et al., 2003), PF-2341066 (Pfizer) (Zou et al., 2007) 
and EMD638330 (Merck KGaA) are HGFR specific ATP-competitors designed for 
cancer therapy. SNU-5 cells that are hypersensitive to HGFR-specific TKIs were 
used as a positive control for treatments (figure 36). 
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Figure 36  Growth of cetuximab long-term treated A431 cells was more efficiently blocked by HGFR 
inhibitors than growth of gefitinib-resistant or medium-treated cells of similar passage number. A431 cells 
were treated with 1µM of HGFR specific tyrosine kinase inhibitors PHA-665752, EMD63830 or PF-2341066 in 
combination with or without 0,33µg/ml cetuximab in a soft-agar colony formation assay. Evaluation was performed 
through fluorescence detection by Cell Titer Blue reagent and read-out with a plate reader after 10 days of 
cultivation. Relative cell numbers (%) were calculated by subtraction of pharmacological background and signal 
normalization to medium-treated samples. Each bar is the average from triplicate values. Bars for medium-treated 
control cells were calculated from sextuplets (mean +/- standard deviation). Pharmacological background was 
determined by treatment of cells with 100µM paclitaxel, which efficiently kills all cells. (d) A431 cells from the 
starting population (low passage) and (e) SNU-5 cells were used as controls. 
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A431 cells from the starting population (short term cultured; low passage) and long-
term cetuximab-treated cells were most efficiently inhibited by single treatment with 
1µM of different HGFR inhibitors, as reflected by the efficacies of inhibition (decrease 
of cell number compared to medium-treated cells) (figure 36). Both populations were 
partially inhibited by PHA-665752 (28% efficacy for long-term cetuximab-treated and 
30% efficacy for the starting population) and EMD638330 (35% and 28%, 
respectively), while they were markedly inhibited by PF-2341066 (55% and 60%, 
respectively). In addition, these data show that growth of both populations could be 
further repressed by combining HGFR inhibitors with cetuximab. 
In contrast, medium-treated A431 cells with a high passage number (long-term 
cultured; figure 36a) were not particularly responsive to single treatment with HGFR 
TKIs, as reflected by the efficacies of inhibition (1% for PHA-665752, 7% for 
EMD638330 and 30% for PF-2341066). Yet, this population was highly sensitive to 
cetuximab in this experiment.   
Gefitinib-resistant A431 cells were also only slightly responsive to the HGFR 
inhibitors as displayed by the efficacies of inhibition (9% for PHA-665752, 13% for 
EMD638330 and 26% for PF-2341066) (figure 36c). This again was in line with the 
relatively low level of HGFR expression in this population (figure 35). Combining 
HGFR TKIs with the EGFR-targeting antibody cetuximab efficiently blocked soft-agar 
growth of gefitinib-resistent cells. However, the combination of HGFR TKIs with 
cetuximab seemed to be additive and not synergistic in any cell population.  
 
3.2.5 Examination of differential gene expression in cancer cell lines upon 
long-term treatment with EGFR-specific cancer drugs 
The morphological alterations that were observed after long-term treatment in 
gefitinib and cetuximab sensitive cell lines, A431 and Difi, but not in primary resistant 
cell lines, H460 and SW707 cells, underlined that the fundamental phenotypical 
changes which occured can be expected due to specific EGFR blockage. Since 
significant molecular alterations, reflected by differential expression of mRNA entities, 
could underlie this rendered morphology, differential gene expression patterns in the 
various populations were examined.  
 
A candidate-based approach with Taqman® low density arrays was performed to 
reveal differentially expressed candidates between the different populations and cell 
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lines. This approach aimed at the identification of factors that were differently 
expressed in primary sensitive cell lines (A431 and Difi) after long-term exposure to 
either drug, but whose expression was not altered in primary resistant cell lines 
(H460 and SW707). The detection of such factors could help to identify mechanisms, 
which are responsible for the development of an acquired resistance to gefitinib or 
cetuximab in primary sensitive cells. In this regard, H460 and SW707 cell lines were 
considered as negative controls. 
 
Table 5 summarizes the data from 25 selected candidate genes that were derived 
from a global expression analysis, which were classified due to their regulation in 
primary sensitive or resistant cell lines after long-term exposure to cetuximab.  
Eight candidate genes were differentially regulated in long-term cetuximab-treated 
Difi and A431 cells, but their expression was unaltered in long-term-treated H460 and 
SW707 cell lines, as compared to medium-treated control cells of similar passage 
number. Notably, CCL5 (chemokine ligand 5) expression was not detected in SW707 
cells and EREG was not expressed in H460 cells. Interestingly, expression of the 
ErbB ligands EGF and BTC was upregulated, while expression of the ligands EREG 
and HB-EGF was downregulated in primary sensitive cancer cells after long-term 
exposure to cetuximab as compared to medium-treated cells of similar passage 
number. Furthermore, A431 and Difi cells showed stronger expression of 
complement factor 3 (C3) and CCL5, and lower expression levels of TIMP1 (TIMP 
metallopeptidase inhibitor 1) and EGFR after long-term cetuximab treatment.  
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Table 5   Differential mRNA expression in human cancer cell lines long-term treated with cetuximab. Two 
cell lines with primary cetuximab sensitivity (Difi, A431) and two cell lines with primary cetuximab resistance 
(H460, SW707) were long-term treated with cetuximab and diferential candidcate gene expression was 
determined in comparision to long-term medium cells of similar passage number. A differential candidate gene 
expression of >2 or <0,5 after long-term cetuximab treatment in both cell lines within one group (e.g. the primary 
sensitive group), connected with no respective differential expression after cetuximab treatment in the other group 
(e.g. the primary resistant group), was considered to be of particular interest, e.g. HB-EGF (green). A differential 
candidate gene expression of >2 or <0,5 after long-term cetuximab treatment in only one cell line within one 
group, connected with no strong change in the other group, was considered to be marginally interesting, e.g. 
TGFα or AREG (orange). A differential candidate gene expression of >2 or <0,5 after long-term cetuximab 
treatment in one or two cell lines within one group, connected with a respective change for one or two cell lines in 
the other group, was considered uninteresting when the change followed the same trend for both groups, e.g. 
ErbB4 (red). (+) Indicates up-regulation of the respective candidate in cetuximab long-term-treated cells as 
compared to medium-treated control cells with similar passage number, (-) indicates down-regulation. Gene 
expression of some candidate genes could not be detected in one (*) of the four cell lines. The evaluation of data 
probed via Taqman® LDAs was performed by Mr. Baumgärtner in the laboratory of Mr. Haas, Merck KGaA.    
 
The following chart shows the calculated fold changes of C3, EGF, HB-EGF and 
CCL-5 mRNA expression levels in long-term cetuximab-treated cell lines, as 
compared to medium-treated cells of similar passage number (figure 37).   
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Figure 37   Complementary factor 3, CCL-5 and natural ligands of EGFR were differentially expressed in 
human cancer cell lines after long-term treatment with cetuximab. Real-time PCR analyses (with Taqman® 
low density Arrays) was performed with mRNA from Difi and A431 cells (primary sensitive to cetuximab; green 
bars) and H460 and SW707 cells (primary resistant to cetuximab, red bars). Relative expression of mRNA from 
cell lines after long-term treatment with cetuximab to mRNA of medium-treated control cell lines of similar 
passage number was calculated as described in material and methods. Relative expression of a candidate gene 
is indicated as fold change in relation to the medium treated control (control = 1). (*) No expression of CCL-5 
mRNA could be detected in SW707 cells. 
 
The same analyses were performed with the gefitinib-treated cancer cell lines. Again, 
25 candidate genes were classified due to their regulation pattern in primary sensitive 
or primary resistant cell lines after long-term exposure to gefitinib (table 6). 
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Table 6   Differential mRNA expression in human cancer cell lines long-term treated with gefitinib. Two cell 
lines with primary cetuximab sensitivity (Difi, A431) and two cell lines with primary cetuximab resistance (H460, 
SW707) were long-term treated with gefitinib and diferential candidcate gene expression was determined in 
comparision to long-term medium cells of similar passage number. A differential candidate gene expression of >2 
or <0,5 after long-term gefitinib treatment in both cell lines within one group (e.g. the primary sensitive group), 
connected with no respective differential expression after gefitinib treatment in the other group (e.g. the primary 
resistant group), was considered to be of particular interest, e.g. EREG (green). Candidates showing different 
trends over different groups were also considered to be interesting, e.g. IL1a (green). A differential candidate 
gene expression of >2 or <0,5 after long-term gefiitinb treatment in only one cell line within one group, connected 
with no strong change in the other group, was considered marginally interesting, e.g. CXCL-10 (orange). A 
differential candidate gene expression of >2 or <0,5 after long-term gefitinib treatment in one or two cell lines 
within one group, connected with a respective change for one or two cell lines in the other group, was considered 
uninteresting when the change followed the same trend for both groups, e.g. AREG (red). (+) Indicates up-
regulation of the respective candidate over in long-term treated cells as compared to medium-treated control cells 
with similar passage number, (-) indicates down-regulation. Gene expression of some candidate genes could not 
be detected in one (*) or two (**) of the four cell lines. The evaluation of data probed via Taqman® LDAs was 
performed by Mr. Baumgärtner in the laboratory of Mr. Haas, Merck KGaA.    
 
As compiled in table 6, EREG mRNA was found to be downregulated in gefitinib-
resistant Difi and A431 cell lines. On the other hand CXCL-6 (chemokine ligand 6) 
mRNA was upregulated in both cells lines that acquired resistance to gefitinib. Both 
genes were unaltered in long-term gefitinib-treated SW707 cells and could not be 
detected in H460 cells. Expression of another candidate gene, interleukine 1 (IL1), 
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was downregulated in A431 cells that acquired resistance to gefitinib, while IL1 
expression increased in long-term gefitinib-treated H460 cells, which are primary 
resistant to the TKI. Other candidate genes (BTC, C3, ErbB4, Mig6 and MMP-7) were 
not considered interesting as putative factors determining response to gefitinib, since 
their expression was altered with the same trend in primary sensitive, as well as in 
primary resistant cell lines. 
 
Calculated fold changes of EREG, CXCL-6 and IL1 mRNA expression levels in long-
term gefitinib-treated cell lines, as compared to medium-treated cells of similar 
passage number are shown in figure 38.   
 
Epiregulin
0,3
0,1
1,4
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
1,60
Difi A431 H460 SW707
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
untreated 
control = 1
CXCL-6
1,1
4,6 4,5
0,00
1,00
2,00
3,00
4,00
5,00
6,00
Difi A431 H460 SW707
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
untreated 
control = 1
*
*
Interleucine-1a
4,6
0,3
0,00
1,00
2,00
3,00
4,00
5,00
Difi A431 H460 SW707
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
untreated 
control = 1* *
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
 
 
Figure 38   Epiregulin and CXCL-6 were differentially expressed in human cancer cell lines after long-term 
treatment with gefitinib. Real-time PCR analyses (with Taqman® low density arrays) was performed with mRNA 
from Difi and A431 cells (primary sensitive to gefitinib; green bars) and H460 and SW707 cells (primary resistant 
to gefitinib; red bars). Relative expression of mRNA from cell lines after long-term treatment with gefitnib to mRNA 
of medium-treated control cell lines of similar passage number was calculated as described in material and 
methods. Relative expression of a candidate gene is indicated as fold change in relation to the medium treated 
control (control = 1) (*) No expression of Epiregulin and CXCL-6 mRNA could be detected in H460 cells. (**) 
Interleukine-1a expression could not be detected in Difi and SW707 cells. 
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4. Discussion 
Innovative cancer treatment strategies focus on the specific inhibition of target 
structures that are either unique or overrepresented in cancer cells. Since the onset 
of apprehending EGFR as a suitable drug target (Sato et al., 1983), a variety of 
specific cancer therapeutics has been developed, with gefitinib and cetuximab being 
the compounds with the broadest clinical use (Johnston et al., 2006). Since cancer 
patient response rates to these therapeutics are found to be sometimes unsatisfying, 
it is necessary to identify patient subpopulations that may profit best from the 
respective regimen.  
This study evaluated existing marker proteins proposed to impart sensitivity to EGFR-
targeting therapy and further postulates new candidate factors with predictive value. 
In addition, this work revealed new insights in the mode of action of the therapeutic 
antibody cetuximab and the tyrosine kinase inhibitor (TKI) gefitinib. 
 
4.1 Response to gefitinib is neither exclusively nor strictly determined by 
presence of EGFR kinase mutations   
EGFR kinase domain mutations have been associated with clinical response of 
NSCLC patients to treatment with gefitinib (Lynch et al., 2004; Paez et al., 2004). And 
meanwhile these findings were reproduced in different laboratory examinations 
(Amann et al., 2005; Sordella et al., 2005). A little later a secondary mutation, T790M, 
appearing in combination with sensitizing mutations was found to confer resistance to 
gefitinib (Kobayashi et al, 2005; Pao et al., 2005a). In this work, two consecutive 
approaches have been chosen to evaluate the impact of EGFR kinase domain 
mutations for gefitinib therapy: the generation of NIH3T3 cells exogenously 
expressing different EGFR variants and the characterization of a panel of NSCLC cell 
lines endogenously expressing EGFR variants. 
 
In soft-agar colony formation assays it could be demonstrated that murine NIH3T3 
cells expressing human EGFR with classical kinase domain mutations (L858R and a 
short deletion mutation encompassing the LREA motive) were hypersensitive to 
gefitinib. This is in line with another study using the same cell model (Greulich et al, 
2005). In addition, it was verified that colony formation of cells with EGFR variants 
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containing a T790M amino-acid exchange mutation was unaffected by gefitinib 
(figure 13). 
 
The study on a panel of NSCLC supported the notion that sensitivity of NSCLC cell 
lines to gefitinib treatment in a soft-agar matrix growth assay is frequently, however 
not exclusively, seen in cells that carry EGFR kinase domain mutations. Notably, a 
NSCLC cell line, HCC2279, was identified that has an EGFR mutation, yet is 
resistant to gefitinib (cf. figure 14). This is in line with in vitro data from others 
(Fujimoto et al., 2005) and underlines the findings from various clinical trials where 
also patients with wild-type EGFR responded very well to TKI treatments (as 
summarized in Irmer et al., 2007a). It was suggested that EGFR kinase mutations 
and KRAS mutations are mutually exclusive and that activating mutations in KRAS 
confer resistance to gefitinib (Pao et al., 2005b; Eberhard et al., 2005). The data 
presented in this work also supported this notion, which is reflected by the growth 
responses observed for Calu6 and H460 cell lines that both carry KRAS mutations. 
On the other hand, A549 cells, which also express mutant KRAS, were moderately 
responsive to gefitinib and were not clearly assignable in the two-armed classification 
approach.  
 
In summary, these in vitro examinations provide verification that response to gefitinib 
is neither exclusively nor strictly determined by the presence of EGFR kinase 
mutations. Obviously, cellular factors other than EGFR-T790M or KRAS mutations, 
which occur in parallel to kinase domain mutations, may specify cellular resistance to 
gefitinib. These factors may not come into play in the genetically engineered NIH3T3 
cells, which are growth dependent on EGFR. While inhibition of EGFR signaling in 
NIH3T3 cells strictly paralled the growth inhibition (figures 11 and 13), this was not 
the case for NSCLC cell lines (figures 14 and 15). This also points toward the 
increased level of complexity when studying tumor cells transformed by multiple 
cancerogenic factors.  
 
4.2 Cellular sensitivity to cetuximab is determined by factors other than EGFR 
kinase domain mutations 
Scarce clinical examinations indicate that response to cetuximab in NSCLC does not 
appear to correlate with the presence of EGFR mutations (Lynch et al., 2004, 
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Mukohara et al., 2005, Tsuchihashi et al., 2005). Apart from a report which shows 
that one cell line (PC9), carrying an EGFR mutation, is growth inhibited by cetuximab 
in a soft-agar assay (Perez-Torres et al., 2006), no systematic in vitro examinations 
have been published in that respect.  
Here, a panel of twelve NSCLC cell lines was characterized concerning their growth 
response under treatment with cetuximab. From these examinations it was evident 
that EGFR kinase mutations in NSCLC do not have any predictive value for 
cetuximab in vitro response. A recent study with 30 colorectal cancer patients 
showed that KRAS mutations are associated with resistance to cetuximab therapy 
(Lievre et al., 2006). Interestingly, cetuximab inhibited growth of A549 cells in a soft-
agar matrix, which may be indicative for its basic potential to repress proliferation of 
cells with KRAS mutations. However, this sensitivity was only classified moderate 
and two other cell lines with an equivalent activating KRAS mutation, Calu6 and 
H460, did not respond to cetuximab under the applied assay conditions. Yet, in vivo 
tumor growth of Calu-6 cells could be delayed by treatment with cetuximab and 
gefitinib in murine xenografts (figure 16), suggesting again that KRAS mutations are 
not necessarily associated with resistance to cetuximab.  
Furthermore, it could be shown that the antibody effectively inhibits in vitro growth of 
gefitinib-sensitive H1650 cells, which lack the tumor suppressor PTEN in addition to 
having an EGFR kinase domain mutation. Lack of PTEN, which negatively regulates 
activity of Akt by dephosphorylating phosphatidylinositol triphosphate (PI3P), was 
suggested to be a prognostic marker for gefitinib resistance (She et al., 2003). While 
the presence of the EGFR mutation might be predominant over the lack of PTEN 
when explaining the observed sensitivity of the cell line towards gefitinib, the data 
from the xenograft experiment suggested that lack of PTEN is not necessarily 
predictive for resistance to cetuximab in NSCLC (cf. figure 16). 
Taken together, sensitivity of NSCLC cell lines to cetuximab was independent of 
EGFR kinase domain mutations. In addition, these observations suggest that lack of 
PTEN is not causative for resistance to cetuximab. In addition, the postulated value 
of KRAS mutations for explaining resistance to EGFR-targeting drugs can could be 
put into question according to results of the investigations performed in this study. In 
summary, in can be inferred from the in vivo examinations that cetuximab may block 
or at least delay growth of any NSCLC cell lines studied, independent from the 
genetic background. The inconsistancy of some results from in vitro and in vivo 
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experiments observed for cetuximab underlines the necessity to perform in vivo and 
clinical exminations in order to cover all aspects of the complex functionality of this 
drug.  
 
4.3 Basal expression profiling of NSCLC cells identifies candidate genes 
putatively predicting response to EGFR-targeting therapy 
Three global gene expression profiling approaches have already been conducted to 
identify candidate genes or signatures associated with response of NSCLC cell lines 
to EGFR-targeting TKIs (Yauch et al., 2005; Balko et al., 2006; Coldren et al., 2006). 
In this study an Affymetrix whole genome chip based expression analyses identified 
46 genes that show a significantly differential expression between gefitinib sensitive 
and resistant cell lines with an unadjusted p <0,001 (table 3). This includes 15 
candidates (32,6%) that were also found in at least one of the other three analyses. 
Furthermore this study revealed novel genes whose expression levels may affect 
outcome of a gefitinib therapy. These include lysophosphatidic acid receptor 1 
(EDG1), which is capable to transactivate EGFR via the release of HB-EGF, a natural 
ligand of EGFR and ErbB4 (Liu and Armant, 2004). A fivefold higher expression of 
EDG1 was found in gefitinib sensitive cell lines may suggest that dependence of cells 
to transactivation of EGFR via EDG1 could confer an enhanced sensitivity to gefitinib. 
 
This work provides the first report that uses whole genome expression profiling to 
correlate cetuximab in vitro responsiveness of cancer cell lines with their relative 
gene expression. A number of potentially relevant candidate genes with differential 
expression between cetuximab-resistant and sensitive NSCLC cells were identified, 
that despite not reaching strict statistical significance fit well in a biological context (cf. 
table 4). The analyses showed syndecan 2 (SDC2) to be six-fold higher expressed in 
cetuximab-resistant cell lines. Syndecan 2 is a member of the heparine sulphate 
proteoglycane (HSPG) family and is known to be implicated in cellular adhesion and 
signaling, as well as in cancer progression and angiogenesis (Essner et al., 2006). 
Interestingly, syndecan 1, which is also a member of the HSPG family, has been 
shown to bind certain ErbB ligands in multiple myeloma cells, such as HB-EGF and 
AREG, and is suggested to facilitate ErbB activation via concentrating ligands at the 
cell membrane (Mahtouk et al., 2006). Interestingly, tetraspanin 8 (TSPAN8) was 
found to be roughly six-fold higher expressed in cetuximab-resistant cells. Members 
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of the tetraspanine family of membrane-associated proteins were found to be 
associated, together with HSPGs, in mediating AREG-driven proliferation (Piepkorn 
et al., 1998). High expression of tetraspanin 8 has been found in NSCLC tumor 
tissues (Remmelink et al., 2005) and was combined with increased invasion and 
metastasis of colorectal cancers (Le Naour et al., 2006). The identification of 
syndecan 2 and tetraspanine 8 as putative markers predicting cellular resistance 
against cetuximab provoke the general hypothesis that membrane associated 
scaffold proteins that concentrate and present natural ligands to EGF receptors may 
provide an alternative mechanism in receptor activation, which cannot be effectively 
blocked by the antibody.        
Of course, the identified candidate genes of interest await validation by immunoblot 
or FACS analyses. Furthermore, it will be interesting to see whether the postulated 
candidates can be confirmed in functional assays. These questions are currently 
subject of an ongoing project that is part of another PhD thesis.  
 
4.4 Long-term exposure of A431 cells to gefitinib, but not to cetuximab, 
causes gain of resistance to EGFR-directed drugs 
A couple of studies on cancer cell lines that were long-term treated with EGFR-
targeting TKIs have been conducted in the past. In all cases, acquisition of resistance 
was observed after several months of drug exposure and recurrent dose escalation 
(Perez-Soler et al., 2003; Kwak et al., 2005; Ando et al., 2005; Kokubo et al., 2005; 
Engelman et al., 2006). In this study A431 cells were treated with gefitinib for 15 
months and acquired resistance to this TKI, as diagnosed by monolayer and soft-
agar growth assays (figures 22 and 23). Furthermore, this work showed that gefitinib-
resistant A431 cells still respond effectively to cetuximab in a soft-agar colony 
formation assay. Growth response of these cells was comparable to medium-treated 
control cells of similar passage number (figure 25). This finding is of high interest as it 
may imply that resistance mechanisms to the TKI gefitinib are fundamentally different 
from those that specify response to cetuximab. Even though it is problematic to draw 
conclusions from laboratory examinations for the clinic, this could indicate that 
patients that relapse from gefitinib can still profit from a cetuximab regimen. 
 
Apart from this work, a cancer cell line was generated that resumed growth after 
xeno-transplantation into mice and long-term exposure to cetuximab. Interestingly, 
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this cell population retained normal in vitro sensitivity to cetuximab as compared to 
the parental cell line. Yet, cells isolated from the relapsed xenograft showed 
increased in vivo resistance to cetuximab (Viloria-Petit et al., 2001). Even though in 
this work cells were exposed to cetuximab under standard cell culture conditions that 
study is the only published reference. Notably, also long-term cetuximab-treated 
A431 from this work did not acquire resistance to the antibody, as accessed by soft-
agar colony formation assays (figure 25). Interestingly, A431 cells that were long-
term exposed to cetuximab showed a considerably decreased response to gefitinib, 
as reflected by monolayer growth assays (figure 22) and also by soft agar colony 
formation assays (figure 23). Inferring from these results, cetuximab long-term 
treatment appears to alter A431 cells in regard to their response to gefitinib, yet this 
is not mirrored by altered in vitro sensitivity towards the antibody itself. This implies 
that long-term exposure of A431 cells to cetuximab causes alterations that also affect 
the mode of EGFR activity or accessibility to gefitinib. 
 
4.5 Cetuximab and gefitinib long-term-treated A431 cells show moderately 
altered expression patterns and different dynamics of EGFR 
Studies on cell lines with acquired resistance to EGFR-specific TKIs consistently 
indicate down regulation of EGFR expression (Perez-Soler et al., 2003; Ando et al., 
2005). In line with these observations, this examination proved decreased EGFR 
protein expression and equally reduced surface levels in gefitinib-resistant A431 cells 
(cf. figures 31 and 29). One study finds an increased ligand-induced internalization of 
EGFR in a gefitinib-resistant lung cancer cell line (Kwak et al., 2005). This work 
revealed a decreased cetuximab-induced internalization of the receptor in gefitinib-
resistant A431 cells (figure 30) that correlated to their modestly decreased response 
to cetuximab in a soft-agar colony formation assay as compared with medium-treated 
control cells of similar passage number (figure 25). In summary, long-term treatment 
of A431 cells with gefitinib caused reduced expression of EGFR and putatively 
diminished receptor dynamics, as reflected by retarded EGFR turnover through 
cetuximab. 
 
A six-week exposure of a cetuximab-sensitive pancreas cancer cell line to the 
antibody has been reported to cause a reduction of EGFR surface levels (Huang et 
al., 2003). In agreement with that observation, A431 cells displayed markedly 
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reduced surface levels of EGFR after long-term exposure to cetuximab (figure 29). 
However, total cellular levels of EGFR in these cells were comparable to the levels in 
medium-treated control cells of similar passage number (figure 31) suggesting that in 
long-term cetuximab-treated cells the majority of EGFR are localized within the cell. 
Since only full-length receptor was accounted for immunoblot signals, intracellular 
EGFR molecules complexed with cetuximab may not be subjected to a rapid 
degradation mechanism. The perception that a multitude of antibody-receptor 
complexes were accumulated within the cell may also help to explain the observation 
that long-term cetuximab-exposed cells showed reduced capacity for antibody-
mediated receptor internalization (figure 30).  
Another notion of this study is that long-term cetuximab-treated-A431 cells, but not 
gefitinib-resistant cells, displayed increased protein levels of ErbB3 and ErbB4 
receptors, as compared to medium-treated cells of similar passage number (figure 
31). The significance of this observation is not clear, yet it eventually points towards 
compensatory signaling via ErbB3 and ErbB4 receptors. However, expression of the 
highly signaling competent receptor ErbB2 cannot be detected in any A431 cell 
population (figure 31). 
 
4.6 Cetuximab and to a minor extent gefitinib, block epithelial-mesenchymal 
transition (EMT) in long-term cultured A431 cells 
A role for EGFR in triggering EMT in breast cancer cells has been described in vitro 
(Lo et al., 2005; Lee et al., 2006b). Furthermore, ectopic expression of the 
constitutively active EGFRvIII receptor in ovary cancer cells caused EMT (Zeineldin 
et al., 2006). These data point towards a general significance of EGFR in the 
induction of this de-differentiation process.  
In this study EMT was observed in the epidermoid cell line A431 after long-term 
culture, as reflected by loss of E-cadherin expression, gain of vimentin expression 
(figure 32) and characteristic morphological alterations (figure 26). In addition, it was 
shown that long-term exposure to cetuximab blocked EMT in this cell line and 
arrested cells in a typically epithelial state (figures 26 and 32). This also appeared to 
hold true for gefitinib, however this population displayed somewhat diminished levels 
of E-cadherin and cellular morphology was rather metastable with more 
mesenchymal features (figures 26 and 32). 
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Complex formation of EGFR with E-cadherin in basolateral areas of epithelial cells 
has been demonstrated to modulate EGFR kinase activity and downstream signaling 
(Pece et al., 1999; Pece et al., 2000; Qian et al., 2004). Furthermore, long-term 
incubation of A431 cells with EGF causes endocytosis and degradation of E-
cadherin, which is paralleled by induction of the transcription factor Snail, a hallmark 
for EMT (Lu et al., 2003). Therefore a potential explanation of the cetuximab-
mediated blockade of EMT lies in the capacity of the antibody to compete with EGF 
for binding sites on the receptor, thereby inhibiting the effects conferred by the ligand. 
Since A431 can activate EGFR through autocrine secretion of ligands (Van de Vijver 
et al., 1991) it can be expected that this drives long-term cultured A431 cells into 
EMT. 
Interestingly, EMT was found to be implicated in explaining cellular growth response 
to EGFR-targeting TKIs. NSCLC cells with epithelial characteristics display an 
increased grade of sensitivity as compared to mesenchymal NSCLC cells (Thomson 
et al., 2005; Yauch et al., 2005; Witta et al., 2006). The observed capacity of 
cetuximab to arrest cancer cells in an epithelial state together with the notion that 
epithelial cells are more responsive to EGFR-targeting TKIs may also explain the 
finding that combined treatment of A431 cells with cetuximab and gefitinib provokes 
cellular responses that are superior to single agent treatments (Matar et al., 2004).      
 
4.7 Activation of HGFR may compensate for cetuximab-mediated blockage of 
EGFR 
Overexpression of HGFR was recently reported in a primarily gefitinib sensitive 
NSCLC cell line, which has acquired resistance to this TKI due to long-term 
exposure. Furthermore, this study found HGFR amplification in 22% of NSCLC 
tumors that relapsed on EGFR-targeting TKIs (Engelman et al., 2007). In this work, a 
screen on the activation level of RTKs in A431 cells after long-term exposure to 
EGFR-targeting drugs, identified HGFR as being hyper-activated in cetuximab, but 
not in gefitinib-treated cell populations (cf. figures 33 and 34). Evaluation by 
immunoblot found a marked increase of HGFR expression in gefitinib-resistant A431 
cells, which however was not accompanied by a significant activation of HGFR 
(figure 35). In contrast, cetuximab long-term-treated cells displayed only a moderate 
rise in total HGFR expression, but exhibited a substantial increase in receptor 
phosphorylation (figure 35). These observations are in line with the results reported 
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by others and further indicate for the first time a role for HGFR in compensating 
blockage of EGFR by cetuximab.  
 
In addition, this work could show that HGFR-specific TKIs cause an appreciable 
growth inhibition in A431 cells that were long-term treated with cetuximab, but not in 
the gefitinib-resistant population or medium-treated A431 cells of similar passage 
number (figure 36). Interestingly, elevated activation of HGFR and sensitivity to 
HGFR TKIs was also observed in A431 cells from the starting population (figures 35 
and 36). As already mentioned, these cells and the population that was long-term 
exposed to cetuximab, showed molecular and morphological features that are typical 
for epithelial cells. The importance of activated HGFR in mediating EMT has been 
well described (Jiang et al., 1999; Comoglio and Boccaccio, 2001). Notably, it is 
known that HGFR may associate with EGFR in cancer cells and that this interaction 
allows ligand-independent activation of HGFR. Yet exposure of cells to an EGFR 
inhibiting antibody reversed HGFR phosphorylation (Jo et al., 2000). From these data 
it can be hypothesized that EGFR-dependent activation of HGFR may be necessary 
for enabling HGFR-mediated onset of EMT. Blockage of EGFR by cetuximab thus 
may impede complex formation between both receptors due to sterical hindrance, 
causing epithelial arrest of cells. The fact that high activation of HGFR, as observed 
in long-term cetuximab exposed A431 cells, alone was not sufficient for eliciting EMT, 
may indicate that the EGFR-HGFR interaction provides a particular signaling output 
which is not stimulated by regular activation of HGFR. Though highly speculative on 
the basis of the data provided in this work, these considerations may provide a novel 
mechanistic insight to RTK-mediated EMT initiation.  
 
4.8 Cell lines with primary resistance or sensitivity to EGFR-targeting drugs 
show differential basal expression patterns after long-term exposure to 
cancer therapeutics 
A candidate-based expression analyses with cell lines long-term treated with EGFR 
specific drugs has been performed in this work. The examination served to identify 
factors that were differently expressed in primary sensitive cell lines (A431 and Difi) 
after long-term exposure to either gefitinib or cetuximab, but whose expression was 
not altered in primary resistant cell lines (H460 and SW707).  
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Eight candidate genes were found to be differentially regulated in long-term 
cetuximab-treated Difi and A431 cells, but unaltered in long-term-treated H460 and 
SW707 cell lines. Namely, CCL5 was up-regulated in cetuximab-sensitive, but not 
resistant cell lines after long-term exposure to this drug (figure 37). Expression of the 
chemokine CCL5 is controlled by TNFα and is part of the inflammatory response 
system, whose components serve as chemoattractants for immune cells. It has been 
shown that impairment of EGFR activity causes increased expression of CCL5 
(Pastore et al., 2005). Even though the role for this in cetuximab caused immune 
response cannot be acknowledged in vitro, it may possess relevance for the clinic. 
Interestingly, also expression of complement component C3 was triggered in 
cetuximab sensitive cell lines (figure 37). This finding may provide another valuable 
insight in the mode of cetuximab-triggered killing of tumor cells through antibody-
mediated complement-dependent cytotoxicity (CDC). Deposition of processed C3 on 
the surface of tumor cells allows binding of cytotoxic T-cells carrying the C3 receptor, 
which is the initial step for activation of the complement system (Gelderman et al., 
2004). The up-regulation of immunogenic factors in cetuximab sensitive cells, though 
in vitro, calls into attention the versatility of antibody-mediated tumor inhibition. In 
addition, both candidates may be favourable due to their unproblematic clinical 
accessibility, since detection of these proteins should be possible from patient’s 
serum. Interestingly, another inflammatory factor (CXCL6) was found to be up-
regulated in cells with acquired resistance to gefitinib, yet not in cells with primary 
resistance to that TKI (figure 38).  
Furthermore, four ErbB ligands were found to be either up- (BTC, EGF) or down-
regulated (EREG, HB-EGF) in cetuximab-sensitive cells after long-term treatment 
with the antibody (table 5). Notably, both ligands that were up-regulated in 
cetuximab-treated cells (BTC and EGF) bind exclusively to EGFR, while the ligands 
that are down-regulated (EREG and HB-EGF) may bind to EGFR as well as to ErbB4 
receptors (Elenius et al., 1997; Komurasaki et al., 2000). It is unclear, wether ligand 
binding sites or competition with cetuximab corresponds to the observed gene 
expression pattern. 
 
4.9 Perspectives    
Against the background of the clinical significance of EGFR-driven cancerogenesis it 
is at hand that a better understanding on the functionality of EGFR-targeting cancer 
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drugs is needed. Firstly, identification of cellular factors that predict resistance or 
sensitivity to EGFR-targeting therapeutics allows for exclusion or selection of patients 
for these regimens. Secondly, understanding the mode of action of EGFR-targeting 
TKIs and monoclonal antibodies provides also valuable insight to cancer drugs that 
aim at other cellular targets with tumorigenic potency and therefore allows refining 
therapy strategies. Thirdly, elucidation of factors that predict resistance to EGFR-
specific therapy may suggest combination therapies that could be superior to single 
drug treatment.  
In terms of preclinical examinations it will therefore be helpful to collect and evaluate 
additional data from mRNA basal expression analyses in patients or cell lines with 
differential response to EGFR-targeting drugs. The new candidates suggested in this 
work to be possibly predictive for cellular response to cetuximab or gefitinib in 
NSCLC will need to be validated on the protein level, followed by retrospective 
clinical examinations. Initial growth-inhibitory in vitro experiments and the availability 
of specific inhibitors against resistance-conferring factors will point out the 
perspectives and limits of combination therapy in the respective tumor context. 
However, in addition to plain analyses of mRNA or protein expression, more detailed 
studies focusing on post-translational modifications by phosphate residues or  
ubiquitin, as well as on subcellular localization of EGFR and other proteins will be 
necessary to better understand the mechanisms of cellular drug response. Moreover, 
the efficacy of cetuximab to block receptor homo- or heterodimerization could further 
be studied by BRET (bioluminescence resonance energy transfer) analyses; 
however, this technique did not yield satisfying results when applied in conjunction 
with this work.  
In-depth characterization of the cellular resistance models established in this work 
will shed light on the causes of primary and secondary resistance to EGFR-targeting 
drugs. Since cetuximab was found to block an epithelial cell line from going through 
EMT, it will be interesting to see if this observation translates into general mode of 
action for this therapeutic antibody. If so, this might have important implications for a 
preferred cetuximab treatment of early, non-invasive tumor stages. For studying 
sensitivity and cross-sensitivity to EGFR-specific cancer therapeutics in the long-term 
drug exposed cell lines, xenograft models will provide additional cognitions in the 
clinical context. 
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5. Summary 
This study characterized a panel of NSCLC cell lines as well as a stably transfected 
cell model expressing wild-type and mutated EGFR variants in terms of response to 
the EGFR-targeting drugs, gefitinib and cetuximab. The examinations support the 
notion that response to gefitinib is neither exclusive nor strictly determined by the 
presence of EGFR kinase mutations. Yet, cells expressing EGFR kinase domain 
mutations tended to generally respond better to treatments with gefitinib compared to 
those with wild-type EGFR. On the other hand, preliminary studies suggesting that 
cellular sensitivity to cetuximab is determined by factors other than EGFR kinase 
domain mutations could be substantiated through a robust set of data. Moreover, 
several promising candidate genes differentially expressed in gefitinib sensitive and 
resistant NSCLC cell lines were revealed by a global mRNA expression analyses. In 
addition, though statistically questionable, several biologically interesting genes that 
are possibly involved in determining in vitro response of NSCLC cells to cetuximab 
have been postulated.  
In this work, four cancer cell models, which are long-term exposed to gefitinib or 
cetuximab were established and characterized in terms of gain-of-resistance towards 
EGFR-targeting compounds, as well as in regard to biological and molecular 
alterations caused by long-term treatments. It was found that gefitinib long-term 
treatment of primary sensitive A431 cells confered growth-resistance to this TKI, but 
not to cetuximab. This observation may have clinical implications for patients that 
relapsed on gefitinib as it suggests that they might still profit from cetuximab therapy. 
On the other hand long-term exposure of A431 cells to cetuximab did not render cells 
resistant to neither the antibody nor gefitinib in regard to in vitro growth-inhibition. 
Furthermore, it appeared that long-term gefitinib-treated A431 cells downregulate 
overall EGFR levels, while long-term cetuximab exposed cells displayed decreased 
EGFR surface levels but constant overall expression. In addition, a candidate-based 
approach identified genes that are differentially expressed in cancer cells with 
primary or secondary resistance to gefitinib or cetuximab. 
Finally, this study for the first time provided evidence that cetuximab may block 
metastasis-facilitating epithelial-mesenchymal-transition (EMT) in an epithelial cell 
line. Moreover, it was suggested that activation of the HGFR may compensate for 
cetuximab-mediated blockage of EGFR. This was also reflected by an increased 
response of this population towards treatment with HGFR inhibitors. 
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5.  Zusammenfassung 
Im Rahmen dieser Arbeit wurden eine Reihe von NSCLC-Zelllinien, sowie eine mit 
verschiedenen EGFR-Varianten stabil transfizierte Modellzelllinie hinsichtlich ihrer 
Responsivität gegenüber den EGFR-spezifischen Tumortherapeutika Gefitinib und 
Cetuximab untersucht. Dabei wurde festgestellt, dass Mutationen in der EGFR-
Kinasedomäne weder hinreichend noch notwendig für eine zelluläre Sensitivität 
gegenüber Gefitinib sind. Dennoch war zu beobachten, dass Mutationen in der 
EGFR-Kinasedomäne für eine allgemein erhöhte Sensitivität gegenüber Gefitinib 
verantwortlich sind. Auf der anderen Seite wurde gezeigt, dass die Sensitivität von 
NSCLC-Zellen gegenüber Cetuximab nicht von Mutationen der EGFR-
Kinasedomäne determiniert wird sondern von anderen Faktoren abhängt. Darüber 
hinaus konnten im Rahmen einer globalen Expressionsanalyse eine Reihe von 
Kandidatengenen identifiziert werden, welche in Gefitinib-sensitiven und -resistenten 
Zelllinien differentiell exprimiert sind. Entsprechend konnten auch biologisch 
interessante Gene identifiziert werden, welche möglicherweise prognostische 
Bedeutung für die Sensitivität von NSCLC-Zellen gegenüber Cetuximab besitzen.  
Zudem wurden in dieser Arbeit vier mit Gefitinib oder Cetuximab langzeitbehandelte 
Krebszelllinien etabliert und charakterisiert. Es konnte festgestellt werden, dass die 
langzeit mit Gefitinib behandelte epitheliale Zelllinie A431 eine Resistenz gegenüber 
Gefitinib, nicht aber gegenüber Cetuximab erwirbt. Diese Beobachtung besitzt 
möglicherweise klinische Relevanz, da sie impliziert, dass Patienten welche nicht 
mehr auf Gefitinib ansprechen durchaus noch auf Cetuximab respondieren können. 
Auf der anderen Seite konnte für Cetuximab-langzeitbehandelte A431 Zellen im 
Wachstumsinhibitions-Assay weder eine Resistenz gegenüber Cetuximab noch 
gegenüber Gefitinib festgestellt werden. Zudem wurde gezeigt, dass Gefitinib-
resistente A431 Zellen eine Verminderung der zellulären EGFR-Proteinexpression 
aufweisen. Demgegenüber war in Cetuximab-langzeitbehandelten A431 Zellen eine 
verminderte Lokalisation von EGFR auf der Zelloberfläche zu sehen, während die 
Proteinexpression insgesamt unverändert blieb. 
Diese Arbeit zeigte erstmalig, dass Cetuximab den Prozess der epithelialen-
mesenchymalen-Transition (EMT) in A431 Zellen blockieren kann; EMT wurde 
klinisch mit der Metastasierung von Tumoren assoziiert. Zudem war die Aktivität von 
HGFR in Cetuximab-langzeitbehandelten A431 Zellen deutlich erhöht, was sich auch 
in einer erhöhten Sensitivität gegenüber HGFR-Inhibitoren widerspiegelte. 
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